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  Summary 
1. SUMMARY (Zusammenfassung) 
1.1. English 
An increase in cytosolic Ca2+ levels ([Ca2+]i) is a key event that occurs 
downstream of many signaling cascades in response to an external stimulus 
and regulates a wide range of cellular processes, including platelet activation. 
Eukaryotic cells increase their basal [Ca2+]i allowing extracellular Ca2+ influx into 
the cell, which involves different mechanisms. Store-operated Ca2+ entry 
(SOCE) is considered the main mechanism of extracellular Ca2+ influx in 
electrically non-excitable cells and platelets, and comprises an initial Ca2+ 
depletion from intracellular Ca2+ stores prior to activation of extracellular Ca2+ 
influx. Although the close relation between Ca2+ release from intracellular stores 
and extracellular Ca2+ influx was clear, the nature of the signal that linked both 
events remained elusive until 2005, when Stromal Interaction Molecule 1 
(STIM1) was identified as an endoplasmic reticulum (ER) Ca2+ sensor essential 
for inositol (1,4,5)-trisphosphate (IP3)-mediated SOCE in vitro. However, the 
function of its homologue STIM2 in Ca2+ homeostasis was in general unknown. 
Therefore, mice lacking STIM2 (Stim2-/-) were generated in this work to study 
initially STIM2 function in platelets and in cells of the immune system. Stim2-/- 
mice developed normally in size and weight to adulthood and were fertile. 
However, for unknown reasons, they started to die spontaneously at the age of 
8 weeks. Unexpectedly, Stim2-/- mice did not show relevant differences in 
platelets, revealing that STIM2 function is not essential in these cells. However, 
STIM2 seems to be involved in mammary gland development during pregnancy 
and is essential for mammary gland function during lactation. CD4+ T cells 
lacking STIM2 showed decreased SOCE. Our data suggest that STIM2 has a 
very specific function in the immune system and is involved in Experimental 
Autoimmune Encephalomyelitis (EAE) at early stages of the disease 
progression. Stim2-/- neurons were also defective in SOCE. Surprisingly, our 
results evidenced that STIM2 participates in mechanisms of neuronal damage 
after ischemic events in brain. This is the first time that the involvement of 
SOCE in ischemic neuronal damage has been reported. This finding may serve 
as a basis for the development of novel neuroprotective agents for the 
treatment of ischemic stroke, and possibly other neurodegenerative disorders in 
which disturbances in cellular Ca2+ homeostasis are considered a major 
pathophysiological component. 
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1.1. Deutsch 
 
Der Anstieg des cytosolischen Ca2+-Spiegels ([Ca2+]i) ist ein Schlüsselereignis, 
das vielen Signalkaskaden, durch extrazellulären Stimulus ausgelöst werden, 
nachgeschalten ist, und eine große Reihe zellulärer Prozesse reguliert, z.B. die 
Aktivierung von Blutplättchen. Eukaryotische Zellen erhöhen ihren basalen 
([Ca2+]i) durch Einstrom von extrazellulärem Ca2+ in die Zelle hinein, was durch 
verschiedene Mechanismen geschehen kann. Store-operated Ca2+-entry 
(SOCE), wird als der Hauptmechanismus für den Einstrom von extrazellulärem 
Ca2+ in nicht elektrisch-erregbaren Zellen sowie Plättchen angesehen und 
beinhaltet einen initialen Ca2+-Ausstrom aus intrazellulären Speichern der dem 
Ca2+-Einstrom aus der Extrazellulärraum vorrausgeht. Obwohl die Beziehung 
zwischen Ca2+-Ausstrom aus intrazellulären Speichern und extrazellulärem 
Ca2+-Einstrom über die Plasmamembran viele Jahre bekannt war, so blieb doch 
das beide Ereignisse verknüpfende Element unbekannt. Im Jahre 2005 jedoch 
wurde Stromal Interaction Molecule 1 (STIM1) als Ca2+-Sensor des 
endoplasmatischen Retikulums (ER) und als essentieller Bestandteil für 
inositol(1,4,5)-triphosphat (IP3)-vermittelten SOCE in vitro identifiziert. Die 
Funktion seines Homologs, STIM2, in der Ca2+ Homeostase blieb jedoch 
unklar. Aus diesem Grund generierten wir STIM2-defiziente (Stim2-/-) Mäuse um 
die Funktion dieses Proteins in Blutplättchen und Immunzellen untersuchen zu 
können. Bis zum Erwachsenenalter entwickelten sich Stim2-/- Mäuse normal in 
Bezug auf Größe und Gewicht und waren fertil. Jedoch sterben die Tiere 
spontan aus unbekannten Gründen, beginnend ab einem Alter von 8 Wochen. 
Unerwarteter Weise, zeigten Stim2-/- Mäuse keine maßgeblichen 
Funktionsunterschiede in Plättchen, was eine essentielle Funktion von STIM2 in 
diesen Zellen ausschließt. Jedoch scheint STIM2 in die Entwicklung der 
Brustdrüsen während der Schwangerschaft involviert und essentiell für die 
Brustdrüsenfunktion während der Säugephase zu sein. Darüberhinaus zeigten 
STIM2 defiziente CD4+ T-Zellen einen verminderten SOCE. Weiter deuten 
unsere Daten auf eine spezifische Funktion von STIM2 im Immunsystem hin, 
mit einem Einfluss auf die frühen Phasen und das Fortschreiten der 
Experimentellen Autoimmun-Enzephalomyelitis (EAE). 
Stim2-/- Neuronen wiesen ebenso wie CD4+ T-Zellen einen gestörten SOCE auf. 
Desweiteren belegen unsere Ergebnisse, dass STIM2 überrascherweise an den 
Neuronen zerstörenden Mechanismen nach ischämischen Ereignissen des 
Gehirns mitwirkt. Dies ist die erste Studie, die von einer Beteiligung von SOCE 
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an ischämischen neuronalen Schäden berichtet. Diese Entdeckungen können 
vielleicht als Basis für die Entwicklung neuer neuroprotektiver Medikamente bei 
ischämischen Schlaganfall dienen - und möglicherweise auch bei anderen 
neurodegenerativen Erkrankungen, bei denen Störungen der zellulären Ca2+ 
Homöostase als hauptsächliche pathophysologische Komponente angesehen 
werden. 
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1.2. Abbreviations 
AR     alpha-adrenoreceptor 
-TG     beta-thromboglobulin 
[Ca2+]     Ca2+ concentration 
[Ca2+]i     cytosolic concentration of Ca2+ 
[Ca2+]O    extracellular Ca2+ concentration 
8-pCPT-cGMP 8-(4-Chlorophenylthio)-guanosine 3′,5′-cyclic 
monophosphate 
aas     amino acid residues 
AC     adenylyl cyclase 
ADP     adenosine diphosphate 
APC     antigen presenting cells 
ATP     adenosine triphosphate 
BMMC    bone marrow derived Mast Cells 
BSA     bovine serum albumin 
Ca2+     calcium 
CaM     calmodulin 
CaMK     Ca2+- calmodulin-dependent kinase 
CaMKI-IV    Ca2+- calmodulin-dependent kinase I-IV 
CCCP     carbonyl cyanide m-chlorophenylhydrazone 
CCE     capacitive Ca2+ entry 
CLEC-2    C-type lectin-like receptor-2 
CNS     central nervous system 
CPA     cyclopiazonic acid 
c.p.m.     counts per minute 
CRAC     Ca2+ release-activated Ca2+ channels 
CRACM    Ca2+ release-activated Ca2+ modulator 
CREB cyclic- AMP-responsive-element-binding 
protein 
CRP     collagen related peptide 
CVX     convulxin 
DAG     diacylglycerol 
DIV     days in vitro 
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DNP-HSA 2,4-Dinitrophenyl hapten conjugated to human 
serum albumin 
DREAM    Ca2+-binding downstream regulatory  
     element modulator 
D-Stim    drosophila melanogaster STIM 
DTS     dense tubular system 
EAE     experimental autoimmune encephalomyelitis 
ECM     the extracellular matrix 
EGFR     epidermal growth factor receptor 
eNOS endothelial nitric oxide synthase 
ER     endoplasmic reticulum 
ERM     ezrin/radixin/moesin domain 
FcRs     IgG Fc gamma receptors 
FcRs     IgE Fc etha receptors 
GPCRs    G-protein coupled receptors 
H&E     haematoxylin and eosin staining 
i.p.     intraperitoneal injection 
i.v.     intravenous injection 
ICRAC     Ca2+ release-activated Ca2+ current 
Ig     antibody, immunoglobulin 
iNOS inducible nitric oxide synthase 
IP3     inositol-1,4,5-triphosphate 
IP3Rs     inositol (1,4,5)-trisphosphate receptors 
IRAG Ins(1,4,5)P3-receptor-associated cGMP kinase 
substrate 
ITAM  immunoreceptor tyrosine-based activation 
motif 
ITK     interleukin-2-inducible T-cell kinase 
ITP     Immune thrombocytopenia purpura 
KLH     keyhole limpet hemocyanin 
LAT     linker of activated T cells 
LPA     lysophosphatidic acid  
LPS     E.Coli Lipolysaccharide 
MCA     middle cerebral artery 
MD-2     myeloid differentiation protein-2 
MEF2     myocyte enhancer factor 2 
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MHC     histocompatibility complex proteins 
MLC     myosin light chains 
MRI     serial magnetic resonance imaging 
MS     multiple sclerosis 
NAADP    nicotinic acid adenine dinucleotide phosphate 
NCXs, Na+/Ca2+ exchangers  plasma membrane Ca2+ transporters 
NFATs    nuclear factor of activated T cells 
NFB     nuclear factor kappa B 
nNOS neuronal nitric oxide synthase 
NO     Nitric Oxide 
NOS Nitric oxide synthase 
Orai Orai Ca2+ release-activated Ca2+ modulator  
PACAP pituitary adenylate cyclase-activating 
polypeptide 
PDGF     platelet derived growth factor 
PDGFR    platelet-derived growth factor receptor 
PF4     platelet factor 4 
PGI2     Prostaglandin I2 (Prostacyclin) 
PKA     protein kinase A 
PKC     protein kinase C 
PKG     protein kinase G 
PLC     phospholipase C 
PLC     phospholipase C beta 
PLC     phospholipase C gamma 
PMC     peritoneal mast cells 
PMCAs    plasma membrane Ca2+ ATPases 
PRL     prolactin 
prp     platelet rich plasma 
RhoGAP    Rho GTPase-activating protein 
ROCs     receptor-operated Ca2+ channels 
RT     room temperature 
RTKs     receptor tyrosine kinases 
RyRs     ryanodine receptors 
SAM     sterile α-motif 
SCID severe combined immune deficiency 
syndrome  
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s.d. standard deviation 
SEM standard error of the mean 
SERCAs sarcoplasmic / endoplasmic reticulum Ca2+ 
ATPases 
sGC     guanylyl cyclise 
SLP76 SRC-homology-2-domain-containing leukocyte 
protein of 76 kDa 
SNP     sodium nitroprusside 
SOC     Store-Operated Ca2+ 
SOCE     Store-Operated Ca2+ Entry 
STIM1    Stromal Interaction Molecule 1 
Stim2+/+BM-/- chimera wild-type mice transplanted with 
Stim2-/- bone marrow  
Stim2-/-BM+/+ chimera Stim2 knockout mice transplanted 
with wild-type bone marrow  
TCR     T cell receptor 
TCR, BCR    T-cell and B-cell antigen receptors 
TG     thapsigargin 
TGII     tissue transglutaminase II 
TLR4     Toll-like receptor 4 
tMCAO    transient middle cerebral artery occlusion 
TP     thromboxane receptor alpha 
TRP     the transient receptor potential channels 
TRPC     the canonical TRP 
TTC     2,3,5-triphenyltetrazolium chloride 
TxA2     thromboxane A2 
VOCs     voltage-operated Ca2+ channels 
vWF     von Willebrand factor 
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2. INTRODUCTION 
 
Calcium (Ca2+) is an ubiquitous second messenger that regulates basic cellular 
functions such as gene expression, contraction, secretion, cell migration cell 
death and more specialized functions like communication between neurons. 
In electrically non-excitable cells, Ca2+ entry is mainly regulated by channels 
located in the plasma membrane, referred to as store-operated Ca2+ (SOC) 
channels because they are activated (operated) by a previous emptying of 
intracellular Ca2+ stores. The subsequent Ca2+ influx into the cells is called 
store-operated Ca2+ entry (SOCE) and the electrophysiological characteristics 
of this Ca2+ influx were studied in 1992 and termed Ca2+ release-activated Ca2+ 
current (ICRAC) [1]. 
Despite intense research, the nature of the signal that triggers the activation of 
SOC channels after store depletion, as well as the molecular identity of the Ca2+ 
sensor within the stores, remained elusive until 2005, when the Stromal 
Interaction Molecule 1 (STIM1) was identified as a endoplasmic reticulum (ER) 
Ca2+ sensor essential for inositol (1,4,5)-trisphosphate receptors (IP3Rs)-
mediated SOCE in vitro [2-4]. Recently, it has also been demonstrated in vivo. 
The lack of STIM1-function in lymphocytes and in platelets results in severe 
impairment of IP3Rs-mediated SOCE [5-7]. Later, it was demonstrated that 
STIM1 interacts functionally with the SOC channel Orai1 in vitro, indicating that 
STIM1 triggers SOCE mainly by STIM1-Orai1 interaction [8]. In 2005 STIM2 
was also proposed to be involved in IP3Rs-mediated signaling [2], but its 
function is still under discussion. In vitro experimental data indicates that STIM2 
is also able to interact with Orai channels, but contrary to STIM1, 
downregulation or overexpression of STIM2 produced none or very weak effect 
on SOCE [2,9]. However, reports published in the last two years supported the 
emerging idea that STIM2 mainly regulates the cytoplasmic [Ca2+] ([Ca2+]i) and 
ER [Ca2+], possibly through interaction with Orai1 SOC channels [5,9].  
A consensus model to describe STIM function in SOCE has been established 
(Fig. 1); the activation of G-protein coupled receptors (GPCRs) or ITAM-
containing receptors (ITAM, immunoreceptor tyrosine-based activation motif) 
located in the plasma membrane leads to activation of inositol-1,4,5-
triphosphate (IP3)-dependent pathways that results in Ca2+ release from the ER 
store. The depletion of the Ca2+ stored in the ER is detected by STIM isoforms, 
since Ca2+ is dissociated from STIMs, and induces conformational changes that 
switch the proteins to the activated state. STIM1 oligomerize and migrates to 
the plasma membrane forming small clusters (punctae) and triggers SOCE by 
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Orai1 channel interaction. STIM2 is more sensitive than STIM1 to small 
decreases in ER [Ca2+] and regulates the basal [Ca2+]i and the ER [Ca2+], 
probably by Orai channel interactions [9]. In both cases, it is believed that 
SOCE mainly leads to refilling of the ER Ca2+ stores [10]. 
Despite the major progress made in understanding SOCE during these three 
years, still more work has to be done to fully uncover the role of STIM and 
SOCE at a cellular level. The present model and the main players will be 
described in more detail in the next sections of the introduction. 
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Figure 1. The SOCE model. Ligand-receptor interaction leads to PLC activation by G-protein-
coupled receptors (G-Prot, R) or ITAM-containing receptors located in the plasma membrane, 
which in turn hydrolyzes phosphotidyl inositolbisphosphate (PIP2) into inositol 1,4,5-
trisphosphate (IP3) and diacylglycerol (DAG). DAG can directly activate Ca2+ channels located 
in the plasma membrane, for instance Transient Receptor Potential (TRP) channels. The 
increase of IP3 in the cytoplasm results in Ca2+ release from the endoplasmic reticulum (ER) 
Ca2+ stores by activation of IP3 receptors (IP3R) located in the ER membrane. The subsequent 
depletion of ER Ca2+ stores is detected by STIM isoforms and they become activated. STIM1 
migrates to the plasma membrane and triggers store-operated Ca2+ entry (SOCE) by Orai1 
channel interaction. Instead, STIM2 is more sensitive than STIM1 to small decreases and 
mainly regulates the basal [Ca2+]i and ER [Ca2+], probably by Orai channel interaction. Modified 
from Dr. Attila Braun original picture. 
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2.1. Ca2+ signaling in eukaryotic cells 
 
Second messengers (cAMP, cGMP, IP3 and Ca2+) are essential intracellular 
mediators of important basic functions in the cell. These small molecules are 
generated or released into the cytosol in response to an extracellular signal. An 
increase in [Ca2+]i is a key event, used as an essential signal that regulates a 
wide range of basic cellular processes involving gene expression, enzyme 
control, exocytosis, adhesion, proliferation, and cell death [11]. This increase is 
generally produced at localized areas in the cell, generating intracellular micro-
domains of elevated [Ca2+]i that show distinct spatial and temporal patterns [12]. 
In unstimulated cells, the basal [Ca2+]i is tightly regulated to keep it constant at a 
concentration approximately 10,000-fold below the extracellular Ca2+ 
concentration ([Ca2+]O, 1-3 mM), process that is vital for sustaining the life of the 
organism [11]. A combined action of molecules that acts as buffers, pumps and 
exchangers controls at any moment in time the [Ca2+]i, introducing additional 
Ca2+ into the cytoplasm or removing this Ca2+ signal from the cytoplasm. These 
molecules form a heterogeneous group located in the plasma membrane and in 
membranes of the diverse organelles such as mitochondria, ER and Golgi 
apparatus, which act as intracellular Ca2+ stores. The active molecules that 
maintain [Ca2+]i in human cells are four different plasma membrane pump 
isoforms (PMCAs, plasma membrane Ca2+ ATPases) [13,14], three plasma 
membrane Ca2+ transporters (NCXs, Na+/Ca2+ exchangers) [15] as well as three 
different ER Ca2+ pump isoforms (SERCAs, sarcoplasmic / endoplasmic 
reticulum Ca2+ ATPases ) [16]. 
SERCA pumps are key proteins for empirical study of intracellular Ca2+ release 
signaling. They continuously pump Ca2+ from the cytoplasm into the ER, 
maintaining the steady-state of [Ca2+] within the lumen of the stores and 
compensating the continuous Ca2+ leak through the plasma membrane. It is 
possible to deplete the ER Ca2+ store by passive release to the cytoplasm using 
a selective inhibitor of SERCA called thapsigargin (TG). This drug has been 
extensively used as a pharmacological tool as it selectively activates 
mechanisms dependent on the release of the intracellularly stored Ca2+ and 
minimizes the roles of other upstream players in the pathway (receptors, G-
proteins, phospholipase C, etc). 
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2.1.1. IP3 dependent signaling 
 
In response to a stimulus, eukaryotic cells can increase their basal [Ca2+]i in two 
related ways: by release of Ca2+ from intracellular stores or allowing 
extracellular Ca2+ influx into the cell. In electrically non-excitable cells, these 
events are consecutive; Ca2+ signaling is initiated upon the activation of 
phospholipase C (PLC) signaling pathways by GPCRs or ITAM-containing 
receptors located in the plasma membrane. Activated PLC hydrolyzes 
phosphotidyl inositolbisphosphate (PIP2) into IP3 and diacylglycerol (DAG). It 
has been reported that DAG and some of its metabolites can induce non-store 
operated Ca2+ entry (non-SOCE) [17]. IP3 triggers the release of Ca2+ from the 
IP3-sensitive intracellular Ca2+ stores, causing a transient increase in [Ca2+]i. 
This is rapidly followed by a sustained extracellular Ca2+ influx and a longer 
increase in [Ca2+]i. This extracellular Ca2+ influx is referred to as ‘‘capacitive 
Ca2+ entry’’ (CCE), also referred to as SOCE (Fig. 2). 
To date, thirteen mammalian PLC isozymes classified in six different subtypes 
have been identified in various tissues and cell types PLC(1-4), PLC(1,2), 
PLC(1,3,4), PLC, PLC, PLC(1,2), showing different molecular masses, 
isoelectric points and Ca2+ dependency (for review see [18]). Additionally, 
alternative splice variants have been reported in several PLC isozymes, for 
instance in rat PLC1, human PLC2, rat PLC4, rat PLC4, and human PLC.  
PLCs (but PLC, expressed only in testis) are widely expressed at different 
levels in all tissues, showing preferences for different organs. For instance, 
PLC1 mRNA is expressed mainly in brain, while PLC2 is expressed in the 
hematopoietic lineage. 
PLCs are regulated by different stimuli and signaling pathways in the cytoplasm. 
PLC isoforms are activated by G and G/ -protein subunits coupled to 
receptors belonging to the rhodopsin superfamily of transmembrane proteins. 
PLC1 is activated in response to polypeptide growth factors that bind to 
receptor tyrosine kinases (RTKs) such as the epidermal growth factor receptor 
(EGFR) and platelet-derived growth factor receptor (PDGFR). PLCs can also 
be activated downstream of a variety of receptors that lack intrinsic tyrosine 
kinase activity, including GPCRs, such as the angiotensin II and bradykinin 
receptors, cytokine receptors. Also immunoreceptors such as the T cell receptor 
(TCR) for PLC1, immunoglobulin and adhesion receptors on immune cells 
such as B cells, platelets and mast cells in the case of PLC2 (for review see 
[18]). PLCs are among the most sensitive isozymes to Ca2+, suggesting a role 
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of [Ca2+]i in PLC regulation. Interestingly, the Rho GTPase-activating protein 
(RhoGAP) was also reported to bind and activate PLC1 directly, inducing 
cytoskeleton reorganization. Various ligands can lead to activation of PLC, 
including several agonists of GPCRs such as thrombin, adrenaline, PGE1, 
lysophosphatidic acid (LPA) and S1P. Finally, recent results suggested that 
PLC isozymes are activated through GPCR stimulation with LPA or the 
pituitary adenylate cyclase-activating polypeptide (PACAP) in Neuro2A cells (for 
review see [18]). 
 
 
2.1.2. Intracellular Ca2+ stores and stored Ca2+ release 
 
Ca2+ release from intracellular stores plays a pivotal role in the modulation of 
intracellular Ca2+ signals [11]. Several cellular organelles have been identified 
as agonist-releasable Ca2+ pools. Among them, the ER (the sarcoplasmic 
reticulum in muscle cells) is considered as the major source of inducible Ca2+ 
release in cellular signaling. The estimated free Ca2+ content in the ER store in 
eukaryotes is ~0.2–2 mM, very close to extracellular conditions (1-3 mM) 
[19,20]. The other organelles that serve as sources of Ca2+ includes the nuclear 
envelope (which regulates gene transcription according to the pattern of Ca2+), 
lysosome-related organelles (nicotinic acid adenine dinucleotide phosphate -
NAADP–sensitive Ca2+ stores), the Golgi apparatus, the mitochondria and 
secretory granules (see for review [21]). They are essential for many cellular 
functions, for instance to contribute to the regulation of basal [Ca2+]i, trigger 
apoptosis and SOCE. The release of Ca2+ from the ER to the cytoplasm is 
mediated by two types of Ca2+ channels located in the ER membrane, the IP3R 
and ryanodine receptors (RyRs). Researchers mainly focused on the IP3R 
signaling predominantly because IP3R is the major Ca2+ channel in the ER 
which depletes the Ca2+ store after its activation by IP3 in electrically non-
excitable and excitable cells. Numerous regulatory proteins, including 
cytochrome c, huntingtin, IP3R-binding protein released with inositol 1,4,5-
trisphosphate (IRBIT), ERp44, Homer, 4.1N, and neuronal Ca2+ sensor 1  
(NCS-1), have been reported to interact with the IP3R isoforms, modifying their 
properties [22]. 
Till date, three isoforms of the IP3R have been found in mammals, known as 
type I, IP3R type II, and IP3R type III. Additional splice forms of type I and type II 
receptors have been found [23]. Despite the 65 % homology in their protein 
sequence, they have different properties, for instance, differences in the 
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magnitude of their response and ligand-binding affinity for IP3 (Kd values of 1, 
2, and 40 nM, respectively). Therefore selective expression of a particular 
receptor type would influence the sensitivity of cellular Ca2+ stores to IP3 [24]. 
Type I receptors are widely expressed in virtually all tissues and cell types, but 
predominantly in cerebellum, lung and heart. Type II receptors are also found in 
brain and lung and additionally present in placenta and thymocytes. Finally, 
type III receptors are mainly expressed in the gastrointestinal tract [23]. The 
IP3R channel is actually a tetramer and, considering that different isoforms can 
be present in the same cell, there is evidence that they are able to form 
heterotetramers [22]. At cellular level, IP3Rs have been found in ER, 
sarcoplasmic reticulum, nuclear envelope, Golgi apparatus and secretory 
vesicles [21,22]. 
Continuing with the Ca2+ mobilisation in non-excitable cells, the depletion of ER 
Ca2+ store leads to activation of particular Ca2+ channels located in the plasma 
membrane , the so-called SOC (CRAC) channels, allowing extracellular Ca2+ 
influx into the cell and SOCE [11,25]. 
 
 
2.1.3. Store-Operated- Ca2+ (SOC) channels 
 
Cells can increase [Ca2+]i up to 10-fold by opening Ca2+ channels in the plasma 
membrane that trigger an influx of extracellular Ca2+. Those Ca2+ channels can 
be divided into three main groups depending on the mechanism that activates 
them: (1) channels activated by changes on membrane voltage (VOCs, voltage-
operated Ca2+ channels); (2) channels activated by receptor-ligand binding 
(ROC, receptor-operated Ca2+ channels); and (3) channels activated by 
previous depletion of intracellular Ca2+ stores (SOCs, store-operated Ca2+ 
channels) [26]. SOC channels are the main regulators of extracellular Ca2+ 
entry in electrically non-excitable cells, mechanism referred to as SOCE. These 
channels are a heterogeneous group of non-selective Ca2+-permeable channels 
with different biophysical properties. Till date, the most relevant SOC channels 
are members of the Orai and TRP family [27,28]. 
The Orai family, also named as CRACM (for Ca2+ release-activated Ca2+ 
modulator), comprises three homologues in humans: Orai1, Orai2 and Orai3, 
and they are considered subunits that homo- or heteromultimerize forming a 
tetrameric SOC channel [29-31]. These tetrameric SOC channels show different 
properties depending on which Orai isoforms are integrated in their structure 
[31-33]. Orai1 is a relatively small (301 amino acid) protein with four predicted 
transmembrane domains and cytosolic N- and C-terminal tails [34], and it has 
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been shown to be the most important isoform since an Orai1 mutant gene was 
identified as the responsible component of a hereditary severe combined 
immune deficiency (SCID) syndrome in humans [34]. The expression of the 
wild-type Orai1 in such a mutant T cells restored SOCE [34]. In addition to the 
three Orai homologues, two spliced variants of Orai2, Orai2 short (Orai2S) and 
Orai2 long (Orai2L) have been described in mice. Orai2S plays a negative 
dominant role in the formation of Ca2+ channels when co-expressed with Orai1 
[35]. Very recently, Orai1 has been shown to be essential for SOCE also in 
mice [36-38]. 
The next relevant SOC channels are the mammalian homologues of the 
transient receptor potential (TRP) family, classified into three closely related 
subfamilies (TRPC, TRPV and TRPM), and two additional distantly related 
subfamilies (TRPP and TRPML). There is considerable evidence supporting a 
role for some members of the canonical TRP (TRPC) subfamily in SOCE. This 
subfamily involves seven related members (TRPC1-7) [27]. Using different 
approaches, such as overexpression of specific TRPC proteins, in vitro 
knockdown or in vivo knockout of endogenous TRPC and pharmacological 
studies, it was possible to determine that several TRPC proteins can be 
activated by depletion of intracellular Ca2+ stores, being potential SOC channel 
candidates [27]. 
In addition to TRPC channels, other members of the TRP family have been 
suggested to be potential mediators of SOCE, for instance TRPV6 (CaT1) 
[39,40]. 
Interestingly, experiments using the in vivo knockout approach in mouse 
strongly suggested that the importance of the different SOC channels in SOCE 
could be highly dependent on the tissue or cell type. For instance, TRPC1 
deletion in mice has very few or no significant effect on platelets, while Orai1 
deletion dramatically reduces SOCE, indicating Orai1 as the main SOC channel 
in platelets [36,41]. However, an 80 % loss of SOCE has been found in 
submaxillary acinar cells of TRPC1 knockout mice [42]. 
Finally, recent studies also suggested that Orai and TRPC isoforms may 
interact directly or indirectly forming heteromeric complexes in order to regulate 
SOCE [43]. Thus, the role of Orai and TRPC in SOCE appears to be complex 
and the underlying mechanisms are not well understood.  
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2.2. Stromal Interaction Molecule 2 (STIM2) 
 
In 2001, STIM2 was identified as a new human homologue of the STIM1 gene, 
representing the second member of a two-gene family in vertebrates [44]. The 
Stim2 gene contains 12 exons and 11 introns located on the human 
chromosome 4p15.1, and on the large arm of the mouse chromosome 5, close 
to the centromere.  
The members of STIM family most probably have evolved from a single gene in 
lower multicellular eukaryotes into two related genes in vertebrates, since 
human STIM1 and STIM2 as well as Drosophila melanogaster Stim (D-Stim) 
have a conserved genomic organization. The D-STIM protein of 570 aas 
exhibits equal similarity to both STIM1 (33 % identical; 50 % of amino acid 
sequence conserved) and STIM2 (31 % identical; 46 % of amino acid sequence 
conserved). No STIM-like genes have been identified in prokaryotes or 
unicellular eukaryotes. No additional STIM-like proteins have been identified 
until now in vertebrates [44]. 
STIM2 protein is a type I transmembrane protein located in the ER. Human 
STIM2 consists of 833 amino acid residues (aas) (105-115 kDa) (Fig. 2), 148 
additional aas when compared to human STIM1. Their N-terminal regions share 
66 % similarity over 577 aas (85 % of the amino acid sequence of STIM1). Only 
the extreme of the C-terminal region shows a significant sequence divergence. 
The domain architecture of both isoforms is highly conserved in vertebrates 
(Fig. 2).  
Mouse STIM2 shares a 92 % identity with human STIM2 in the aminoacid 
sequence according the pairwise alignment generated by BLAST 
(http://blast.ncbi.nlm.nih.gov/). Their domain structure is also highly conserved 
(Fig. 2).  
Human STIM2 is post-translationally modified in vivo, such as maturation by 
cleavage of N-terminal ER signaling peptide (14 aas), glycosylation and variable 
degrees of phosphorylation, but the phosphorylated sites are still unknown 
(Fig. 2) [44]. 
STIM2 mRNA is expressed by most human tissues. The STIM2 protein is 
expressed by many human cell lines together with STIM1, indicating that STIM 
isoforms are co-expressed in the same cell, at least in the established cell lines 
[44]. 
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Figure 2. STIM protein family. Representation of domain organization of the STIM family in 
human (hSTIM), mouse (mSTIM) and drosophila (D-STIM). N and C represent the amino- and 
the carboxyl-terminus, respectively. Colour boxes represent the different domains. Numbers 
above and below the domains indicate their boundaries and the amino acid position. (CC) pair 
of highly conserved cysteines. (G) glycosylation sites. Boundaries of EF-hand and SAM motifs 
in hSTIM were biophysically characterized by [45-47], while transmembrane, coiled-coil and 
Ser/Pro/His/lys regions were predicted by computer models and protein sequence alignment. 
Boundaries of mSTIM and D-STIM were predicted by computer models and protein sequence 
alignment.  
 
 
2.2.1. Domain architecture 
 
The N-terminal region of STIM2 is located in the ER lumen and contains a 
canonical EF-hand Ca2+-binding motif, a “hidden” EF-hand Ca2+-binding motif 
discovered recently and a sterile -motif (SAM) domain, a well-known protein–
protein interaction motif (Fig. 2) [48-50]. 
The N-terminal portion is separated from the C-terminal region by a single-pass 
transmembrane motif that is highly conserved in all STIM proteins. The C-
terminal region contains a high degree of -helical structures. A large proportion 
close to the transmembrane domain comprises a region similar to an 
ezrin/radixin/moesin (ERM) domain that contains two coiled-coil domains (for 
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review see [51]). The coiled-coil domains mediate interactions between STIM 
proteins, allowing them to bind each other and form homo and heterodimers 
(Fig. 2) [52-54]. 
Finally, further towards the C-terminus, STIM2 contains a proline/histidine-rich 
motif and a lysine-rich tail of 17 aas (Fig. 2) [44]. 
 
 
2.2.1.1. EF-hand-SAM region 
 
Since the EF-hand and SAM (EF-SAM) domains are vital to STIM function and 
SOCE regulation, they are now discussed in detail. The EF-hand domain is a 
Ca2+ sensor used by STIM protein to detect changes in Ca2+ concentration 
inside the ER. STIM isoforms become activated when Ca2+ bound to the EF- 
hand motif is released as a result of a decrease in Ca2+ levels inside the ER 
store after IP3Rs–mediated depletion. It has been reported that STIM EF-hand 
mutants that are not able to bind Ca2+ are constitutively active and continually 
activate SOCE independently of ER [Ca2+], in vitro [2,32,55] and in vivo [56]. 
The SAM domain is important for STIM oligomerization, since mutants in this 
domain lack the ability to form inducible punctae [57]. 
Ca2+-binding  experiments in vitro using human STIM1 EF–SAM (residue 58–
201) or STIM2 EF–SAM (residue 149–292) fragments show that both isoforms 
bind Ca2+ with similar affinity (STIM2 Kd~0.5 mM; STIM1 Kd~0.2–0.6 mM) 
[45,58], which is within the range of values reported for ER [Ca2+] [19,20]. 
However, STIM2 differs from STIM1 in that it is already partially active at basal 
ER [Ca2+] and becomes fully activated earlier during ER store depletion. 
Despite the same Ca2+ affinity shown by STIM EF-SAM fragments, the full 
STIM2 protein showed a lower [Ca2+] sensitivity than STIM1 in transfected cells 
in vitro [9]. This discrepancy indicates that other protein regions in addition 
contribute to the different [Ca2+] sensitivity or activation threshold shown by both 
isoforms. 
The “hidden” EF-hand domain does not bind Ca2+, but it is critical for 
intramolecular association, folding and stability of the EF-hand and SAM 
domains. Very recently it has been reported that structurally critical mutations in 
the canonical EF-hand, ‘‘hidden’’ EF-hand, or SAM domain disrupt Ca2+ 
sensitivity due to the destabilization of the entire EF-SAM region [46]. 
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2.2.1.2. C-terminal region 
 
Besides the N-terminus, the C-terminal region is also an essential part of STIM 
proteins. It shows a significant sequence divergence between both isoforms and 
in STIM1, the C-terminal region is essential for the interaction with SOC 
channels [59]. Human STIM2 contains a proline- and histidine-rich motif 
(PHAPHPSHPRHPHHPQHTPHSLPSPDP) at a similar position to a serine- and 
proline-rich region (SPSAPPGGSPHLDSSRSHSPSSPDPDTPSP) in STIM1. 
The significant divergence in these regions could indicate a divergence in 
function of STIM isoforms. Finally, similar lysine-rich tails of 14 and 17 residues 
in STIM1 and STIM2 respectively are located at the very end of the C-terminal 
region. 
Linear peptides from C-terminal polybasic region of human STIM1 (residues 
667-685) and STIM2 (residues 730-746) bind to calmodulin with high or low 
affinity in presence or absence of Ca2+, respectively [60]. Most of studies on 
interactions of the C-terminal region have been performed with the STIM1 
isoform. The addition of TG (the SERCA pump inhibitor that stimulates SOCE 
by passive depletion of intracellular Ca2+ stores) to human salivary gland cells 
as well as dispersed mouse submandibular gland cells increase 
coimmunoprecipitation of TRPC1 and Orai1 with STIM1 [61].  
By in vitro co-expression of different human STIM1 mutants that lack the 
different C-terminal regions in HEK293 cells, three recent works reported that 
the ERM domain in the C-terminus (aas 251-535, Fig. 2), containing the coiled-
coil domains, mediates the binding of STIM1 to TRPC(1, 2,4 and 5) and the 
STIM1 migration to the plasma membrane.  
Furthermore, the cationic lysine-rich region is essential for gating of TRPC1 
[54,59,62]. Li et al. further delineated these regions (aas 425-672) as possible 
STIM1-Orai1 interaction sites [54]. Interestingly, in vitro coimmunoprecipitation 
experiments after transient coexpression of STIM2 and Orai1 proteins in 
HEK293 cells revealed that also STIM2 can physically interact with Orai1, 
probably though the STIM2 C-terminal region [63]. 
 
 
2.2.2. STIM2 function 
 
The STIM2 function has been controversial and still is under discussion. First 
studies found that iRNA knockdown of STIM1, but not STIM2, strongly reduced 
SOCE in mammalian cells [2-4,9,64]. Liou et al. reported a slight reduction in 
SOCE also by knockdown of STIM2 in HeLa cells [2]. Soboloff et al. suggested 
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that STIM2 inhibits SOCE when expressed alone [53], but coexpressed with 
Orai1 causes substantial constitutive SOCE [65]. In contrast, Brandman et al. 
suggested that STIM2 could act as a regulator that stabilizes basal [Ca2+]i and 
ER Ca2+ levels [9]. Parvez et al, using in vitro transient coexpression of human 
STIM2 and different SOC channels in HEK293 cells, reported that STIM2 is 
able to interact with Orai (1,2 and 3) channels and mediates SOCE via two 
store-dependent and store independent modes [63]. Therefore, further studies 
are necessary in order to understand STIM2 function in the cell. 
 
 
2.3. Platelets 
 
 
Figure 3. Platelet structure (kindly donated by Dr. Ginés Escolar, Platelet Research 
Laboratory, Hospital Clínic, Barcelona: http://www.platelet-research.org/1/intro.htm). 
 
Platelets are 2 µm diameter discoid cell fragments derived from the cortical 
cytoplasm of the megakaryocytes located in the bone marrow and are only 
present in mammals. Their physiological number in blood varies from 1.5 x105 
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to 3x105 platelets per μl in humans, and 1x106 platelets per μl in mice. Their life 
span is only 10 days, before they are cleared from the blood stream by 
macrophages in liver and spleen. They play an important role in hemostasis, 
thrombosis, and several other biological processes. Platelets are anucleated but 
still conserve a cytoskeleton and intracellular organelles such as mitochondria, 
glycogen granules, storage granules (-granules and dense granules), 
lysosomes, and peroxisomes (Fig. 3). The -granules contain proteins such as 
platelet factor 4 (PF4), -thromboglobulin (-TG), platelet derived growth factor 
(PDGF), fibrinogen, thrombospondin, plasminogen activator inhibitor I, von 
Willebrand factor (VWF), P-selectin and glycoprotein (GP) IIbIIIa (IIb3) [66]. 
Dense granules contain Ca2+, adenosine triphosphate (ATP), adenosine 
diphosphate (ADP), pyrophosphate, serotonin and histamine [66,67]. Upon 
platelet activation, the contents of platelet granules are secreted, further 
promoting both platelet adhesion and activation. The plasma membrane 
extends into the cytoplasm forming a complex canalicular system into the cell 
[68]. 
Under normal conditions, resting platelets circulate close to the endothelial wall 
of the blood vessel. As a response to vascular injury and subsequent exposure 
to subendothelial extracellular matrix (ECM) platelets rapidly become activated, 
adhere to ECM and to each other to form a platelet plug, which allows the 
reestablishment of normal blood flow and avoids blood’s leakage in the 
disrupted blood vessels (Fig. 4) [69]. Upon platelet activation, platelets change 
shape to a spherical structure and extend long pseudopods, a process driven 
by cytoskeleton rearrangement, and the contents of platelet granules are 
secreted, further promoting both platelet adhesion and activation (Fig. 4). 
Although murine platelets differ from human platelets in numbers, size, and 
structure, functionally they are very similar and murine transgenic models have 
been shown to be very useful to study platelet physiology [70,71]. 
 
 
2.3.1. Platelet activation pathways 
 
Activation of platelets is a complex process that includes stimulation of plasma 
membrane receptors, reorganization of the cytoskeleton involved in shape 
change and relocation of intracellular secretory granules, secretion of 
substances and secondary autocrine and paracrine activators that further 
activates receptors in the plasma membrane. Upon injury of the blood vessel, 
the first step of platelet activation is triggered by adhesion to subendothelial 
matrix proteins such as collagens, laminins, fibronectin or vWF (Fig. 4). 
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Additionally, other soluble agonist circulating in the blood such as thromboxane 
A2 (TxA2) and ADP released from activated platelets, and thrombin generated 
by the coagulation cascade can trigger platelet activation [69]. 
The mechanisms of platelet adhesion are determined by the prevailing 
rheological conditions. Blood flows with a greater velocity in the centre of the 
vessel than near the wall, thereby generating shear forces between adjacent 
layers of the fluid that become maximal at the wall. The drag, which opposes 
platelet adhesion and aggregation, increases with the prevailing shear rates. 
Under conditions of high shear, such as is found in small arteries and arterioles, 
this tethering event is mediated by the platelet receptor glycoprotein (GP)Ib-
IX-V receptor complex via VWF bound to collagen. However, this interaction is 
not relevant under conditions of low shear found in veins and large arteries. The 
GPIb-VWF interaction is insufficient to mediate stable adhesion, presenting a 
fast association and dissociation, allowing platelets to slow down and move in 
close contact with the vessel wall on the site of vascular injury, a process also 
known as ‘‘rolling’’ [72,73]. During this phase, platelets establish contacts with 
its two main collagen receptors: GPVI and integrin 21 [73]. GPVI binds 
collagen with low affinity, therefore is unable to mediate adhesion by itself, but 
triggers an inside-out activation of integrin IIb3 and 21 that change from a 
low- to high-affinity binding state [73,74] and induce the release of the second 
wave mediators TxA2, ADP and epinephrine. These agonists together with 
locally produced thrombin (a protease which cleaves and activates PAR1 and 
PAR4 receptors) act synergistically stimulating receptors coupled to 
heterotrimeric G-proteins (Gq, G12/G13, Gi) [75], which activates different Ca2+-
dependent signaling cascades required for full platelet activation (Fig. 4). 
Activated 21 now binds collagen strongly, and together with other high-affinity 
β1-integrins which bind to fibronectin (51) and laminin (61) as well as the 
major platelet integrin IIb3 which binds with fibronectin and vWF bound to 
collagen, finally results in stable platelet adhesion. The secretion of the second 
wave mediators is a self-amplifying process that allows the recruitment of 
additional platelets for the formation of the growing thrombus, since high 
concentrations of these soluble agonists may be sufficient to mediate platelet 
activation independently of GPVI [76]. Platelet-platelet interactions are mainly 
mediated by the active form of integrin IIb3 through the plasma protein 
fibrinogen (Fig. 4). Finally, it has been shown that GPIb is also important in the 
recruitment of additional platelets to the growing thrombus [77]. 
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Figure 4. Model for platelet adhesion to the subendothelial matrix at sites of vascular 
injury. The GPIb–vWF interaction mediates the initial contact (tethering) to the exposed ECM in 
the vessel wall, essential at high shear rates ( > 500 sec-1). In a second step, GPVI–collagen 
binding initiate cellular activation followed by shifting of integrins from low- to high-affinity state 
and the release of second-wave agonists, such as ADP, ATP, and TxA2. In parallel, the 
exposed tissue factor (TF) in the ECM locally triggers the formation of thrombin, which cleaves 
and activates PAR1 and PAR4 receptors, acting synergistically together with GPVI, and 
mediates cellular activation and firm adhesion. Finally, the firm adhesion of platelets to collagen 
through activated 21 and IIb3 results in sustained GPVI signaling and enhanced release of 
second-wave agonists. Released ADP, ATP, and TxA2 amplify integrin activation on adherent 
platelets, allowing the recruitment of additional platelets for the formation of the growing 
thrombus. Platelet-platelet interactions are mainly mediated by the active form of integrin IIb3 
through the plasma protein fibrinogen. Picture source: [69]. 
 
 
2.3.2. Platelet activation and Ca2+ homeostasis 
 
A central event in the platelet activation is an increase in the intracellular Ca2+ 
concentration (Fig. 5). Although different agonists trigger different signaling 
pathways, most activate PLC isoforms, leading to production of DAG and IP3, 
following a classical activation cascade (described in section 2.1.1) that finally 
triggers SOCE. IP3 induces release of Ca2+ from the ER, while DAG is involved 
in Ca2+ entry from the extracellular compartment by activation of non-store-
operated Ca2+ channels, such as some members of the TRP family [11,78]. 
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Figure 5. Signaling mechanisms linking platelet receptors to integrin activation. Collagen-
GPVI interaction activates the ITAM-signaling pathway, which in turn activates PLC isoforms, 
whereas stimulation of G protein–coupled receptors by thrombin, thromboxane (TxA2) or ADP 
triggers pathways involving Gq, Gi/z,G12/13, which in turn activate PLC isoforms, 
phosphoinositide-3-kinase (PI-3-K), Rho-specific guanine nucleotide exchange factor (Rho-
GEF) and inhibits adenylyl cyclase (AC). The diacyl glycerol (DAG) and the inositol-1,4,5-
trisphosphate (IP3) generated by PLC isoforms increases the [Ca2+]i, which leads to aggregation 
and the secretion of second-wave mediators, while Rho-GEF activates RhoA-dependent 
pathways that in turn regulates actin cytoskeleton and leads to platelet shape change. Adhesion 
molecules such as integrins, GPIb-IX-V complex or GPVI also activates PLC isoforms, leading 
to a further increase of [Ca2+]i. Inhibition of AC activity by ADP and epinephrine receptors avoids 
activation of cAMP-dependent inhibition pathways. Picture source: David Varga-Szabo et al. 
Arterioscler. Thromb. Vasc. Biol. 2008;28;403-412. 
 
In platelets, two subfamilies of the PLC enzymes are expressed, the PLC 
(comprising four isoforms, 1-4) and the PLC (comprising two isoforms, 1-2). 
Human platelets express the 1-3 and the 2, whereas mouse platelets express 
all isoforms. In both, 3 and 2 are the predominant isoforms, together with 2 
in humans and 1 in mouse platelets [79,80].  
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The PLC isoforms are regulated by GPCRs through the -subunit of the G-
protein Gq, in response to soluble agonists such as thrombin (PAR1 and PAR4 
receptors in humans and PAR3 and PAR4 receptors in mice), ADP (P2Y1), and 
TXA2 (TP and TP). Additionally, PLC2 can be also regulated by 
phosphatidylinositol 3-Kinase (PI-3-K), which is activated by the ADP receptor 
P2Y12 (coupled to the G-protein Gi) (Fig. 5) [81]. 
PLC2 is located downstream the signaling cascade similar to that used by 
immunoreceptors and involves tyrosine phosphorylation cascades downstream 
of the receptor-associated immunoreceptor tyrosine activation motif (ITAM). 
This pathway is triggered by activation of the major platelet collagen receptor 
GPVI, the platelet adhesion complex vWF-GPIb-V-IX and CLEC-2, the receptor 
for the snake venom toxin rhodocytin (Fig. 5). The PLC2 isoform is also 
regulated by the Fc receptor IIA (FcRIIA) in human platelets [73,82-85].  
Activation of GPVI leads to tyrosine phosphorylation of the ITAM located in the 
FcR-chain by the Src kinases Fyn and Lyn. This leads to phosphorylation and 
subsequent activation of the SH2 domain–containing tyrosine kinase (Syk), 
which phosphorylates the adaptor molecule “linker for activation of T cells” 
(LAT), which in turn recruits additional adaptor molecules such as SRC-
homology-2-domain-containing leukocyte protein of 76 kDa (SLP76) and 
effector enzymes including PLC2, finally leading to Ca2+-mobilization [73]. 
There are evidences that the signaling pathway downstream CLEC-2 and the 
vWF-GPIb-V-IX complex might be similar to GPVI signaling, but how the 
molecules exactly co-operate in both pathways is not clear. The main players 
also include the non-receptor tyrosine kinases Src, Fyn, Lyn and Syk, adapter 
proteins such as LAT and SLP-76 and the effector enzyme PLC2 (Fig. 5) 
[82,83]. 
The PLC2 isoform is also regulated by integrins such as IIb3 and 21, 
during a series of intracellular events referred to as “outside-in signaling”. This 
process is activated by ligand-integrin interactions and leads to stable platelet 
adhesion (for review, see [86]). For instance, upon fibrinogen binding to integrin 
IIb3, the integrin cytoplasmic tail becomes associated with actin skeleton 
through interactions with cytoskeletal proteins like talin, vinculin and actinin. 
Then, a number of signaling molecules are recruited: serine/threonine and 
tyrosine kinases (PKC, Src, Syk, FAK, PI-3-K), serine threonine and tyrosine 
phosphatases (PP2A, PTP1B, SHP1) and SHIP among others, which finally 
leads to PLC activation (for review, see [86]). 
Concerning to the intracellular structure, platelets show a more specialized 
intracellular store system than other eukaryotic cells. Two separate Ca2+ stores 
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have been reported in human platelets: the dense tubular system (DTS, the 
equivalent to the ER in other mammalian cells) and lysosome-like acidic 
organelles (Fig. 3) (for a review, see [21]). There is consensus that the major 
intracellular Ca2+ pool in platelets is the DTS. The complete identity of the acidic 
stores has not been clarified yet, several acidic organelles show properties of 
releasable Ca2+ pools, including lysosomes, dense granules, and the Golgi 
apparatus.  
Two of the three IP3R isoforms have been found in platelets, IP3R1 and IP3R2. 
Pharmacological evidence suggested the existence of two distinct Ca2+ stores 
based on their differences in the affinity to IP3 [87] or their sensitivity to the 
SERCA inhibitor thapsigargin and to 2,5-di-(t-butyl)-1,4-hydroquinone (TBHQ) 
[87-89].  
The release of Ca2+ from the described intracellular stores induces SOCE, 
basal [Ca2+]i rises and activates Ca2+-dependent effector pathways in 
platelets. For example, the Ca2+-dependent Calmodulin (CaM) activates the 
myosin light chain kinase (MLCK), which in turn phosphorylates myosin light 
chains (MLC) inducing actin cytoskeleton remodelling and triggering platelet 
shape change [86]. Phosphorylation of MLC can be also regulated by the Ca2+-
independent Rho/ROCK pathway. This pathway is stimulated by the G12 and 
G13 proteins coupled to PAR receptors, which are activated by thrombin and 
TxA2 [90,91].  
DAG also activates protein kinase C (PKC) involved in the “inside-out” integrin 
activation and the secretion of granules with contains the second wave 
mediators.  
Studies also identified a Ca2+-sensitive signaling pathway that acts 
synergistically with PKC in the “inside-out” activation of integrin αIIbβ3. The 
CalDAG-GEFI/Rap1 signaling pathway is regulated by elevations in [Ca2+]i and 
DAG, and has been reported to play an essential role in platelet aggregation 
and thrombus formation [92,93]. 
 
 
2.4. Lymphocytes T, mast cells, macrophages and Ca2+ 
signaling 
 
In cells of the immune system, including T cells, B cells, mast cells, 
macrophages and other cell types, Ca2+ signals control differentiation, 
proliferation, apoptosis, and a variety of transcriptional programs, including 
production of cytokines and chemokines. Most of these events need sustained 
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Ca2+ influx to keep the [Ca2+]i higher than basal levels [25,94]. In immune cells, 
the predominant pathway of Ca2+ entry is thought to involve SOCE, a 
mechanism that was described before in chapter 2.1. CRAC channels (SOC 
channels in immune cells) such as Orai are expressed in lymphocytes [25]. The 
existence of patients with severe combined immunodeficiency (SCID) 
associated with defects in Orai channel function and SOCE highlights the 
importance of CRAC channels and such a Ca2+ influx mechanism in immune 
response in human [34,95-97]. 
Other Ca2+ channels have been found in lymphocytes, such as P2X receptors, 
L-type voltage-gated Ca2+ channel subunits, TRPV channels, TRPC channels, 
and some TRPM channels, but their physiological importance in lymphocytes is 
a hot topic still in discussion [25,98,99]. 
CRAC channels open in response to activation of immunoreceptors, such as T 
cell receptor (TCR) in T cells and the Fc receptors (FcR) in mast cell and 
macrophages, resulting in tyrosine phosphorylation and activation of PLC1 
[25,98,100]. 
 
 
2.4.1. T cell activation pathways and Ca2+ signaling 
 
Several subsets of T cells have been characterized. The most important are the 
T helper (TH or CD4+) and the T cytoxic (TC or CD8+) cells, each with a distinct 
function in the adaptive immune system (specific defense to pathogens). CD4+ 
cells are involved in activating and directing other immune cells and are very 
important in the immune system, while CD8+ cells are capable of inducing the 
death of infected somatic cells, tumor cells, damaged or dysfunctional cells. 
The main activating pathway in T cells involves the T cell receptor (TCR) 
complex, which consist in six different transmembrane proteins (Fig. 6). These 
proteins include the Ag-binding subunits (TCR) that are non-covalently 
associated with the signal-transducing chains CD3, CD3, CD3, and TCRζ 
and/or TCRη [25]. All these signaling chains contain an ITAM sequence. Upon 
antigen recognition, these molecules associate together forming the TCR-CD3 
complex. One of the initial events following TCR-CD3 complex formation is the 
phosphorylation of tyrosine residues in the ITAM motifs, a process regulated by 
the Src-family protein tyrosine kinases (PTKs) Lck or Fyn (Fig. 6). This event 
results in the recruitment and activation of a second family of PTKs, such as 
LCK and ZAP70, which initiate phosphorylation events of adaptor proteins, such 
as SLP76 and LAT. This leads to the recruitment and activation of the 
   
 -32- 
  Introduction 
interleukin-2-inducible T-cell kinase (ITK), PLC1 and subsequent depletion of 
the intracellular Ca2+ stores and SOCE (for a review, see [101]). 
 
Ca2+
Ca2+ Ca2+
ER
IP3R
 
Figure 6. Simplification of the activating signaling cascade in T-cells. Antigen recognition 
through the TCR results in the activation of protein tyrosine kinases, such as LCK and ZAP70 
(ζ-chain-associated protein kinase of 70 kDa), which initiate phosphorylation events of adaptor 
proteins, such as SLP76 (SRC homology-2-domain-containing leukocyte protein of 76 kDa) and 
LAT (linker for activation of T cells). This leads to the recruitment and activation of the TEC 
kinase ITK (interleukin-2-inducible T-cell kinase), the adaptor molecule GADS (GRB2-related 
adaptor protein) and phospholipase C1 (PLC1). Similarly, binding of G-protein-coupled 
chemokine receptors results in the activation of PLC. PLC1 and PLC catalyse the hydrolysis 
of the membrane phospholipid phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P2) to IP3 
(InsP3) and DAG. IP3 binds to and opens IP3Rs in the membrane of the ER, resulting in the 
release of Ca2+ from intracellular Ca2+ stores. Modification of the original picture: [25].  
 
 
2.4.2. Mast cell activation pathways and Ca2+ signaling 
 
Two subclasses of Fc receptor (FcR) for immunoglobulin E (IgE) exist: low 
affinity receptors (FcRII) and high affinity receptors (FcRI). In mast cells, the 
main activating pathways involve the FcRI, expressed at the cell surface. Mast 
cells contribute to host-defense mechanisms that are associated with innate 
immunity (non-specific defense) and play a central role in allergic inflammatory 
responses (Fig. 7). 
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Figure 7. Simplification of the activating signaling cascade in mast cells. In mast cells, 
following FcεRI aggregation, the adaptor molecule LAT becomes phosphorylated in a LYN- and 
SYK (spleen tyrosine kinase)-dependent manner. This results in direct or indirect binding of 
cytosolic adaptor molecules to LAT, for instance GADS (GRB2-related adaptor protein) and 
SLP76, as well as exchange factors and adaptor molecules such as VAV and the signaling 
enzyme PLC1. The release of Ca2+ from intracellular Ca2+ stores follows the activation of PLC, 
which leads to an increase of [Ca2+]i. Modification of the original picture: [102]. 
 
They are also responsible for the exaggerated reactions to antigen observed in 
anaphylaxis, atopy, and rhinitis [103]. Although multiple receptors are capable 
of mediate or modify mast cell activation, the manifestations of mast-cell-driven 
allergic reactions are considered to be mainly a consequence of the release of 
potent inflammatory mediators after mast cell activation by the IgE-antigen 
complex bound to FcRI. This receptor is a tetramer that comprises an -chain, 
a -chain and two -chain (forming a homodimer linked by a disulphide bridge) 
(for a review, see [102]). The -chain is responsible for binding IgE, the -chain 
and the -chain contains one and two ITAM motif respectively, and they are 
responsible for initiating signaling. FcRI requires the recruitment and activation 
of Src family tyrosine kinases and Syk to induce the early receptor-proximal 
signaling events (Fig. 7). Syk is recruited via ITAM motifs located in the -chain-
cytoplasmic domains. The resulting phosphorylation of Syk and subsequent 
activation, leads to the phosphorylation of the transmembrane adapter 
molecules LAT. Upon phosphorylation, these proteins serve as scaffolds for 
PLC1 and multimolecular signaling complexes comprising various cytosolic 
adapter molecules such as Gads, Grb2, SLP76, and SHC as well as GTP 
exchangers including Sos and Vav1. As a result, PLC1 switches to the active 
state, giving rise to stored Ca2+ depletion and SOCE. Finally, these signals lead 
to mast cell degranulation and eicosanoid generation and also contribute to 
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activation of transcription factors required for cytokine and chemokine 
production (for a review, see [102]). 
 
 
2.4.3. Macrophage activation pathways and Ca2+ signaling 
 
 
Figure 8. Simplification of the activating signaling cascade in macrophages. Syk kinase is 
activated after FcR (for instance FcRIII) aggregation and ITAM phosphorylation. Subsequent 
signaling pathways associated with the activation by FcRs are similar to that observed for other 
ITAM-containing receptors such as TCR in T cells. Picture source: [104]. 
 
Macrophages are phagocytes derived from activated monocytes that play an 
important role in innate and adaptive immunity. Their role is to engulf and digest 
cellular debris and pathogens or act as antigen presenting cells (APC) to 
stimulate lymphocytes and other immune cells to respond to pathogens. The 
main activating pathways in macrophages involve the IgG Fc receptors (FcR), 
expressed at the cell surface. FcRs belong to the immunoglobulin 
superfamily and are the most important Fc receptors for inducing phagocytosis 
of opsonized (IgG-coated) pathogens. They are also expressed in other cells 
such as mast cells, neutrophils, eosinophils or dendritic cells [104]. In the 
mouse, there are 3 classes of activating FcR: the high affinity receptor FcRI, 
the low-affinity receptor FcRIII, and the recently described FcRIV [127]. All of 
these FcRs form heterooligomeric complexes with the FcR -chain (FcR), 
which contains an ITAM motif that is required for cell activation (Fig. 8). The 
IgG-antigen complex is detected by the FcRs and crosslinks with the FcR. 
This complex formation results in tyrosine phosphorylation of the ITAM motif 
with subsequent recruitment of SH2-containing molecules, Syk kinase and 
adaptor proteins that regulate the activation of PLC1 and other effector 
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proteins (Fig. 8). Subsequent signaling pathways associated with the activation 
by FcRs are similar to that observed for other ITAM-containing receptors such 
as TCR in T cells. Finally, activation of PLC leads to increase of cytoplasmic 
IP3 and IP3R-mediated release from intracellular Ca2+ stores (for a review, see 
[104]). 
 
 
2.4.4. Ca2+-dependent effector signaling in cells of the immune system 
 
As a result of the elevated [Ca2+]i, several Ca2+-dependent signaling proteins 
are activated, such as the Ca2+- calmodulin-dependent kinase (CaMK) and its 
target cyclic- AMP-responsive-element-binding protein (CREB), the 
phosphatase calcineurin and its target nuclear factor of activated T cells 
(NFATs), the myocyte enhancer factor 2 (MEF2) which is activated via the 
calcineurin and CaMK pathways, as well as the nuclear factor kappa B (NFB) 
[25,105]. In addition, Ca2+ signaling directly regulates the Ras-MAPK signaling 
pathway, which plays an important role during double-negative and double-
positive selection stages during thymocyte maturation [106-108]. 
Simultaneously, after PIP2 hydrolysis by PLC, liberated DAG can directly 
activate non-store-operated Ca2+ influx through some TRPC channels and 
stimulate the GTPase Ras–mitogen-activated protein kinase signaling cascade, 
which in turn activates the AP-1 transcriptional complex (that includes c-Jun and 
c-Fos proteins). In lymphocytes, the transcription factors AP-1, NFAT and NF-
B modulate gene expression [17,25,105,109]. Thus Ca2+ signaling is 
integrated with other signaling pathways, resulting in cytokine gene expression, 
cell proliferation and a activation of a large number of activation-associated 
genes [94,110]. 
 
 
2.5. Neurons and Ca2+ signaling 
 
In neurons, Ca2+ signals derived from intracellular stores or extracellular space 
are essential for fundamental functions, including synaptic transmission and 
plasticity. Under pathological conditions, such as cerebral ischemia, a ´calcium 
overload´ can induce neuronal cell death [11,111-114].  
Two principal types of Ca2+ channels are firmly established to mediate Ca2+ 
entry into neurons: voltage-operated Ca2+ channels (VOCCs) and ionotropic 
receptor-operated (ligand-gated) channels (ROCs), including N-methyl-D-
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aspartate receptors (NMDARs) and some -amino-3-hydroxy-5-
methyliooxazole-4-propionate acid receptors (AMPARs), which are activated by 
the excitatory neurotransmitter glutamate, the major excitatory neurotransmitter 
in the central nervous system [115,116]. Glutamate excitotoxicity is a common 
mechanism contributing to neurodegeneration in ischemia [112,114,116].  
The increased [Ca2+]i in neurons is sensed and transmitted by Ca2+-binding 
proteins. Most of them contain EF-hands motifs. The EF-hand proteins in 
neurons comprise the ubiquitous calmodulin, S100 proteins, neuronal Ca2+ 
sensors (NCS), and calmyrins which are similar to NCS [117,118].  
The downstream signaling pathways are complex and mostly related to 
phosphorylation cascades. The main players involved in this process are 
calmodulin (CaM) dependent kinases I-IV (CaMKI-IV), PKC, protein kinase A 
(PKA), IP-3-k, Ca2+-dependent phosphatase calcineurin B, cAMP 
phosphodiesterase, adenylyl cyclise (AC), Ca2+/Calmodulin-dependent neuronal 
nitric oxide synthase (nNOS) and calpains, which are Ca2+-activated proteases 
[112].  
Transcription factors that are dependent on Ca2+ signaling in neurons include 
the NFAT, CREB and the Ca2+-binding downstream regulatory element 
modulator (DREAM), also known as calsenilin [112]. 
Ca2+ release from the ER also occurs in neurons via the RyRs, which are more 
characteristic of neurons and muscle cells and IP3Rs, which are widely 
expressed. The RyR-mediated Ca2+ release has been shown to be very 
important for neuronal plasticity, secretion, gene transcription and other 
neuronal functions [119,120]. In contrast, less is known about the functional 
significance of IP3R-mediated Ca2+ release and the presence of SOC, SOCE 
and store replenishment in neurons [27,121,122]. For instance, PLC1 null mice 
showed epileptic seizures which led to the sudden death of the mice [123]. IP3-
induced Ca2+ release was almost completely abolished in neurons from IP3R 
type I null mice. Most of newborn died perinatally and survivors exhibited severe 
neurological symptoms, ataxia and epilepsy [124]. 
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2.6. Aim of the work 
 
Agonist-induced elevation of [Ca2+]i is a central step in electrically non-excitable 
cells and platelet activation, but the underlying mechanisms are not fully 
understood. A major pathway for Ca2+ entry in non-excitable cells involves 
receptor-mediated release of intracellular Ca2+ stores followed by SOCE. STIM1 
has been shown to play an essential role in activation SOC channels in T-cells. 
However, the STIM2 function in mammalian physiology was in general unknown 
when I started my work. Since the EF-hand domain is highly conserved 
between STIM isoforms it was suspected that STIM2 could be an important 
player in the regulation of Ca2+ homeostasis in platelets. The high divergence in 
the C-terminal region between both isoforms suggested different functions. 
 
The goals of the presented work can be divided into three parts: 
- Generation and characterization of mice with a germline 
knockout of the Stim2 gene. 
- The main goal is to study the function of STIM2 in platelets, 
using STIM2-deficient platelets and the knockout technology as 
in vivo model. 
- Assess STIM2 function in immune cells and neurons, where an 
important role was suspected. 
 
 
 
  Materials 
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3. MATERIALS 
 
3.1. Reagents 
 
1.1.1. Chemicals 
 
2,3,5-triphenyltetrazolium chloride (TTC) 
(Sigma, Germany) 
ADP (Sigma, Germany) 
Adrenaline (Sigma, Germany)  
Apyrase (grade III) (Sigma, Germany) 
Atipamezol (Pfizer, Germany) 
BamHI (Invitrogen, Germany) 
Bovine serum albumin (BSA) (Sigma, 
Germany) 
Carbonyl cyanide m-chlorophenylhydrazone 
(CCCP) (Sigma, Germany) 
Carmine (Sigma, Germany) 
Complete Freund’s adjuvant (CFA) Gibco® 
(Invitrogen, Germany) 
Convulxin (Alexis, San Diego) 
Cyclopiazonic acid (CPA) (Sigma, Germany) 
Collagen-related peptide (CRP) [125] 
DAPI (Merck, Germany) 
DMEM+GlutaMax®-I (Invitrogen, Germany) 
DMSO (Invitrogen, Germany) 
DNP-HAS (Fermentas, Lithuania) 
Dylight-488 (Pierce, Ilynois) 
EcoRI (Invitrogen, Germany) 
Enhanced chemoluminiscence detection 
substrate (ECL) (MoBiTec, Germany)  
Epinephrine (Sigma, Germany) 
FeCl3 (Sigma, Germany) 
Fentanyl (Janssen-Cilag GmbH, Germany)  
Fibrilar type I collagen (Horm) (Nycomed, 
Germany)  
Flumazenil (Delta Select GmbH, Germany)  
Fetal calf serum (FCS) GIBCO® (invitrogen, 
Germany) 
Fura-2 acetoxymethyl ester (AM) (Molecular 
Probes, Oregon)  
Geneticin (G418) (Sigma, Germany) 
H3-Thymidine (Amersham GE Healthcare, 
UK) 
High molecular weight heparin (Sigma, 
Germany) 
Human fibrinogen (Sigma, Germany) 
Ionomycin (Molecular Probes, Oregon) 
Kanomycin (Roth, Germany) 
KLH (Sigma, Germany) 
LIF ESGRO (Millipore, Massachusetts) 
Luxol fast blue (LFB) (Sigma, Germany) 
Medetomidine (Pfizer, Germany) 
Midazolam (Roche Pharma AG, Germany)  
  Materials 
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MOG35-55-peptide (Biotrend, Germany) 
N,N,N´,N´-tetrakis-ethylenediamine (TPEN) 
(Sigma, Germany) 
Naloxon (Delta Select GmbH, Germany)  
Neomycin (Sigma, Germany) 
Non-essential aminoacids (NEAA) 
(Invitrogen, Germany) 
Nonidet P-40 (NP-40) (Roche Diagnostics, 
Germany)  
NotI (Invitrogen, Germany) 
Penicillin/streptomycin (PAN, Germany)  
Pertussis toxin (Alexis, San Diego) 
Pluronic F-127 (Invitrogen, Germany)  
Prostacyclin (PGI2)(Calbiochem, Germany)  
Rhodocytin [126] 
Serotonin (Sigma, Germany) 
Staurosporine (Sigma, Germany) 
Thapsigargin (Molecular Probes, Oregon)  
Thrombin (Roche Pharma AG, Germany) 
Tetramethylbenzidine (TMB) (BD 
Pharmingen, Canada) 
TiterMax adjuvant (Alexis, San Diego) 
U46619 (Alexis Biochemicals, San Diego) 
  Materials 
1.1.2. Buffers 
 
All buffers were prepared and diluted in Milli-Q water. 
LB medium, pH 7.5: Bacto-Tryptone 1 %, yeast extract 0.5 %, NaCl 1 %, all 
from Roth (Germany) 
DNA isolation buffer: Tris-HCl (pH 8.0) 50 mM, EDTA 100 mM, NaCl 100 mM, 
SDS 1 %, all from Roth (Germany),  Proteinase K 100 µg/mL (Invitrogen, 
Germany). 
Phosphate-buffered saline (PBS), pH 7.14: NaCl 137 mM, KCl 2.7 mM, 
KH2PO4 1.5 mM, Na2HPO4x2H2O 8 mM, all from Roth (Germany).  
Tris-buffered saline (TBS), pH 7.3: NaCl 137 mM (0.9 %), Tris-HCl 20 mM, all 
from Roth (Germany). 
LB-Agar plates: LB medium, agar 1.5 %, ampicillin 100 µg/mL or kanomycin 
50 µg/mL. 
Tyrode’s buffer, pH 7.3: NaCl 137 mM, KCl 2.7 mM, NaHCO3 12 mM, 
NaH2PO4 0.43 mM, Glucose 0.1 %, HEPES 5 mM, BSA 0.35 %, CaCl2 1 mM, 
MgCl2 1 mM all from Roth (Germany). 
TE buffer: Tris-HCl 10 mM, EDTA 1 mM (pH 8.0) all from Roth (Germany). 
TAE buffer, pH 8.5: Tris-acetate 40 mM, EDTA 1 mM all from Roth (Germany). 
PCR reaction medium 25 µL: 2.5 μL PCR buffer (10x), 2.5 μL MgCl2 (10x), 
0.5 μL dNTPs (10 mM), 0.5 U Taq polymerase (all from invitrogen, Germany), 
0.5 μL forward primer (100 ng/μL), 0.5 μL reward primer B (100 ng/μL), 25 ng 
DNA, H2O to 25 μL 
FACS buffer: PBS (Invitrogen, Germany), 0.1 % BSA, 2 mM CaCl2 (Roth, 
Germany). 
Tyrosine Phosphorylation lysis buffer, pH 7.5: 300 mM NaCl, 20 mM TRIS, 
2 mM EGTA, 2 mM EDTA, 2 % NP-40, 1 tablet/10 mL Complete Mini (Protease 
inhibitor cocktail, Roche, Germany), 2 mM Na3VO4. 
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ES cell culture 
ES cell freezing medium: DMEM+GlutaMax®-I 70 %, foetal bovine serum 
(FCS, ES Cell tested) 20 %, DMSO 10 % all from invitrogen (Germany). 
ES cell medium: DMEM+GlutaMax®-I 70 %, foetal bovine serum (FCS, ES Cell 
tested) 20 %, non-essential aminoacids (NEAA), 2-mercaptoethanol 2 mM, 
Leukemia inhibitory factor (LIF) 1000 U/mL all from invitrogen (Germany). 
EF medium: DMEM+GlutaMax®-I 70 %, foetal bovine serum (FCS) 10 %, non-
essential aminoacids (NEAA) all from invitrogen (Germany). 
Trypsin-EDTA solution: Trypsin-EDTA ready-to-use 0.25 % (invitrogen, 
Germany). 
ES cell selection medium: ES cell medium, geneticin (G418) 500 µg/mL, all 
purchased from invitrogen (Germany). 
ES cell DNA lysis buffer: Tris-HCL 100 mM (pH 8.5), EDTA 5 mM, SDS 0.2 %, 
NaCl 200 mM (all from Roth, Germany), Proteinase K 100 µg/mL (Invitrogen, 
Germany). 
 
Southern blot analysis 
10XSSC, pH 7.6: Sodium citrate 150 mM, NaCl 1.5 M all from Roth (Germany). 
Church Buffer: Sodium phosphate buffer 0.25 M, EDTA 1 mM, Bovine serum 
albumin (BSA) 1 %, SDS 7 %, Salmon sperm DNA 0.1 mg/mL all from Sigma 
(Germany). 
Denaturation buffer: NaCl 1.5 M, NaOH 0.5 M all from Roth (Germany). 
Gel depurination solution: HCl 0.25 M (Roth, Germany). 
Neutralization Buffer: Tris-HCl 0.5 M (pH 7.2), NaCl 1.5 M, EDTA, 1 mM; 
autoclave all from Roth (Germany). 
Sodium phosphate buffer 0.5 M, pH7.2: Na2HPO4x2H2O (1 M) 34.2 %, 
NaH2PO4xH2O (1 M) 15.8 % all from Roth (Germany). 
Church washing buffer (5L): 200 mL 0.5 M sodium phosphate buffer, 
pH7.2+250 mL 20 % SDS all from Roth (Germany).  
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Western Blot 
Blocking buffer: Fat-free milk powder 5 % (Applichem, Germany), PBS. 
Blotting buffer A: Tris, pH 10.4 0.3 M, Methanol 20 % all from Roth 
(Germany). 
Blotting buffer B: Tris, pH 10.4 25 mM, Methanol 20 % all from Roth 
(Germany). 
Blotting buffer C: ε-amino-n-caproic acid 4 mM (Sigma, Germany), Methanol 
20 % (Roth, Germany). 
Laemmli buffer: Tris 40 mM, Glycin 0.95 M, SDS 0.5 % all from Roth 
(Germany). 
RIPA buffer: Triton-X100 1%, Dioxycholate (DOC) 0.5 %, SDS 0.1 %, NaCl 
150 mL, Tris-HCl pH. 8 50 mM (all from Roth, Germany), Dithiothreitol (DTT) 
10 mM (Sigma, Germany), protease inhibitors cocktail 1 tablet/10 mL (Roche, 
Germany). 
SDS sample buffer, 2X: β-mercaptoethanol (reducing conditions) 10 %, Tris 
buffer (1.25 M), pH 6.8 10 %, Glycerin 20 %, SDS 4 % all from Roth (Germany), 
Bromophenol blue 0.02 % (Sigma. Germany)  
Washing buffer: PBS, Tween 20 0.1 %. 
 
Histology 
Carmine solution: Carmine 0.2 %, aluminium potassium sulphate 0.5 % all 
from Sigma (Germany), filtered. 
Carnoy's Fixative solution: Ethanol 60 %, methanol 30 %, glacial acetic acid 
10 % all from Roth (Germany). 
Eosin solution: Eosin 0.05 % (Sigma, Germany), glacial acetic acid 0.06 % 
(Roth, Germany). 
Hematoxylin solution: Hematoxylin ready-to-use (Sigma, Germany), filtered. 
NISSL solution: Cresyl violet acetate 0.1 % (Sigma, Germany), glacial acetic 
acid 0.3 %, filtered (Roth, Germany).  
PFA fixative solution: Paraformaldehyde (PFA) 4 % in PBS. 
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1.1.3. Plasmids 
 
Topo TA (Invitrogen, Germany) 
PBlueScript KS minus (Stratagene, California) 
PBlueScript KS minus containing IRES – NEO- PGK promoter – LacZ – poly A 
construct 
 
1.1.4. Bacteria 
XL10-Gold® Ultracompetent Cells (Stratagene, California) 
 
1.1.5. Oligonucleotides 
 
BAC probe amplification: 
Stim2/BACprobe_F: 5´-GAAGAGAAGCACAGTCTTTG-3´ 
Stim2/BACprobe_R: 5´-CTGGAAACTGTGGCACGATT-3´ 
 
External probe amplification: 
Stim2/Extprobe_F1: 5´-GTGCTTCAGAGCTTTTCTGT-3´ 
Stim2/Extprobe_R1: 5´-CAAGACTAACACCAAATGAA-3´ 
 
Stim2 gene 5´-arm amplification: 
5´flanking/Stim2KO/i3_F1: 5´-GATTGCTGCCAACTCTGAGT-3´ 
5´flanking/Stim2KO/E4_R: 5`-CTCAACTGTCCAATTGTGAA-3´ 
 
Stim2 gene 5´-arm sequencing: 
5´flanking/Stim2KO/i3_F1: 5´-GATTGCTGCCAACTCTGAGT-3´ 
Stim2KO/i3seq1_F: 5´-GTAGGCTCAGCATGGGAATA-3´ 
Stim2KO/i3seq2_F: 5´-CAGTAAGGAACTTATACATC-3´ 
Stim2KO/i3seq3_F: 5´-GCAGAGAGAATCTTATCCTG-3´ 
Stim2KO/i3seq4_F: 5´-GTTCAGATCCAGTCTTTCC-3´ 
 
3´-arm probe amplification: 
STIM2/BACprobe_F: 5´-GAAGAGAAGCACAGTCTTTG-3´ 
STIM2/BACprobe_R: 5´-CTGGAAACTGTGGCACGATT-3´ 
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Stim2 mouse PCR genotyping 
 
Stim2 wild-type 5´: 5´-CCCATATGTAGATGTGTTCAG-3´ 
Stim2 wild-type 3´: 5´-GAGTGTTGTTC-CCTTCACAT-3´ 
Stim2 knock-out 5´: 5´-TTATCGATGAGCGTGGTGGTTATGC-3´ 
Stim2 knock-out 3´: 5´-GCGCGTACATCGGGCAAATAATATC-3´ 
 
 
3.1.1. Antibodies 
 
Primary antibodies 
Name/Clone Antigen Type Host Final conc. Company 
Dylight-488 
conjugated anti-
GPIX Ig 
derivative 
GPIX IgG1 Rt 5 µg/mL [132] 
PE-Cy5-anti-
GPIb GPIb IgG Rt 5 µg/mL Emfret Analytics 
9EG7 1 integrin IgG2a,κ Rt 1:150 BD Pharmingen 
21H4 2 integrin IgG2b  5 µg/mL Emfret Analytics 
YL1/2 -tubulin IgG2a Rt 1:1000 Chemicon 
RA3-6B2 B220 (CD45R) IgG2a, Rt 1:250 BD Pharmingen 
Asp175 (5A1E) Cleaved-Caspase-3 IgG Rb 1:150 Cell Signaling 
KT3 CD3 IgG2a Rt 1:100 AbD Serotec 
145-2C11 CD3 IgG1, Hm 10 µg/mL eBioscience 
RM4-5 CD4 IgG2a, Rt 1:250 BD Pharmingen 
IM7 CD44 IgG2b, Rt 1:750 BD Pharmingen 
MEL44 CD62L IgG2a, M 1:200 BD Pharmingen 
LY-2(53-6.7) CD8 IgG2a, Rt 1:200 BD Pharmingen 
ULF1 CD9 IgG2a Rt 5 µg/mL [132] 
SPE-7 DNP-HSA IgE M 30 µg i.v.  10 µg/mL Sigma 
BM8 F4/80 IgG2a, Rt 1:250 eBioscience 
290322 FcRI IgG2a Rt 1:200 R&D Systems 
275003 FcRIII IgG2a Rt 1:250 R&D Systems 
2.4G2 FcRII,IIIa IgG2b, Rt 10 µg/mL BD Pharmingen 
9E9 FcRIV IgG Rt 5 µg/mL [127] 
Xia.C3 GPIb IgG2a Rt 5 µg/mL Emfret Analytics 
EDL1 GPIIbIIIa IgG2a Rt 5 µg/mL [132] 
JON1 / 6C10 GPIIb/IIIa IgG2b Rt 
4-100 µg i.v. 
5 µg/ml Emfret Analytics 
JON3 / 5D7 GPIIb/IIIa IgG1 Rt 4-100 µg i.v. Emfret Analytics 
JON/A GPIIb/IIIa IgG2b Rt 5 µg/mL [143] 
6C10 GPIIIa (CD61) IgG2b Rt 5 µg/mL Emfret Analytics 
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p0p6 GPIX IgG2b Rt 5 µg/mL [132] 
DOM1 GPV IgG1 Rt 5 µg/mL [132] 
JAQ1 GPVI IgG2a Rt 5 µg/mL Emfret Analytics 
B56 Ki-67 IgG1,  M 1:20 BD Pharmingen 
AP20 MAP2a/b IgG1 M 1:200 Abcam 
A60 NeuN IgG1 M 1:1000 Chemicon 
4G10 phospho-Tyrosin IgG2b, M 1:1000 Millipore 
BRU1 P-selectin IgG1 Rt 5 µg/mL Emfret Analytics 
STIM1 STIM1 IgG Rb 1:500 Cell Signaling 
STIM2 STIM2 IgG Rb 1:400 Cell Signaling 
STIM2(CT) STIM2 IgG Rb 1:400 ProSci 
H57-597 TCR IgG Hm 1:200 eBioscience 
Hm = hamster      M = mouse      Rb = rabbit      Rt = rat      i.v. = intravenous 
 
 
Secondary antibodies 
Goat anti-rabbit, rabbit anti-mouse and rabbit anti-rat IgG (-HRP) were 
purchased from DAKO (Germany) and Jackson Immunoresearch 
(Pennsylvania). Goat anti-rabbit (-Cy3) was purchased from Dianova 
(Germany). Goat anti-mouse (-Alexa 488) was purchased from BD Bioscience 
(Canada). Goat anti-Hamster was purchased from Jackson Immunoresearch 
(Pennsylvania).  
 
 
 
 
  Methods 
4. METHODS 
 
4.1. Western blot 
 
Western blotting was performed using standard protocols in total protein lysates 
from different mouse organs extracted with RIPA buffer and mixed with 2x SDS 
sample buffer. The mixture was heated at 95 °C for 5 minutes (min) and loaded 
in 7.5 % SDS-PAGE gel. Samples were separated for 1 hour (h) in a SDS-
PAGE chamber (Bio-Rad, California) containing Laemmli buffer at 25 mA/gel 
and transferred onto a polyvinylidene difluoride membrane (Immobilon-P 
transfer membrane, Millipore, Massachusetts). Briefly, Semi-dry blotting was 
performed as follows: One tower of Whatman paper was built in between the 
two electrode surfaces of a dry blotting system (Biometra, Germany). The lower 
layer of Whatman paper was embedded with blotting buffer A, a second layer 
embedded with blotting buffer B was placed on top. The transfer membrane 
was activated with methanol, washed with blotting buffer B and placed on the 
tower of Whatman papers. On top, the gel with the sample was placed and 
finally a further layer of Whatman paper embedded in blotting buffer B was 
placed. The blotting was performed at 60 mA/gel for 1 h at RT. To prevent non-
specific antibody binding, membrane was incubated in blocking buffer overnight 
at 4 °C. The following primary antibodies were used for western blotting: rabbit 
anti-STIM2-CT (1:400, ProSci Incorporated, Poway), rabbit anti-STIM1 (1:500, 
Cell Signaling, Massachusetts), rat anti-α-tubulin (1:1000, Chemicon 
international, Massachusetts). The membrane was incubated 3x with washing 
buffer for 10 min at RT. All HRP-conjugates antibodies were purchased from 
Jackson ImmunoResearch (Suffolk, UK) or Dianova (Hamburg, Germany). After 
several washing steps bound antibodies were detected with enhanced 
chemiluminescent Western LightningTM. 
 
 
4.2. Knockout mice generation 
 
Experiments were conducted in accordance to the regulations of the local 
authorities (Regierung von Unterfranken) and were approved by the institutional 
review boards of all participating institutions. Stim2-/- knockout mice were 
generated by deletion of most part of exon four to seven of the Stim2 gene 
using standard molecular techniques. Mice generation was performed as 
previously described [128]. 
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4.2.1. Isolation of BAC clones containing the Stim2 gene 
 
Genomic DNA clones where isolated from a 129Sv BAC library (Chori, USA) by 
southern blot (described below) using a specific probe targeting the exon 4 of 
the Stim2 gene that had been isolated by PCR using the primers: 
Stim2/BACprobe_F and Stim2/BACprobe_R. 
 
 
4.2.2. Isolation of plasmid DNA from BAC clones 
 
Plasmid DNA was isolated from the BAC clones using the BACHAMTM kit 
(Epicentre®, Wisconsin) according to the manufacturer’s specifications. For the 
isolation of a specific DNA fragment, PCR or DNA restriction enzyme digestion 
were used. 
 
 
4.2.3. Isolation of DNA from agarose gels 
 
PCR products or digested DNA were separated by electrophoresis using a 1 % 
agarose gel. One cm3 of agarose gel containing the desired fragment was 
isolated and DNA fragments were extracted using the PCR NucleoSpin® Extract 
II kit (Macherey-Nagel, Germany). Subsequently, DNA fragments were 
subcloned in the appropriate vector and transformed in XL10-Gold® 
ultracompetent cells (Stratagene, California) using general methods of 
molecular biology. 
 
 
4.2.4. Colony hybridization 
 
Approximately 100 bacteria colonies were picked and transferred to an agarose 
petri dish containing a HybondTM-N+ membrane (Amersham GE Healthcare, 
UK). Bacteria clones grown overnight on the membrane and next day 
membrane was treated as described below for Southern blot method. Positive 
clone containing the Stim2 gene was detected using the same probe used for 
BAC clone identification.  
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4.2.5. Isolation of plasmid DNA from competent bacteria 
 
Plasmid DNA preparations of bacteria cultures - “Mini/Midi/Maxi Preps” – were 
performed according to the manufacturer’s specifications (Qiagen, Germany). 
DNA was resuspended in TA buffer and concentrations were assessed 
photometrically at 260 nm by a BioPhotometer (Eppendorf, Germany). 
 
 
4.2.6. Long term PCR amplification 
 
The 5´- and 3´- homologue arms were amplified using the Triple Master PCR 
System (Eppendorf, Germany), according the manufacturer’s specifications. 
This kit allows amplifying very long DNA products (up to 40 Kb) with a high 
fidelity. 
 
 
4.2.7. Culture of embryonic stem (ES) cells 
 
Generation of feeder cells resistant to geneticin was performed as previously 
described [128]. Feeder cells were obtained from E18 embryos heterozygous 
for a collagen IX null allele which contains a neomycin-resistant cassette [129].  
ES cell culture was performed as previously described [128]. Culture flasks 
were previously prepared with a monolayer culture of irradiated feeder cells, 
which provide the essential factors that keep the pluripotency of the ES cells. 
Frozen R1 ES cells (Andras Nagy Lab, Canada) were thawed and grown in co-
culture on the feeder layer in the presence of ES cell medium. Cells were 
detached with trypsin-EDTA solution and passaged every two days to fresh 
culture flasks containing new feeder cultures. 
 
 
4.2.8. DNA electroporation in ES cells 
 
Approximately 100 µg of Stim2 targeting vector was linearized by 2 h digestion 
with NotI restriction enzyme. Digested targeting vector was purified by gel-
electrophoresis separation and isolation using the PCR NucleoSpin® Extract II 
kit (Macherey-Nagel, Germany). 60 µg of sterile linearized DNA was mixed 
together with 4x107 ES cells in 700 µL PBS and placed into an electroporation 
GenePulser® cuvette (Bio-Rad, California). DNA was electroporated into the 
cells by a pulse of 0.8 kV and 3 µF (the time constant should be 0.04 msec) at 
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RT, using the electroporation system GenePulser XcellTM (Bio-Rad, California). 
The cell death percentage was between 30-50 %. 
 
 
4.2.9. Positive selection of electroporated ES cells 
 
Electroporated cells were seeded in 10 cm culture dish and next day cells were 
positively selected with ES cell selection medium. This medium contains the 
antibiotic geneticin, which kills the wild-type cells that did not incorporate the 
neomycin resistant gene of the targeting vector. Cells were selected for 8 days 
and during this time they formed colonies from a single clone. 360 colonies 
were picked, transferred in 24 well plates and selected for additional 8 days. 
 
 
4.2.10. Freezing ES clones 
 
Cell clones were washed two times with PBS, trypsinized and half of the cells 
were frozen at -80 °C with ES cell freezing medium. The remaining half was 
cultured for 4 days and cells were used for DNA extraction and genotyping. 
 
 
4.2.11. ES cell genotyping 
 
ES DNA was extracted as described below for mouse DNA isolation. Targeted 
stem cell clones were screened by Southern blot as described below using a 
gene specific external probe. Stim2+/- positive ES clones were thawed and re-
cultured for blastocyst injection in collaboration with Dr. Michael Bösl (Max 
Planck Institute of Neurobiology, Martinsried) to generate chimeric mice. 
 
 
4.3. Bone marrow mice generation 
 
For the generation of bone marrow chimeras, 5-6 weeks old Stim2+/+ and Stim2-
/- female mice were irradiated with a single dose of 10 Gy, and bone marrow 
cells from 6 weeks old Stim2+/+ or Stim2-/- mice from the same litter were 
injected intravenously into the irradiated mice (4x106 cells/mouse). Water 
supplemented with 2 g/L neomycin was provided to the mice. Bone marrow 
chimerism was confirmed by western blot, studying the STIM2 expression in 
platelets isolated as described below. 
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4.4. Mouse DNA isolation 
 
5 mm2 of ear tissue was digested in 500 μL DNA digestion buffer at 56 °C 
overnight under shaking conditions. Next day samples were mixed (1:1 vol) with 
Phenol/Chloroform, then vortexed for 5 min and centrifuged at 14000 rpm for 
10 min and the aqueous phase containing the DNA was pipetted and 
precipitated with isopropanol (1:1 vol). After centrifugation at 14000 rpm for 
10 min, the DNA pellet was washed twice with ice cold 70 % ethanol. The DNA 
pellet was left to dry and finally resuspended in 50 μL H2O. 
 
 
4.5. Mouse genotyping 
 
4.5.1. PCR genotyping 
 
Two separated reactions with different primer pairs were performed to amplify 
the wild-type (Stim2 wild-type 5´ and Stim2 wild-type 3´) or the knockout allele 
(Stim2 knockout 5´ and Stim2 knockout). 
 
PCR programs:  
Wild-type allele: 1) 96 °C 3 min; 2) 94 °C 30 sec; 3) 51.5 °C 30 sec; 4) 72 °C 
1 min; 5) repeat step 2.-4. 30 cycles; 6) 72 °C 10 min; 7) 4 °C hold. 
 
Knockout allele: 1) 96 °C 3 min; 2) 94 °C 30 sec; 3) 55 °C 30 sec; 4) 72 °C 
1 min; 5) repeat step 2.-4. 30 cycles; 6) 72 °C 10 min; 7) 4 °C hold. 
 
 
4.5.2. Southern blot 
 
15 μg of ES cell or mouse DNA were digested overnight at 37 °C with 
20 U/sample of BamHI restriction enzyme (Invitrogen, Germany). Next day 
fragments were separated in 0.7 % agarose gel electrophoresis for several 
hours and separation of the bands were documented together with a ruler on a 
UV imaging system (Herolab GmbH Laborgeraete, Germany). Gels were placed 
in gel depurination solution for 10 min, then in denaturation solution 2 x 20 min 
and finally in neutralization solution 2 x 20 min. DNA transfer was performed by 
capillarity in 20 x SSC buffer on HybondTM-N+ membranes (Amersham GE 
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Healthcare, UK). Membranes were air-dried and the DNA was covalently bound 
using a UV-linker (1200 J/m2, UV Stratalinker®1800, Stratagene, California).  
Radioactive labeling of the probe: 50-100 ng of DNA probe was denaturated 
at 95 °C for 5 min and labeled with radioactive 32P--dCTP (50 μCi; Amersham 
GE Healthcare, UK) using the rediprime II labeling kit (Amersham GE 
Healthcare, UK) according to the manufacturer’s instructions. To reduce 
unspecific background, unincorporated nucleotides were removed by gel 
filtration with Probe Quant G-50 MicroColumns (Amersham GE Healthcare, 
UK). The probe was ready for hybridization reaction after boiling at 95 °C for 
5 min. 
Hybridization: Membranes containing the DNA samples were blocked for 2 h 
in church buffer at 65 °C in a water bath shaker and after 2 h the labeled probe 
was added and hybridized for 16 h under the same conditions. Next day 
membranes were washed twice for 20 min in church washing buffer. Signals 
were detected by exposure of 3-7 days to X-ray film (Amersham GE Healthcare, 
UK) at -80 °C. 
 
 
4.6. Histology 
 
Organs were fixed in 4 % paraformaldehyde (PFA) for 2 h at 4 °C, embedded in 
paraffin (Histolab Products AB, Germany), cut into 7 μm thick sections and 
mounted in glass slices. After removal of paraffin, tissues were stained with 
hematoxylin and eosin (Sigma, Germany) or with Nissl staining method 
following standard protocols. Whole inguinal mammary glands were isolated, 
stretched on glass slides and fixed in Carnoy's fixative for 2 to 4 h at RT. They 
were washed in 70 % EtOH for 15 min afterwards and changed gradually to 
distilled water. Glands were stained in carmine solution at RT overnight and 
next day they were washed in 70 % EtOH for 15 min, cleared in xylene and 
mounted with Eukitt® (Sigma, Germany). 
 
 
4.7. Blood analysis 
 
150 µL blood was collected from the retroorbital plexus, clotted, and centrifuged 
to separate the serum. Analyses of different blood parameters were performed 
in collaboration with Dr. Thomas Renné from Institute of Clinical Biochemistry of 
Würzburg. 
   
 -52- 
  Methods 
4.8. Platelet analysis 
 
4.8.1. Platelet isolation 
 
Mice were anesthetized with ether and bled from the retroorbital plexus. Blood 
was collected into an Eppendorf tube containing 300 μl heparin in TBS 
(20 U/mL), pH 7.3. Blood was centrifuged (Eppendorf, Germany) at 1800 rpm 
for 5 min. The supernatant was centrifuged again at 800 rpm for 6 min at to 
obtain platelet rich plasma (prp). To wash platelets, prp was centrifuged at 
2500 rpm for 5 min in the presence of prostacyclin (PGI2) (0.1 μg/mL) and the 
pellet was resuspended in Ca2+-free Tyrode’s buffer containing PGI2 
(0.1 μg/mL) and apyrase (0.02 U/mL). Repeating the washing two times, the 
platelet pellet was resuspended in Tyrode’s buffer containing apyrase 
(0.02 U/mL) (500 μL) and left to incubate for at least 30 min at 37 °C before 
analysis. 
 
 
4.8.2. Platelet counting 
 
Blood (50 μL) was obtained from the retroorbital plexus of anesthetized mice 
using heparinised microcapillaries and collected into an eppendorf tube 
containing 300 μL heparin in TBS (20 U/mL), pH 7.3. Platelet counts and size 
were determined using a Sysmex KX-21N automated hematology analyzer 
(Sysmex Corp, Japan). Platelet counts were additionally confirmed by Flow 
cytometry. 
 
 
4.8.3. Flow cytometry 
 
Approximately 1x106 platelets were activated with the indicated agonists or 
reagents (10 min, RT) in Tyrode’s buffer and stained for 10 min with saturating 
amounts of fluorophore-conjugated antibodies. The reaction was stopped by 
addition of 500 μL PBS, and samples were immediately analyzed on a 
FACScalibur (Becton Dickinson, New Jersey). 
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4.8.4. Platelet life span experiments 
 
Circulating platelets were labeled in vivo by i.v. injection in the retroorbital 
plexus of 5 μg Dylight-488-anti-GPIX Ig derivative in 200 μL PBS. 30 min after 
antibody injection (and every 24 h for 5 days) 50 μL blood was taken from the 
retroorbital plexus of the treated mice and diluted 1:20 in heparin containing 
PBS. The diluted whole blood was in turn incubated with 10 μL of the platelet 
marker PE-Cy5-anti-GPIb for 10 min at RT. The Dylight-488 positive platelet 
population was determined as the percentage of the whole PE-Cy5 positive 
population by flow cytometry. 
 
 
4.8.5. Intracellular Ca2+ measurements 
 
Platelets isolated from blood and washed as described above, were suspended 
in Tyrode’s buffer without Ca2+ and loaded with fura-2 AM (5 μM) in the 
presence of Pluronic F-127 (0.2 μg/mL) (both from Molecular Probes) for 30 min 
at 37 °C. After labeling, platelets were washed once and resuspended in 
Tyrode’s buffer in the absence or presence of 1 mM Ca2+. 500 µL of the platelet 
suspension was placed in quartz cuvettes previously blocked with 1 % bovine 
serum albumin (BSA) (Sigma, Germany). Stirred platelets were activated with 
different agonists and fluorescence was measured with a PerkinElmer LS 55 
fluorimeter (PerkinElmer, Massachusetts). 
Excitation was alternated between 340 and 380 nm, and emission was 
measured at 509 nm. Each measurement was calibrated using 1 % Triton X-
100 and 0.5 M EGTA. The system software automatically calculates the [Ca2+]i 
from the fluorescent ratios. Briefly, fluorescence ratios were converted to 
relative [Ca2+]i according to the following equation: 
 
[Ca2+]i = 224 x (R-Rmin) / (Rmax-R) x Fmax/Fmin 
 
where 224 nM is the KD value of fura-2 AM Ca2+ binding; R represents the 
actual fluorescence ratio; Rmax is the maximum fluorescence ratio determined 
from cells suspended in Tyrode's buffer supplemented with 0.1 % Triton-X100 
and 1 mM CaCl2; Rmin is the mean fluorescence ratio determined from cells 
preincubated with 5 μM fura-2 AM and resuspended in Tyrode's buffer 
supplemented with 0.1 % Triton-X100, 1 mM CaCl2, 5 mM EGTA; Fmax and Fmin 
represent the fluorescence values (arbitrary units) of fura-2 AM for Rmax and 
Rmin, respectively. 
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4.8.6. Aggregometry experiments 
 
Platelets were isolated from blood and washed as described above. Washed 
platelets were resuspended in Tyrode’s buffer and adjusted to a concentration 
of 3x108 cells/mL. Heparinized prp was used in ADP stimulated platelets. 
Agonists or reagents were added 20 sec after light transmission was started 
and recorded over 10 min on an Apact 4-channel optical aggregation system 
(APACT, Germany). Before starting the measurements, Tyrode’s buffer (for 
washed platelets) or plasma (for prp) was set as 100 % aggregation and 
washed platelet suspension (for washed platelets) or prp (for prp) was set as 
0 % aggregation. The activity of most agonists was assessed in Tyrode’s buffer 
supplemented with 100 µg/mL human fibrinogen, except in case of thrombin 
and ADP measurements.  
 
 
4.8.7. Tyrosine phosphorylation assay 
 
Platelets from three mice were isolated from 700 µL blood as described above , 
pulled and resuspended in 350 µL Tyrode’s buffer without Ca2+ and 
supplemented with 10 µM indomethacin, 5 mM EDTA and additional 2 U/mL 
apyrase to avoid platelet aggregation after activation. Platelets were activated 
with 2.5 µg/mL convulxin and 50 µL aliquots were taken after 30, 60, 120 and 
240 sec. An additional aliquot was taken before activation and considered as 
time point 0 sec. Platelets were kept at 37 °C at constant stirring during the 
entire procedure. 50 µL aliquots were immediately mixed 1:1 with the tyrosine 
phosphorylation lysis buffer at 4 °C, centrifuged at 14000 rpm for 10 min at 4 °C 
and supernatant was mixed with 25 µL NuPAGE 4x LDS sample buffer 
(Invitrogen, Germany). The mixture was heated at 70 °C for 10 min and 
samples were run on NuPAGE Novex 4-12 % (gradient) Bis-Tris gel (Invitrogen, 
Germany) according to the instructions of the provider. Next steps were 
performed according to standard protocols for western blotting described above. 
The primary antibody anti-phosphotyrosine 4G10 (1:1000, Millipore, 
Massachusetts) was used to detect tyrosine phosphorylated proteins. An anti-
mouse secondary Ig HRP-conjugated was used to detect the 4G10 antibody 
(1:1000, Dianova, Germany). 
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4.8.8. Flow chamber assay 
 
Blood (700 μL) was collected into 300 μL TBS buffer, pH 7.3, containing 
20 U/mL heparin and diluted 2:1 with Tyrode’s buffer. Coverslips (24 x 60 mm) 
were coated with 0.25 mg/mL of fibrillar type-I collagen (Horm) (Nycomed, 
Germany) and blocked for 1 h with 1 % BSA (Sigma, Germany). Perfusion 
studies were performed as follows. Transparent flow chambers with a slit depth 
of 50 μm, equipped with the coated coverslips, were connected to a syringe 
filled with the diluted whole blood. Perfusion was performed using a pulse-free 
pump under high shear stress equivalent to a wall shear rate of 1000 s-1 or 
1700 s-1 (4 min). Thereafter, chambers were rinsed by 4 min perfusion with 
Tyrode’s buffer at the same shear stress and phase-contrast [130]. The entire 
process was recorded by time-lapse (1 sec for 4 min) using a 40x objective on 
an inverted microscope Zeiss HBO 100 (Zeiss, Germany). Image analysis was 
performed using MetaVue® software. Thrombus formation was expressed as 
the mean percentage of total area covered by thrombi. 
 
 
4.8.9.  Spreading assay 
 
Platelets were isolated from blood and washed as described above. Washed 
platelets were resuspended in Tyrode’s buffer and adjusted to a concentration 
of 2x108 cells/mL. 60 µL of the platelet suspension was stimulated with 
0.05 U/mL thrombin and immediately placed on coverslips (24 x 60 mm) that 
had been coated overnight with 100 µg/mL human fibrinogen (Sigma, Germany) 
and blocked for 1 h with 1 % BSA (Sigma, Germany). Coverslips were mounted 
in 1 % BSA-coated glass slides and placed on an inverted microscope Zeiss 
HBO 100 (Zeiss, Germany). Time-lapse images were recorded (every 5 sec for 
20 min) with a 40x objective and analyzed using MetaVue® software. Starting 
points and percentages of adhered and completely spread platelets were 
considered as indicators of platelet adhesion and spreading dynamics. 
 
 
4.8.10. In vivo experiments 
 
4.8.10.1. Tail bleeding time experiments 
 
Mice were anesthetized by intraperitoneal injection of a mixture of fentanyl 
(Janssen-Cilag GmbH, Germany), midazolam (Roche Pharma AG, Germany) 
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and medetomidine (Pfizer, Germany), and a 2 mm segment of the tail tip was 
cut off with a scalpel. Tail bleeding was recorded by absorbing blood drops with 
Whatman® filter paper every 20 sec, avoiding the direct contact with the wound 
surface. Bleeding was determined to have ceased as soon as no blood was 
observed on the paper. For ethical concerns, experiments were stopped within 
20 min by wound cauterization with a cauterizing scalpel Kausto-Lux II (MECAN 
b.v., Netherlands) and the anaesthesia was antagonized with atipamezol 
(Pfizer, Germany), flumazenil and naloxon (both from Delta Select GmbH, 
Germany). 
 
 
4.8.10.2. Intravital microscopy of thrombus formation in FeCl3 injured 
mesenteric arterioles 
 
Four week old mice were anesthetized as described previously and the 
mesentery was exteriorized through a midline abdominal incision. Arterioles 
(35-60μm diameter) were visualized with a Zeiss Axiovert 200 inverted 
microscope (x10) equipped with a 100-W HBO fluorescent lamp source and a 
CoolSNAP-EZ camera (Visitron, Germany). Digital images were recorded every 
second and analyzed off-line using Metavue® software. Injury was induced by 
topical application of a 3 mm2 Whatman® filter paper saturated with FeCl3 
(20 %) for 10 sec. Adhesion and aggregation of fluorescently labeled platelets 
(Dylight-488 conjugated anti-GPIX Ig derivative) in arterioles was monitored for 
30 min or until complete occlusion occurred (blood flow stopped for > 1 min). 
 
 
4.9. Isolation and analysis of cells of the immune system 
 
4.9.1. Isolation of cells of the immune system 
 
Bone Marrow Mast cells (BMMCs) were derived as described before [131]. 
Briefly, bone marrow cells (1x106/mL) from 6 to 8 weeks old male mice (129/Sv) 
were cultured (37 °C, 5 % CO2) in a single cell suspension in RPMI 1640 
medium containing 20 %, 1 % X63Ag8-653-conditioned medium as a source of 
IL-3, 2 mM L-glutamine, 1x10-5 M 2-mercaptoethanol, 50 units/mL penicillin, and 
50 mg/mL streptomycin. At weekly intervals, the non-adherent cells were 
reseeded at 1x106 cells/mL in fresh medium. By 4 to 6 weeks in culture, more 
than 99 % of the cells were c-kit- and FcR1-positive as assessed by 
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phycoerythrin-labeled anti-c-kit antibodies (BD Pharmingen, Canada) and FITC-
labeled IgE (anti-erythropoietin 26), respectively. 
Resident peritoneal macrophages were flushed out of the peritoneal cavity of 
the mice with 10 mL PBS without Ca2+ supplemented with 1 % BSA, washed 
twice with the same solution and suspended in Tyrode’s buffer. 
 Cells from the primary and secondary lymphoid organs (bone marrow, 
thymus, spleen and lymph nodes) were isolated from 8 week old mice as 
follows. Organs were isolated, placed inside a 70 µm cell strainer (BD FalconTM, 
Canada) with ice-cold FACS buffer and gently smashed with a piston, from a 
10 mL syringe.  
Spleen cell suspensions were further subjected to hypo-osmotic shock for red 
blood cell depletion.  
Both tips of the femurs were cut and the bone marrow was flushed in ice-cold 
FACS buffer and filtered with 70 µm cell strainer (BD FalconTM, Canada).  
Cells were collected, centrifuged at 1600 rpm for 5 min and washed twice. CD4+ 
T cells were purified by negative magnetic separation from spleen and lymph 
nodes using the MACS® CD4+ T cell isolation kit (Miltenyi Biotec, Germany) and 
suspended in Tyrode’s buffer. 
 
 
4.9.2. Cellularity assessment in primary and secondary lymphoid organs 
 
Cells were isolated as described above. Cells counts were determined using a 
Sysmex KX-21N automated hematology analyzer (Sysmex Corp, Japan).  
 
 
4.9.3. Intracellular Ca2+ measurements in cells of the immune system 
 
Cells were isolated as described above and suspended in Tyrode’s buffer 
without Ca2+. Intracellular Ca2+ measurements were performed as described 
above for platelets. Stirred cells were activated with different agonists and 
fluorescence was measured with a PerkinElmer LS 55 fluorimeter (PerkinElmer, 
Massachusetts). 
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4.9.4. In vivo anaphylaxia experiments 
 
FcR-mediated hypothermia was induced by i.v. injection of 30 µg anti-DNP IgE 
(company) per mouse 24 h before and the next day the body temperature was 
measured every 10 min after injection of the DNP-HSA antigen (250 µg per 
mouse) with a rectal probe. 
FcR-mediated hypothermia was induced by injecting high dosage 
(100 µg/mouse) anti-GPIIb/IIIa antibodies (JON1 and JON3). The rat anti-
mouse GPIIb/IIIa antibodies have been described previously [132]. The isotypes 
of JON1 and JON3 are IgG2b and IgG1, respectively. Body temperature was 
measured every 10 min with a rectal probe. 
 
 
4.9.5. Induction of Immune thrombocytopenia purpura (ITP) in mice 
 
Initial platelet counts were assessed as described above for each mouse. 
These values were considered 100 % and subsequent counts (until day 4) were 
normalized to these values. Mice were i.v. injected with the indicated amounts 
(4, 7 or 11 µg per mouse) of anti-GPIIb/IIIa antibodies (JON1 and JON3) to 
induce thrombocytopenia. After injection, platelet counts were assessed every 
24 h. 
 
 
4.9.6. Flow cytometry in cells of the immune system 
 
Cells were isolated as described above and resuspended in FACS buffer at 
4 °C. FcRs in T cells (but not macrophages) were blocked with 25 µL FACS 
buffer supplemented with 10 µg/mL 2.4G2 (BD Pharmingen, Canada) antibody 
for 15 min at 4 °C. Cells were subsequently labeled with a fluorescent-
conjugated primary antibody against surface molecules in dark for 30 min at 
4 °C. For intracellular staining, labeled cells were fixed overnight at 4 °C, and 
permeabilized with the fixation/permeabilization kit (eBioscience, San Diego). 
Then, cells were blocked with rat serum (1:50) for 30 min at RT and labeled with 
a fluorescent-conjugated primary rat antibody against intracellular antigens for 
30-45 min at RT. The reaction was stopped by adding PBS and cells were 
washed twice before flow cytometry assessment. 
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4.9.7. Antibody isotype titer determination in mouse serum 
 
Concentrations of antibodies of the IgM, IgG2a, IgG1, and IgE isotype were 
determined by the ELISA Quantitation Kits (Bethyl Laboratories, Texas), 
according to the manufacturer’s recommendations. ODs were measured and 
translated into protein concentrations using the MultiSkan EX ELISA reader 
(THERMO electron corp., Massachusetts). 
 
 
4.9.8. Keyhole limpet hemocyanin (KLH) immunizations 
 
Mice were immunized subcutaneously with an emulsion of 45 µL of PBS 
containing 25 µg of KLH (Sigma, Germany) and 15 µL of TiterMax (Alexis, San 
Diego). Twenty days after the initial immunization, mice were boosted with 
25 µg of KLH in 250 µL of PBS i.p. Blood was taken on days 16 and 34 and 
anti-KLH Ig were detected in serum by ELISA using KLH-coated plates 
(150 µg/mL in PBS at a final volume of 100 µL/well). Wells were blocked with 
BSA (5 % in PBS) before serum was added. Bound anti-KLH Ig were detected 
with anti-mouse IgG-biotin (Dianova, Germany) followed by streptavidin-
peroxidase (Dianova, Germany) and tetramethylbenzidine (TMB) was used as 
substrate. ODs were measured at 450 nm.  
On day 43 or 63, CD4+ T cells were purified by negative magnetic separation 
from total splenocyte suspensions and 5x104 or 1x105 CD4+ cells were 
cocultured with 5x104 or 1x105 irradiated splenocytes (B6) in 96-well U-bottom 
plates to asses T cell proliferation rates. Different concentrations of KLH (0.1, 
1 and 10 µg/mL) were added to the co-cultures to re-stimulate T cells that 
specifically react to KLH. Stimulated Anti-CD3 Ig (0.1 mg/mL) T cells were used 
as a positive control. Proliferation was measured by determining [3H]-thymidine 
incorporation (12.5 mCi; Amersham GE Healthcare, UK) during the final 16 h of 
a 3-day culturing period. Radioactive incorporation was determined by beta 
counting (c.p.m., counts per minute). 
 
 
4.9.9. Induction and evaluation of experimental autoimmune 
encephalomyelitis (EAE) 
 
EAE was induced by immunization of mice with 200 µg myelin oligodendrocyte 
glycoprotein (MOG35-55) peptide (Biotrend, Germany). Complete Freund’s 
adjuvant (CFA) Gibco® (Invitrogen, Germany) was supplemented with MOG to 
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obtain a 1 mg/mL emulsion and 2x 100 µL were injected subcutaneously at two 
different sites of the flank of deeply anesthetized mice. Pertussis toxin was 
injected at the day of immunization and two days later (400 ng, Alexis, San 
Diego). All animals were kept under standard conditions and had constant 
access to water and food. 
The clinical course of EAE was monitored using the following score system: 
grade 0, no abnormality; grade 1, limp tail tip; grade 2, limp tail; grade 3, 
moderate hind limb weakness; grade 4, complete hind limb weakness; grade 5, 
mild paraparesis; grade 6, paraparesis; grade 7, heavy paraparesis or 
paraplegie; grade 8, tetraparesis; grade 9, quadriplegia or premoribund state; 
grade 10, death. 
 
 
4.9.10. Immunohistochemistry 
 
Mice spinal cord cryo sections were slowly thawed and dried at RT, fixed with 
4 % paraformaldehyde (Merck, Germany), washed with PBS buffer and 
incubated with 5 % BSA in PBS for 30 min. Then, primary antibody (rat anti-
CD3, 1:100, AbD Serotec, UK) were added and incubated for 12 h at 4 °C. 
Secondary antibody (Cy 3 labeled goat anti-rat 1:300, Dianova, Germany) was 
incubated for 60 min at room temperature. Staining with 0.5 g/mL DAPI 
(Merck, Germany) was performed for 7 min. Pictures were collected by 
Axiophot immunofluorescence microscopy (Zeiss, Germany). Haemalaun-
staining (1 ‰ haematoxylin (Sigma-Aldrich, Germany) in aqua dest. containing 
0.2 ‰ NaIO3 (Fluka, Sigma, Germany), 5 % KAlSO3 (Merck, Germany), 5 % 
chloral hydrate (Merck, Germany) and 1 ‰ citric acid (Serva, Germany) was 
performed for 10 min. For detection of demyelination slides were incubated with 
Luxol fast blue (LFB) solution for 12 h at 60 °C (0.1 %, Sigma, Germany), 
washed in 95 % alcohol, and then placed in lithium carbonate (0.05 %, Sigma, 
Germany). 
 
 
4.10. Isolation and analysis of neuronal tissue 
 
4.10.1. Isolation and culture of neurons 
 
Neuronal cultures were obtained from Stim2-/- or control embryos at day 18 of 
development (E18) according to previously described preparation protocols 
[133]. In brief, pregnant mice were sacrificed by cervical dislocation and 
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embryos were removed and transferred into warmed Hank’s buffered salt 
solution (HBSS) Gibco® (Invitrogen, Germany). After preparation of hippocampi, 
the tissue was collected in a tube containing 5 mL of 0.25 % trypsin in HBSS. 
After five min of incubation at 37 °C, the tissue was washed twice with HBSS. 
Thereafter, the tissue was dissociated in 1 mL of neuronal medium by triturating 
with fire polished Pasteur pipettes of decreasing tip diameter. Neurons were 
diluted in neuronal medium (10 % 10x modified earl’s medium (MEM); 0.2205 % 
sodium bicarbonate; 1 mM sodium pyruvate; 2 mM L-glutamine; 2 % B27 
supplement (all Gibco®, Invitrogen, Germany); 3.8 mM glucose; 1 % 
penicillin/streptomycin (Biochrom AG, Germany), and plated in a density of 
60.000 cells/cm² on poly-D-lysine coated cover slips in 4-well plates (Nunc, 
Denmark). Prior to experiments all cell cultures were incubated at 37.0 °C and 
5 % CO2 and held in culture for up to 5-7 days. To induce ischemic conditions 
pH was changed to 6.4, glucose concentrations were lowered and the O2 was 
restricted as described for the slice preparations. In additional sets of 
experiments 300 nM of staurosporine (Sigma, Germany) or 2 µM of N,N,N´,N´-
tetrakis (2-pyridylmehtyl) ethylenediamine (TPEN) (Sigma, Germany) were 
added to the cell cultures. 
For Ca2+ measurements, primary neuronal cultures were obtained from E18 
embryos or P0 newborns as described above except for the following: Tissue 
was collected from whole cortices and cells were cultured in Neurobasal-A 
medium Gibco® (Invitrogen, Germany) containing 2 % B27 supplement, 1 % 
GlutaMAX-I and 1 % penicillin/streptomycin (all Gibco, Germany). Cells were 
plated in a density of 50,000 cells/cm2 on poly-L-lysine coated coverslips in 24-
well plates (Sarstedt, USA) and were held in culture for up to 14 days. 
 
 
4.10.2. Brain slice preparation and culture 
 
Brain slices including the hippocampus were prepared from 6-10 weeks old 
Stim2-/- mice and wild type littermates as described earlier [134]. In brief, 
coronal sections were cut on a vibratome (Vibratome, Series 1000 Classic, St. 
Louis) in an ice-chilled solution containing (mM): Sucrose, 200; PIPES, 20; KCl, 
2.5; NaH2PO4, 1.25; MgSO4, 10; CaCl2, 0.5; dextrose, 10; pH 7.35 adjusted with 
NaOH. After preparation slices were transferred to a holding chamber 
continuously superfused with a solution containing NaCl 120 mM, KCl 2.5 mM, 
NaH2PO4 1.25 mM, HEPES 30 mM, MgSO4 2 mM, CaCl2 2 mM and dextrose 
10 mM. PH values were adjusted using HCl. To induce in vitro ischemic 
conditions ph values were reduced from 7.25 to 6.4 and lowered glucose 
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concentration to 5 mM under hypoxic conditions. Restriction of O2 was achieved 
by perfusion with an external solution that had been bubbled with nitrogen for at 
least 60 min prior to and throughout the recordings [135]. 
 
 
 
4.10.3. Immunocyto- and immunohistochemistry in neurons 
 
After incubation of the hippocampal cell culture or brain slices, they were fixed 
with 4 % PFA (Merck, Germany), washed 3 times with 10 mM PBS and 
incubated for 60 min at 4 °C in 10 mM PBS containing 5 % goat serum (GS; 
PAA Laboratories, Austria) and 0.3 % Triton X100 (Sigma, Germany). Primary 
antibodies mouse anti-NeuN (1:1000, Chemicon International, Massachusetts), 
mouse anti-MAP2a/b (1:200, abcam, United Kingdom), rabbit anti-cleaved 
Caspase-3 (1:150, Cell Signaling, Massachusetts) were diluted in 10 mM PBS 
and incubated for 12 h at 4 °C. After washing steps with 10 mM PBS, secondary 
antibodies (Alexa 488 labeled goat anti-mouse 1:100, BD Bioscience Canada; 
Cy-3 labeled goat anti-rabbit 1:300, Dianova, Germany) were incubated in the 
same manner. Staining with 0.5 µg/mL DAPI (Merck, Germany) was performed 
for 7 min. Finally, cultures were washed and subsequently covered with DABCO 
(Merck, Darmstadt). Pictures were collected by immunofluorescence 
microscopy (Axiophot; Zeiss, Jena). 
 
 
4.10.4. Ca2+ imaging 
 
Measurements of [Ca2+]i in single cortical neurons were carried out using the 
fluorescent indicator fura-2 AM in combination with a monochromator-based 
imaging system (T.I.L.L. Photonics, Germany) attached to an inverted 
microscope (BX51WI, Olympus, Germany). Emitted fluorescence was collected 
by a CCD camera. Cells were loaded with 5 µM fura-2-AM (Molecular Probes, 
The Netherlands) supplemented with 0.01 % Pluronic F127 for 35 min at 20-
22 °C in a standard bath solution containing (mM): 140 NaCl, 5 KCl, 1 MgCl2, 
2 CaCl2, 10 glucose and 10 HEPES, adjusted to pH 7.4 with NaOH. For 
measurements of [Ca2+]i, cells were held in standard bath solution and 
fluorescence was excited at 340 and 380 nm. Fluorescence intensities from 
single cells were acquired in intervals of 2 sec or 20 sec. After correction for the 
individual background fluorescence, the fluorescence ratio R = F340/F380 was 
calculated. Quantities for [Ca2+]i were then calculated by the equation: 
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 [Ca2+]i = KD β(R - Rmin)/(Rmax - R) 
 
with KD = 224 nM [136], β = 2.64, Rmin = 0.272 and Rmax = 1.987 obtained from 
single dye-loaded cells in the presence of 5 µM ionomycin added to standard 
bath solution or to a solution containing 10 mM EGTA instead of 2 mM CaCl2. 
Individual cells in a given culture dish showed variable kinetics but similar peak 
amplitudes of the Ca2+ transients. Thus, for the average example traces 
illustrated in Fig. 37, the peak amplitude, but not the kinetics are comparable 
between dishes and/or cell types. For oxygen-glucose deprivation (OGD) 
experiments, cells were immediately transferred to a sealed, N2-purged 
(~2 l/min) chamber continuously superfused with a N2-bubbled solution 
containing (mM): 140 NaCl, 5 KCl, 1 MgCl2, 2 CaCl2 and 10 HEPES, adjusted to 
pH 7.4. All experiments were carried out at 20-22 °C. All chemicals were 
obtained from Sigma (Germany). 
 
 
4.10.5. tMCAO model 
 
Experiments were conducted on 10-12 weeks old Stim2-/- or bone marrow 
chimeras according to published recommendations for research in mechanism-
driven basic stroke studies [137]. Transient middle cerebral artery occlusion 
(tMCAO) was induced under inhalation anesthesia using the intraluminal 
filament (6021PK10; Doccol Company, California) technique. After 60 min, the 
filament was withdrawn to allow reperfusion. For measurements of ischemic 
brain volume, animals were sacrificed 24 h after induction of tMCAO and brain 
sections were stained with 2 % 2,3,5-triphenyltetrazolium chloride (TTC; Sigma, 
Germany). Brain infarct volumes were calculated and corrected for edema as 
described [138]. Neurological function and motor function were assessed by two 
independent and blinded investigators 24 h after tMACO as described [138]. 
 
 
4.10.6. Stroke assessment by MRI 
 
Magnetic resonance imaging (MRI) was performed repeatedly at 24 h and 
5 days after stroke on a 1.5 Tesla MR-unit (Vision Siemens, Germany) as 
described [138]. For all measurements, a custom made dual channel surface 
coil designed for examination of the mice head was used (A063HACG; Rapid 
Biomedical, Germany). The image protocol comprised a coronal T2-w sequence 
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(slice thickness 2 mm), and a coronal 3D T2-w gradient echo CISS 
(Constructed Interference in Steady State; slice thickness 1 mm) sequence. MR 
images were visually assessed blinded to the experimental group with respect 
to infarct morphology and the occurrence of intracranial hemorrhage (IHC). 
 
 
4.11. Statistical analysis 
 
Statistical analysis was performed using the SigmaPlot® software (Systat 
Software Inc, California). Statistical methods used are given in the figure 
legends. For the stroke model, results are presented as means ± SD. Infarct 
volumes and functional data were tested for Gaussian distribution with the 
D'Agostino and Pearson omnibus normality test and then analyzed using the 
two-tailed Student's t test. p < 0.05 was considered statistically significant. 
 
  Results 
5. RESULTS 
 
5.1. STIM2 is expressed in most organs in mouse and is the 
main isoform in brain 
 
To determine the relevance of STIM2 in different organs, the abundance of both 
STIM1 and STIM2 isoforms was studied in total protein lysates using western 
blot (Fig. 9). A STIM2-specific band of 105 kDa and a STIM1-specific band of 
90 kDa was detectable in most tissues, except kidney. STIM2 showed an 
expression pattern partially overlapping with STIM1, except for brain, thymus 
and platelets. Importantly, STIM2 was clearly detectable in brain, whereas 
STIM1 was hardly detectable (Fig. 9A). In fact, densitometric analysis of 
STIM2/STIM1 ratio clearly showed that STIM2 is the dominant isoform in brain 
and increased in liver, whereas in all other organs tested STIM1 was clearly the 
dominant (Fig. 9B). This data indicates a higher expression of STIM1 in most 
organs but brain, where STIM2 seems to be the predominant isoform. 
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Figure 9. STIM2 is the main STIM isoform in brain. (A) Western blot analysis of STIM1 and 
STIM2 expression in different organs of 8 weeks old wild-type mice. Tubulin expression was 
used as loading control. (B) Representative densitometric analysis of STIM2 compared to 
STIM1 and normalized with tubulin expression in different organs of 8 weeks old wild-type mice, 
given as STIM2/STIM1 expression ratio (n = 3). LN = lymph nodes, Plt = platelets.  
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5.2. Stim2 gene isolation and generation of a Stim2 knockout 
mouse 
 
The STIM2 knockout (Stim2-/-) mouse was generated together with my 
laboratory college Dr. Attila Braun. Two genomic DNA clones encoding the 
murine Stim2 gene (RPCI22-446E8; RPCI22-394I22) were isolated from a 
129Sv BAC library (BACPAC resources center-BPRC-, Children’s Hospital 
Oakland Research Institute-CHORI-, USA), using a probe specific for the 
exon 4 of murine Stim2, isolated by PCR (primers: Stim2/BACprobe_F and 
Stim2/BACprobe_R). The targeting vector was designed to delete the Stim2 
gene region that comprises most of the exon 4 and exon 7 (Fig. 11A). The 
deleted area was substituted by a selection cassette containing the Neomycin 
resistant gene (Neo) and the -galactosidase gene (LacZ). The deletion is 
predicted to result in a frame shift and creation of a premature termination site 
in the next exon. The targeting vector was built as follows (Fig. 10). The 5´-
flanking arm was isolated by long term PCR amplification (Triple Master PCR 
System, Eppendorf, Germany; primers: 5´flanking/Stim2KO/i3_F1 and 
5´flanking/Stim2KO/E4_R) from the Stim2 BAC clone and was subcloned in 
Topo XL® vector. It comprises a 3.6 kb region that contains the intron 3 and part 
of the exon 4 (Fig. 10A). The 3´-flanking arm was isolated by digestion of the 
Stim2 BAC clone with the restriction enzyme EcoRV. Digested DNA fragments 
were subcloned into PBlueScript KS minus vector and the different clones were 
screened by colony hybridization using a probe specific for the 3´-flanking arm 
(primers: Stim2/BACprobe_F and Stim2/BACprobe_R). The 3´-flanking arm 
comprises a 5.6 kb region that contains the intron 7 to exon 10 (Fig. 10A). 
These flanking regions facilitate the homologous recombination between the 
Stim2 knockout targeting vector and the Stim2 allele (Fig. 11A). The PCR 
products were sequenced to confirm the absence of any point mutation or 
alteration in their DNA sequence. After that, the 5´- and 3´-flanking arms were 
subcloned into the pWH9 vector, which comprises the pBluescript vector 
(Fig. 10B) containing a selection cassette (IRES-NEO-PGK promoter-lacZ-
polyA). The 5`- and the 3`-arm were subcloned upstream and downstream the 
selection cassette, respectively. The construct was sequenced again with T3 
and T7 primers in order to confirm the correct orientation of the flanking arms. 
The Stim2 knockout targeting vector was mapped and verified by different 
restriction enzymes (Fig. 10C). 
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Figure 10. The Stim2 targeting construct. (A) Restriction map of the Stim2 knockout targeting 
vector showing the most important restriction sites and the expected sizes of the digested DNA 
fragments. (B) Schematic representation of the BlueScript KS minus vector. The targeting 
construct was finally inserted in XhoI-NotI restriction sites. (C) Agarose gel electrophoresis 
showing the enzymatic digested Stim2 targeting vector and their different products. 
pKS = BlueScript KS minus vector, Kb = Kilobase. 
 
The targeting vector was linearized with NotI and electroporated into R1 
embryonic stem (ES) cells derived from 129Sv mouse strain and selected with 
the antibiotic geneticin (G418). The ES clones containing the IRES-NEO-LacZ 
cassette were resistant to geneticin and were able to survive. Targeted ES 
clones were screened by southern blot using a specific external probe for the 
Stim2 gene (Fig. 11B, clone 239). This external probe was generated by PCR 
amplification (Stim2/Extprobe_F1 and Stim2/Extprobe_R1) of the Stim2 BAC 
clone. The amplificated region comprises a 500 bp fragment outside the 
targeting construct downstream of the 3´-flanking arm (Fig. 11A). Stim2+/- ES 
cells were injected into C57Bl/6 blastocyst in collaboration with Dr. Michael Bösl 
(Max Planck Institute of Neurobiology, Martinsried), to generate chimeric mice. 
Chimeric mice were backcrossed with C57Bl/6 (Harlan Laboratories) and 
subsequent progenies were intercrossed to obtain Stim2-/- mice (Fig. 11C). 
Mouse genotypes were determined by PCR analysis (Stim2 wild-type 5´ and 
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Stim2 wild-type 3´; Stim2 knock-out 5´ and Stim2 knock-out 3´) or by southern 
blot (Fig. 11D). 
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Figure 11. Targeting strategy for the generation of Stim2-/- mice. (A) The targeting vector 
was generated by deletion of most part of the exon four to seven and introduction of Neo-LacZ 
selection cassette. The neo-LacZ cassette is flanked upstream and downstream by 3 Kb 
(containing most of the intronic area between exon 3 and 4) and 5 Kb (containing exon 8 to 10) 
homologous arms, respectively. Neo-LacZ: neomycin resistance and -galactosidase cDNA 
cassette. (B) Southern blot analysis of BamHI-digested DNA from targeted ES clones labeled 
with the external probe. Example of a Stim2 heterozygous (+/-) ES clone (number #239) used 
for blastocyst injection. (C) Southern blot analysis of BamHI-digested genomic DNA of wild-type 
(+/+), heterozygous (+/-) or Stim2 knockout (-/-) mice labeled with the external probe. (D) PCR 
analysis of knockout (Geo-PCR) or wild-type (WT-PCR) allele in wild-type (+/+), heterozygous 
(+/-) or Stim2 knockout (-/-) mice. (E) Western blot analysis of STIM2 and STIM1 expression in 
brain and lymph node (LN) of 8 weeks old wild-type and Stim2-/- mice. 
 
 
5.3. Stim2-/- mice are viable and fertile, but adults die 
spontaneously 
 
Mice heterozygous for the STIM2-null allele were apparently healthy and had a 
normal life expectancy (not shown). Intercrossings of these animals yielded 
Stim2-/- mice at the expected Mendelian ratio (Stim2-/-: 27.7 %, heterozygous: 
51.0 %, wild-type: 21.3 %, n = 249), which developed normally in size and 
weight to adulthood and were fertile (Fig. 12A, B, D).  
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Figure 12. Characterization of Stim2-/- mice. (A) Mendelian distribution of Stim2-/-(-/-), 
heterozygous (+/-) and wild-type (+/+) mice as determined in 3-4 weeks old litters. (B) 
Representative picture of 8 weeks old Stim2-/- (-/-) and a littermate wild-type (+/+) male mouse. 
(C) Lifespan experiment for 10 Stim2-/- (-/-, gray line) and 10 littermate wild-type (+/+, black line) 
male mice over 35 weeks. (D) Body weight evaluation of 6 to 12 weeks old Stim2-/- (triangles) 
and wild-type (squares) control mice (n  13), represented as mean body weight ± s.d. 
Differences were considered significant if p < 0.05 (Mann-Whitney U-test).  
 
Western blot analysis confirmed the absence of STIM2 in Knockout brain and 
lymph nodes (LN) whereas STIM1 expression levels were unaltered (Fig. 11D). 
Histological examination of major organs showed no obvious abnormalities 
(Fig. 13). 
Starting at the age of 8 weeks after birth pronounced sudden death in Stim2-/- 
mice was observed, and for unknown reasons, only 10 % of the animals 
reached the age of 30 weeks (Fig. 12C). In humans and small animals, sudden 
death is a rare and not well understood phenomenon observed in 
cardiovascular alterations such as heart hypertrophy and arrhythmia, genetic 
malformations of the heart and epileptic episodes and seizures in the brain 
[139,140]. Analysis of heart physiology by electrocardiography (ECG) in 
collaboration with PD. Dr. Sebastian Maier, Inner Medizin, Cardiology, 
University of Würzburg revealed a normal heart function (Data not shown). 
Therefore cardiac reasons were discarded. 
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G
H
wt Stim2-/-
wt Stim2-/-
indicate megakaryocytes. (D) Longitudinal sections of liver. (E) Longitudinal (upper) and coronal 
(lower panels) sections of skeletal muscle. (F) Longitudinal sections of Kidney. (G) Longitudinal 
sections of whole brain (upper right), cerebellum (upper right), hippocampus (CA1, CA2, CA3 
fields and dentate gyrus, lower left) and frontal pole and somatomotor areas of the neocortex. 
(H) Coronal sections of the heart. Scale bars are as follows; upper panels: 400 µm in all cases 
but (H) 100 µm; (G) left: 2.5 mm, right: 250 µm; (H) 1 mm. lower panels: 50 mm in all cases but 
(E) 100 µm and (G) 250 µm. Inset: 50 µm in all cases. 
Figure 13. Histological analysis of the 
main organs in Stim2-/- and wild-type 
mice. Organs were fixed in 4 % PFA, 
embedded in paraffin and 7 µm sections 
were cut and stained with H&E or Nissl 
(brain). (A) Longitudinal sections of thymus. 
(B) Coronal sections of spleen. Black arrows 
indicate megakaryocytes. (C) Longitudinal 
section of the bone marrow. Black arrows 
 
Analyses of different blood parameters (in collaboration with Dr. Thomas Renné 
(from Institute of Clinical Biochemistry of Würzburg) were performed to detect 
possible alterations in the physiology of the different organs (Fig. 14). No 
obvious differences were detected in 8 weeks old Stim2-/- as compared to 
control mice. Additionally, no sudden death was observed over a period of 
50 weeks in 8 weeks old wild-type chimeric mice reconstituted with Stim2-/- 
bone marrow, suggesting that blood cells are also not involved in this process 
(data not shown). Thus, sudden death in Stim2-/- mice is neither associated with 
alterations in the tested blood parameters, nor with macroscopic alterations in 
the structure of the main organs, and it is most likely not related to heart 
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dysfunction. Therefore, a possible hypothesis could be that sudden death can 
be related to brain dysfunction, although the mechanism remains unclear. 
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Figure 14. Blood analysis of 8 weeks old mice. (A, B) Levels of different parameters in 
8 weeks old wild-type (black bar) and Stim2-/- (gray bar) mice blood expressed as a mean ± s.d., 
(n = 5). As follows; Ions (Na = Sodium; Cl = chlorine; Fe = iron; K = potassium; Ca = calcium; 
PO4 = inorganic phosphates), Transaminases (GOT and GTP), Gluc = glucose, AK = alkaline 
phosphatise, Chol = Cholesterin, Trig = Triglycerides, TPZ = Prothrombin time, PTT = Partial 
thromboplastin time, AT3 = Antithrombin III, Crea = Creatinin, GGT = Gamma-
Glutamyltranserase, TP = Total Protein, F1 = Fibrinogen. Differences were considered 
significant if p < 0.05 (Mann-Whitney U-test). 
 
 
5.4. Stim2-/- females are not able to feed their offspring 
 
As mentioned before in section (5.3), mating of virgin heterozygous mice 
yielded apparently healthy Stim2-/- mice at the expected Mendelian ratio. In 
contrast, offspring from virgin Stim2-/- breeding died after 7 days (Fig. 15A). The 
fact that Stim2-/- newborns developed normally and were viable in heterozygous 
breeding indicated that Stim2-/- mothers were not able to feed their offspring. In 
order to confirm this hypothesis, virgin wild-type or Stim2-/- females were mated 
with Stim2-/- or wild-type males respectively, and the weight of their 
heterozygous offspring was measured over time (Fig. 15B).  
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Figure 15. Stim2-/- females fail to feed their litters. (A) Table comparing the number of 
offspring 7 days after birth between heterozygous (+/- x +/-) or homozygous (-/- x -/-) crossings. 
(B) Gain of weight over time of heterozygous newborn fed by wild-type (black square), Stim2-/- 
primiparous (gray circle) or Stim2-/- multiparous (gray triangle) females, represented as mean 
weight (gr.) ± s.d. (n  23). (C) Percentage of living offspring fed by wild-type (black square), 
Stim2-/- primiparous (gray circle) or Stim2-/- multiparous (gray triangle) females over time 
(n  23). 
 
As a result, heterozygous offspring fed by a primiparous (mated for the first 
time) Stim2-/- female were not able to gain weight and they finally died after 
7 days. Additionally, heterozygous offspring fed by multiparous (mated more 
than one time) Stim2-/- females were able to survive longer and gain more 
weight, but they finally died at day 13 after birth (Fig. 15B, C). This indicates 
that Stim2-/- females are not able to feed their offspring, probably due to a 
mammary gland dysfunction, and that such an alteration can be partially 
rescued in further pregnancies. 
The mammary gland is a unique organ that undergoes further development 
during adult stage, which is dependent on hormone signals. This gland shows 
repeated cycles of development, lactation, and involution for each pregnancy. In 
newborn, the mammary gland consists of only few rudimentary ducts in the 
vicinity of the nipple. Pronounced ductal outgrowth and branching starts at 
puberty and in pregnancy an expanded lobulo-alveolar compartment develops. 
Functional differentiation of the secretory epithelium coincides with parturition 
and large amounts of milk are produced and secreted during lactation (for 
additional information, please refer to [141,142]). 
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To investigate possible alterations of the mammary gland development during 
pregnancy, macroscopic analyses of mammary glands in primiparous and 
multiparous females were performed at different time points (virgin, at day 14 of 
pregnancy (P14) and lactating day 2 (L2)) (Fig. 16). Whole mammary gland 
stained with carmine and the H&E paraffin sections revealed normal ductal 
outgrowth, density and branching at virgin state in Stim2-/- and wild-type control 
females (Fig. 16A). Interestingly, Stim2-/- females showed a better developed 
alveolar system in the mammary gland at P14 as compared to wild-type control 
females (Fig. 16B), indicating an accelerated development or/and cell 
proliferation. Primiparous Stim2-/- females showed condensed alveoli in the 
mammary gland with a very small luminal area at L2, in contrast with the well 
expanded alveoli found in wild-type control females (Fig. 16C). This indicates 
that alveoli had not differentiated further to a secretory epithelium during 
delivery, a step considered as the final phase of mammary gland development 
during pregnancy, and failed to expand the luminal area. Stim2-/- mice showed 
condensed alveoli that contained milk (pink material) in the reduced luminal 
area (Fig. 16C, yellow arrow) indicating secretion of milk. During lactation, the 
milk components are synthesized by the epithelial cells at the walls of the 
alveoli, stored in droplets in the cytoplasm and secreted into the luminal area. 
However, the accumulation of milk droplets in the cytoplasm of the epithelial 
cells in Stim2-/- females at L2 suggest decreased secretion of milk into the 
luminal area (Fig. 16C, dark arrow). 
Taken together, these results suggest that Stim2-/- mammary gland developed 
faster during pregnancy as compared to wild-type controls but failed to develop 
further during delivery, impeding a complete expansion of alveoli and impairing 
the production of sufficient amounts of milk to feed their offspring. In contrast, 
the mammary gland of multiparous Stim2-/- females showed better developed 
alveoli structure at L2 as compared with primiparous Stim2-/- females, showing 
milk storage inside an almost completely expanded luminal area, indicating 
secretion of milk and better development of alveoli (Fig. 16D, yellow arrow). 
Thus, regarding the fact that multiparous Stim2-/- females were also not able to 
feed their offspring, the reduced luminal area found in the alveoli in primiparous 
Stim2-/- females can not explain itself impairment in offspring feeding. Therefore, 
this part of the analysis of Stim2-/- mice will be continued further in the future. 
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Figure 16. Histological analysis of female mammary glands at virgin, day 14 of pregnancy 
(P14) or day 2 of lactation (L2). Whole inguinal mammary glands were isolated from 8 weeks 
Stim2-/- and wild-type females, fixed in 4 % PFA and stained with carmine (left and central 
panels) or cut in 7 µm paraffin sections and stained with H&E (right panels). (A) Mammary 
glands isolated from virgin, (B) primiparous at P14, (C) primiparous at L2 and (D) multiparous at 
L2 Stim2-/- and wild-type females. Yellow arrows indicate presence of milk (pink colour) inside 
the luminal area, black arrows indicate droplets accumulated inside the secretory mammary 
endothelial cells. Scale bars are: left and middle panels: 100 µm, right panels: 50 µm; insets: 
50 µm. 
 
 
5.5. Analysis of STIM2-deficient platelets 
 
5.5.1. STIM2-deficient platelets are normal in number, size and surface 
glycoprotein expression and display a normal life span in vivo 
 
Analysis of protein expression by western blot showed that STIM2 is 
significantly expressed in wild-type platelets and is absent in STIM2 knockout 
platelets (Fig. 17A). Platelet size, counts and surface glycoprotein expression 
were analyzed in STIM2-deficient and wild-type platelets using Sysmex cell 
counter and flow cytometry, respectively (Fig. 17A-C). STIM2-deficient platelets 
were comparable in size, numbers and glycoprotein expression to wild-type 
controls (platelet size: 5.74  0.23 fl in Stim2-/-; 5.79  0.23 fl in wt; n = 11; 
p  0.05. platelet counts: 1000  200 plt/µL in Stim2-/-, 1000  170 plt/µL in wt; 
n = 5; p  0.05).  
To study platelet life span in the blood stream in vivo, platelets were labeled by 
injection of a fluorescence-coupled antibody against GPIX surface protein 
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(Dylight-488 conjugated anti-GPIX Ig derivative) intravenously (i.v) in Stim2-/- 
and wild-type mice (Fig. 17D). The antibody does not alter platelet function 
[132], and the percentage of labeled cells was assessed along 5 days by flow 
cytometry. After a single injection, Stim2-/- mice showed normal platelet 
clearance from the blood stream as compared to wild-type controls, excluding 
preactivated STIM2-deficient platelets in resting conditions. Finally, H&E-
stained paraffin sections of bone marrow and spleen did not show any alteration 
in macroscopic structure or in megakaryocyte numbers (Fig. 13C).  
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Figure 17. Stim2-/- mice showed no alteration in platelet production and life span. (A) 
Western blot showing STIM2 expression in wild-type and absence in Stim2-/- platelets. Platelet 
counts in wild-type (black bar) and Stim2-/- (gray bar) determined by flow cytometry, represented 
as mean platelets (x106)/µL blood ± s.d. (n = 8). (B) Platelet volume determination by a 
SYSMEX cell counter in wild-type (black bar) and Stim2-/- (gray bar) blood, represented as 
mean platelet volume (femtoliters) ± s.d. (n = 8). (C) Expression level of prominent platelet 
surface receptors in resting platelets measured by flow cytometry, represented as mean relative 
fluorescence intensity ± s.d. (n = 8). (D) Platelet life span determination in wild-type (black bar) 
and Stim2-/- (gray bar) mice. Platelets were labeled in vivo by injection of 0.5 µg/g mouse weight 
Dylight-488 conjugated anti-GPIX Ig derivative. The percentage of fluorescently-labeled 
platelets in whole blood was determined in 24 h intervals by flow cytometry. Data are 
represented as mean % of fluorescently labeled platelets ± s.d. (n = 5). Differences were 
considered significant if p < 0.05 (Mann-Whitney U-test). 
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Taken together, these results indicate that STIM2 deletion does not affect the 
platelet formation and production from megakaryocytes. 
 
 
5.5.2. Unaltered Ca2+ homeostasis in STIM2-deficient platelets 
 
During my thesis work, STIM2 was proposed by Brandman et al. to function as 
a Ca2+ sensor in the ER, regulating basal [Ca2+]i and ER Ca2+ levels [9]. 
Therefore, the effect of STIM2 deficiency on Ca2+ homeostasis was tested upon 
activation in platelets loaded with Fura-2, a fluorescent free-[Ca2+] indicator 
(Fig. 18). Under resting conditions, basal [Ca2+]i was normal in Stim2-deficient 
platelets as compared to wild-type controls (wt: 48.25 ± 15.97 nM; Stim2-/-: 56 ± 
16.77 nM; n = 5; p > 0.05) (Fig. 18A). To assess SOCE, Ca2+ release from the 
ER Ca2+ store was induced by the sarco-/ER Ca2+ ATPase (SERCA) inhibitor 
TG (5 µM) in the absence of extracellular Ca2+ (Fig. 18A, B). Ten min after TG 
stimulation, Ca2+ release from ER was also similar in STIM2-deficient and wild-
type platelets (wt: 114.75 ± 38.18 nM; Stim2-/-: 129.50 ± 39.11 nM; n = 5; p > 
0.05), indicating normal Ca2+ levels in ER Ca2+ stores in STIM2-deficient cells 
(Fig. 18A, B). After addition of 1 mM extracellular Ca2+, a second [Ca2+]i peak 
indicated the presence of SOCE in STIM2-deficient platelets, which showed no 
differences in amplitude as compared to wild-type controls (wt: 1426.25 ± 
703.77 nM; Stim2-/-: 1262.14 ± 606.77 nM; n = 5; p > 0.05) (Fig. 18A, B). Thus, 
STIM2 deletion does not alter basal [Ca2+]i, ER Ca2+ levels and SOCE in 
platelets. 
Additionally, [Ca2+]i changes were assessed in the presence of extracellular 
Ca2+ upon platelet stimulation with agonists activating G-protein-coupled 
signaling pathways, such as thrombin, ADP or the TxA2 analogue U46619 (data 
not shown), as well as ITAM-coupled signaling pathways, such as the collagen 
related peptide (CRP) that stimulates the collagen receptor glycoprotein (GP)VI 
(Fig. 18A, B). After agonist addition, [Ca2+]i raised exceeding the basal [Ca2+]i 
level, indicating SOCE (Fig. 18A). In this case, comparable results were 
obtained in STIM2-deficient and wild-type control platelets with all agonist 
tested, indicating no altered Ca2+ homeostasis and SOCE after platelet 
stimulation through the main activation pathways (Fig. 18B). Thus, STIM2 does 
not seem to play a major role in regulation of basal [Ca2+]i, ER Ca2+ levels, 
SOCE and Ca2+ signaling in response to all major agonists. A crucial role for 
STIM1, a homologue of STIM2, in SOCE in platelets has been described [6]. 
Western blot analysis of STIM expression revealed a dominant expression of 
STIM1 in platelets, although this method does not provide quantitative 
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information (Fig. 9B). Therefore, a possible hypothesis could be that STIM1 can 
compensate STIM2 deficiency indicating a redundant function of STIM2 in 
SOCE in platelets, at least under the tested conditions. 
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Figure 18. Normal Ca2+ homeostasis and SOCE in STIM2-deficient platelets upon agonist 
stimulation. Washed Fura-2 loaded platelets were stimulated with the indicated agonist in the 
presence or absence of 1 mM extracellular Ca2+, and [Ca2+]i was assessed using a Perkin-
Elmer LS55 fluorimeter. (A) Bar graphs representation of maximal [Ca2+]i changes after addition 
of the indicated agonists, given as mean increase of [Ca2+]i (Δ[Ca2+]i (nM)) ± s.d. 
(B) Representative Ca2+ measurements of the upper bar graphs. Values represented as mean 
[Ca2+]i (nM) ± s.d, (n  5). Black arrows indicate the time points of agonist addition, 
TG = thapsigargin, Thr = thrombin. Differences considered significant if p < 0.05 (Mann-Whitney 
U-test). 
 
 
5.5.3. Normal function of Stim2-deficient platelets in vitro 
 
To test the functional consequences of STIM2 deficiency in platelets in vitro, 
activation studies were performed upon agonist stimulation using flow cytometry 
(Fig. 19) and aggregometry (Fig. 20). Flow cytometric studies of GPIIbIIIa 
(integrin IIb3) activation using the JON/A-PE antibody (preferentially binds to 
the high affinity conformation of mouse integrin IIb3) [143], and of 
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degranulation-dependent P-selectin surface exposure after platelet activation 
showed that STIM2-deficient platelets become fully activated in response to 
thrombin, CRP, ADP+U46619, convulxin (CVX) or rhodocytin (Fig. 19). CVX 
and rhodocytin are platelet aggregators isolated from snake venom that bind to 
the receptor GPVI and Clec-2, respectively. Therefore, the loss of STIM2 does 
not impair integrin activation and degranulation in response to GPVI (ITAM 
signaling) as well as G-protein coupled agonist activation. 
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Figure 19. Stim2-deficient platelets are normally activated in vitro. Flow cytometric analysis 
of αIIbβ3 integrin activation and degranulation-dependent P-selectin exposure in response to 
the indicated agonists. Representative dot plots of wild-type and STIM2-deficient platelets 
(n = 8 per group). Epi = Epinephrine. 
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To study the effect of STIM2 deficiency on platelet aggregation in vitro, platelets 
were isolated from wild-type and Stim2-/- mice and stimulated with different 
agonist in presence of 1 mM extracellular Ca2+ (Fig. 20). 
Stimulation of wild-type platelets with 5 µM TG induced platelet aggregation, 
indicating that passive Ca2+ depletion from the ER store is sufficient to produce 
normal aggregation in platelets, without additional stimulation of upstream 
activating pathways (Fig. 20A, upper lane left). Stimulation of STIM2-deficient 
platelets with 5 µM TG produced the same effect as compared to wild-type 
controls (wt: 58.71 ± 18.94 %; Stim2-/-: 55.17 ± 24.65 %; n = 6; p > 0.05) 
(Fig. 20B). 
Furthermore, STIM2-deficient platelets aggregated normally and reached 
similar maximum aggregation rates as compared to wild-type controls in the 
presence of thrombin, collagen, CRP, ADP, U46619 or rhodocytin (Fig. 20A, B). 
Addition of 0.2 µM ADP did not induce aggregation either in wild-type control or 
STIM2-deficient platelets (Fig. 20A, lower lane left). In contrast, 5 min 
incubation with 10 µM epinephrine prior to platelet stimulation with 0.2 µM ADP 
induced significant platelet aggregation (Fig. 20A, lower lane middle). Under 
these conditions, no differences in maximum aggregation rates were observed 
between STIM2-deficient platelets and wild-type control platelets (wt: 25.30 ± 
7.10 %; Stim2-/-: 30.73 ± 5.89 %; n = 4; p > 0.05) (Fig. 20B).  
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Figure 20. Stim2-/- platelets aggregate normally in vitro. Wild-type or STIM2-deficient 
platelets were isolated, stimulated with the indicated agonist and the activity was assessed by 
recording light transmission in an aggregometer. TG = thapsigargin, Thr = thrombin, 
Col = collagen, Rhod = rhodocytin and Epi = epinephrine. (A) Representative aggregation 
measurements of platelets isolated from wild-type (black line) and Stim2-/- mice (gray line), given 
as light transmission (%). Black arrows indicate the time points of agonist addition. (B) Bar 
graph representation of maximal platelet aggregation after stimulation with the indicated 
agonists on platelets isolated from wild-type (black line) and Stim2-/- mice (gray line), given as 
mean Max. Aggregation (%) ± s.d. (n > 5 per group). (C) Bar graph representation of 
disaggregation slopes after maximal aggregation induced by addition of 5 µM ADP in platelet-
rich-plasma (prp). Disaggregation was calculated as the difference on light transmission values 
after the maximal aggregation per minute, given as mean disaggregation (%/max.aggr*min) ± 
s.d. (n = 5 per group). The higher is the value, the faster is the disaggregation. Differences were 
considered significant if p < 0.05 (Mann-Whitney U-test). 
 
STIM2-deficient platelets showed a tendency (but no significant) to 
disaggregate faster as compared to wild-type control platelets when activated 
with 5 µM ADP in prp (wt: 24.26 ± 6.15 %/max.aggr*min; Stim2-/-: 27.17 ± 
5.34 %/max.aggr*min; n = 6; p > 0.05) (Fig. 20C). The disaggregation was 
calculated as the difference on light transmission values after the maximal 
aggregation per minute.  
Thus, despite this minor difference in disaggregation after ADP activation, the in 
vitro results indicate that the absence of STIM2 does not significantly affect 
platelet activation in vitro. 
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5.5.4. Tyrosine phosphorylation assay 
 
To test a possible altered activation pathway in Stim2-/- platelets, tyrosine 
phosphorylation of signaling proteins was analysed in washed platelets upon 
activation with a strong agonist (Fig. 21). Platelets were stimulated with 
2.5 µg/mL CVX. Aliquots were collected at different time points from the same 
sample. For western blot analysis, the anti-phosphotyrosine IgG 4G10 was 
used to detect phosphorylated tyrosines in whole protein lysates. Wild-type 
platelets showed a band migrating at 35 kDa which decreased in intensity 
60 sec after activation with 2.5 µg/mL CVX, indicating dephosphorylation 
activity. In contrast, this band decreased in intensity 120 sec after activation in 
Stim2-/- platelets, indicating a delay in dephosphorylation. According to the 
molecular weight of the band LAT was proposed as candidate. However the 
importance of this delayed dephosphorylation observed in Stim2-/- platelets is 
not clear. 
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Figure 21. Stim2-/- platelets showed a delayed dephosphorylation in a 35 kDa unidentified 
protein. Platelets isolated from Stim2-/- or wt mice were incubated with constant stirring in 
Tyrode’s buffer, supplemented with 0.5 M EDTA to avoid aggregation, and stimulated with 
2.5 µg/mL CVX. Aliquots were collected at the indicated time points for western blot analysis 
using the anti-phosphotyrosine Ig 4G10 (n = 3). Black arrow indicates the size of the band. 
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5.5.5. Normal spreading and thrombus formation of Stim2-/- platelets ex 
vivo 
 
In vivo, platelet activation on the exposed ECM or a growing thrombus occur in 
flowing blood, where shear conditions, rheological characteristics of the blood 
stream and rapid clearance of produced soluble mediators play important roles 
for thrombus formation and stabilization. Under these conditions, Stim2-/- 
platelets could potentially show different activity than during in vitro conditions. 
Therefore, the ability of Stim2-/- platelets to form thrombi ex vivo on collagen-
coated surfaces was analyzed in a whole blood perfusion system [130] under 
medium (1000 s-1) or high shear conditions (1700 s-1) (Fig. 22). As in the wild-
type controls, Stim2-/- platelets adhered to collagen fibers, formed aggregates 
within 3 min and grew into large thrombi within 5 min (Fig. 22B, D).  
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Figure 22. Normal thrombus formation in Stim2-/- mice ex vivo. Wild-type and Stim2-/- whole 
blood were perfused over a collagen-coated surface at a medium (1000 s-1, upper) or high 
shear rate (1700 s-1, lower) for 4 min. (A, C) Surface area covered by wild-type (black bar) or 
Stim2-/- (gray bar) platelets/thrombi is given as a mean of 5 experiments ± s.d. 
(B, D) Representative phase contrast images taken 4 min after washing at the end of the 
experiment. Scale bar, 100 µm. Differences were considered significant if p < 0.05 (Mann-
Whitney U-test). 
 
As consequence, the surface area covered by platelets and the total thrombus 
volume were similar to wild-type controls at high (50  6 % for wt; 50  8 % for 
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Stim2-/-; n = 5; p > 0.05) or medium (40  8 % for wt; 38  10 % for Stim2-/- 
n = 5; p > 0.05) shear conditions (Fig. 22A, C). These findings indicate that 
STIM2 is not required for platelet activation on collagen, and on the surface of 
growing thrombi under conditions of medium or high shear ex vivo. 
Finally, an in vitro spreading assay was performed on human fibrinogen–coated 
(100 µg/mL) slides to evaluate the effect of STIM2 absence on integrin-
mediated adhesion and subsequent activation of “outside-inside” signaling 
pathways, platelet shape change and spreading (Fig. 23). Upon platelet 
activation in the presence of 0.05 U/mL thrombin, Stim2-/- platelets could spread 
normally within the expected time of 20 min. Hence, no differences were 
observed as compared to wild-type control platelets. In conclusion, absence of 
STIM2 does not alter the ability of platelets to spread and to perform shape-
change upon activation, indicating a normal activation of the "outside-in" 
signaling of the integrin IIb3. 
 
wt Stim2-/-
 
Figure 23. Stim2-/- platelets spread normally on fibrinogen. Representative phase contrast 
images of wild-type (wt) or Stim2-/- (Stim2-/-) platelets activated with 0.05 U/mL thrombin on 
100 µg/mL human fibrinogen-coated coverslips. Scale bar, 5 µm. 
 
 
5.5.6. Normal function of Stim2-/- platelets in murine in vivo models 
 
As platelet aggregation may contribute to pathologic occlusive thrombus 
formation, the effects of STIM2 deficiency on ischemia and infarction were 
studied by in vivo fluorescence microscopy following ferric chloride-induced 
mesenteric arteriole injury. In all wild-type control mice, the formation of small 
aggregates was observed ~5 min after injury, increased in size after 10 min, 
with progression to complete vessel occlusion within 20 min (mean occlusion 
   
 -86- 
  Results 
time: 1110 ± 250 sec) (Fig. 24B, C). Similar results were obtained in Stim2-/- 
mice, displaying no differences in thrombus formation as compared to wild-type 
control mice (n = 6 each). 
An additional assay was performed to address the effect of STIM2 deletion in 
platelet hemostatic function: the tail bleeding time model (Fig. 24A). After cutting 
a 1 mm tail tip in anesthetized mice, wild-type control mice were able to stop 
bleeding within 300 sec. Similar results were obtained in Stim2-/- mice (n = 12 
each).  
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Figure 24. Normal bleeding time and thrombus formation in Stim2-/- mice in vivo. (A) One 
mm tail tip was cut and individual tail bleeding times were monitored for 20 min. (B) Thrombosis 
was induced in mesenteric arterioles in wild-type (black bar) and Stim2-/- (gray bar) mice by 
topical application of FeCl3 and the time to complete occlusion was determined by Intravital 
microscopy. Mean occlusion time ± s.d. (C) Representative pictures of one experiment. 
Occlusion occurred in both, the wild-type and Stim2-/- mouse. Indicated time points represent 
minutes after FeCl3-induced injury. Scale bar, 25 µm. Differences were considered significant if 
p < 0.05 (Mann-Whitney U-test). 
 
Thus, taken all platelet results together, the conclusion is that STIM2 deletion 
has no effect in platelet activity, thrombus formation and haemostasis neither in 
vitro, nor in vivo. This may be explained by a compensation of STIM2 function 
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by its homologue isoform STIM1, which shows stronger expression in platelets 
(Fig. 9 A, B).  
 
 
5.6. Analysis of STIM2 deficiency in immune cells 
 
In immune cells, the predominant pathway of Ca2+ entry is thought to involve 
IP3R-mediated SOCE. Previous reports suggested a possible role of STIM2 in 
Jurkat T cells, and cells of the immune system [2,53]. Therefore, the effect of 
STIM2 deletion in the innate (mast cells and macrophages) and the adaptive (B 
and T cells) immune system was studied, together with my colleagues David 
Stergner and Timo Vögtle, respectively. 
 
 
5.6.1. The effect of STIM2 deletion on the innate immune system: Mast 
cells 
 
5.6.1.1. Stim2 deletion does not alter Ca2+ homeostasis and SOCE in mast 
cells 
 
To analyze the effect of STIM2 deficiency on Ca2+ homeostasis and SOCE in 
mast cells, [Ca2+]i changes were assessed in Fura-2-loaded peritoneal (PMC) 
and bone marrow in vitro differentiated (BMMC) mast cells (kindly produced by 
AG Huber, University of Freiburg) from Stim2-/- and wild-type adult littermates 
(Fig. 25). Under resting conditions, no significant differences in basal [Ca2+]i was 
observed in Stim2-/- PMC (wt: 44.00 ± 7.42 nM; Stim2-/-: 43.50 ± 29.03 nM; 
n = 5; p > 0.05) or BMMC (wt: 42.83 ± 17.26 nM; Stim2-/-: 68.20 ± 32.62 nM; 
n = 6; p > 0.05) as compared to wild-type control mast cells (Fig. 25C). To 
assess SOCE, Ca2+ store release was induced by addition of 5 µM TG in the 
absence of extracellular Ca2+. 10 min after TG stimulation, Ca2+ release from 
intracellular stores was also similar in BMMC (wt: 30.67 ± 15.58 nM; Stim2-/-: 
41.30 ± 21.86 nM; n = 6; p > 0.05) or PMC (wt: 21.67 ± 12.58 nM; Stim2-/-: 12.33 
± 2.52 nM; n = 5; p > 0.05) and wild-type control mast cells, indicating normal 
Ca2+ levels in intracellular stores in Stim2-/- cells (Fig. 25A, C). After addition of 
1 mM extracellular Ca2+, a second [Ca2+]i peak indicated the presence of SOCE, 
which showed no significant differences in amplitude between Stim2-/- PMC 
(wt: 88.33 ± 57.52 nM; Stim2-/-: 57.67 ± 29.26 nM; n = 5 each; p > 0.05) or 
BMMC (wt: 86.75 ± 53.05 nM; Stim2-/-: 48.00 ± 28.80 nM; n = 6; p > 0.05) and 
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wild-type control mast cells (Fig. 25C). Thus, STIM2 deletion does not alter 
basal [Ca2+]i, nor basal ER Ca2+ levels or SOCE in mast cells. 
Mast cell activation mediated by the high-affinity receptors for IgE (FcRs) is 
considered to be a key event in mast cell function for the allergic inflammatory 
response. This comprises secretion of inflammatory mediators, activation of 
transcription factors, and the elaboration of cytokines. LAT-mediated signals are 
initiated following activation and aggregation of FcRI, resulting in the 
synergistic activation of PLC1 and PKC. This leads to an increase in Ca2+ 
mobilization and degranulation [102].  
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Figure 25. Normal Ca2+ homeostasis and SOCE in Stim2-/- mast cells. Fura-2-loaded bone 
marrow (BMMC) or peritoneal (PMC) in vitro differentiated mast cells were stimulated with 5 μM 
TG for 10 min or IgE+DNP-HSA  for 180 sec, in the absence or presence of 1 mM extracellular 
Ca2+, respectively, and [Ca2+]i was monitored. (A, B) Representative measurements of [Ca2+]i in 
wild-type (black line) and Stim2-/- mice (gray line), given as [Ca2+]i (nM) ± s.d. Black arrows 
indicate the time points of agonist addition. (C) Bar graph representation of basal [Ca2+]i levels 
(basal), [Ca2+]i increase after store depletion (TG) and maximal increase of [Ca2+]i after 
extracellular Ca2+ addition (Ca2+) compared to baseline levels (black bar for wild-type, gray bar 
for Stim2-/- mice), given as mean Δ[Ca2+]i ± s.d. (n = 5 per group). (D) Bar graph representation 
of maximal increase in [Ca2+]i after addition of 20 ng/µL DNP-HAS antigen in the presence of 
extracellular Ca2+, compared to basal [Ca2+]i levels (black bar for wild-type, gray bar for Stim2-/- 
mice). Results given as mean Δ[Ca2+]i ± s.d. (n = 5 per group). Differences were considered 
significant if p < 0.05 (Mann-Whitney U-test). 
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Experiments using Ca2+-sensing fluorescent dyes and patch clamp suggest that 
FcRI-mediated Ca2+ influx in mast cells may occur by SOCE [144]. Therefore, 
Changes in [Ca2+]i in response to FcR stimulation via FcR crosslinking were 
also assessed using IgE antibodies directed against 2,4-Dinitrophenyl hapten 
conjugated to human serum albumin (DNP-HSA) as substrate in the absence of 
extracellular Ca2+ (Fig. 25B, D). Mast cells were incubated overnight with 
150 ng/µL anti-DNP-HSA IgE and the next day, the [Ca2+]i was assessed in the 
presence 20 ng/µL of the antigen DNP-HSA and 1 mM extracellular Ca2+. Five 
min after stimulation with DNP-HSA, [Ca2+]i increase was similar in Stim2-/- mast 
cells (Stim2-/- PMC: 75.63 ± 32.94 nM; Stim2-/- BMMC: 40.00 ± 13.23 nM, n = 9; 
p > 0.05) as compared to wild-type control cells (wt PMC: 78.75 ± 12.50 nM; 
wt BMMC: 44.50 ± 5.07 nM; n = 10) indicating unaltered SOCE in STIM2-
deficient mast cells (Fig. 25D). Thus, the Ca2+ measurements indicate that 
STIM2 deletion has no effect in [Ca2+]i homeostasis and SOCE in mast cells 
after stimulation via store depletion by TG or IgE-mediated FcR activation. 
 
 
5.6.1.2. Stim2-/- mice are protected against IgE-mediated anaphylaxia 
independently of mast cells 
 
Mast cells play a central role in allergic inflammatory responses. The 
manifestations of mast-cell-driven allergic reactions, for instance anaphylaxis, 
are considered to be mainly due to the release of pro-inflammatory mediators 
following antigen-induced aggregation of FcRs [102]. To test a possible effect 
of STIM2 deletion on mast cells function during inflammation, despite the fact 
that Ca2+ homeostasis was not affected, IgE-mediated response of mast cells 
was tested in systemic anaphylaxia murine in vivo model (Fig. 26). Mice 
received by intravenous injection (i.v.) a dosage of 30 µg anti-DNP IgE per 
mouse. 24 h later, 250 µg of DNP-HSA antigen was injected i.v. and the body 
temperature was subsequently measured every 10 min using a rectal probe. 
Wild-type mice showed a pronounced decrease in body temperature, reaching 
the minimum 40 min after injection (31.42 ± 0.95 °C; n = 6) (Fig. 26A). 
Surprisingly, Stim2-/- mice showed a significant mild decrease in body 
temperature, reaching the minimum 20 min after injection (34.62 ± 1.09 °C; 
n = 6; p < 0.01). The differences in body temperature between wild-type and 
Stim2-/- mice were significant at all time points tested. Thus, this result indicates 
that Stim2-/- mice are protected from IgE-mediated systemic anaphylaxia. Since 
our previous results showed that Ca2+ homeostasis and SOCE are not 
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significantly altered in mast cells lacking STIM2, bone marrow chimeras were 
generated using wild-type mice transplanted with Stim2-/- bone marrow (Stim2+/+ 
-/-BM) to study the possible contribution of endothelial or other cells to the 
protective phenotype found in IgE-mediated systemic anaphylaxia (Fig. 26B). 
Wild-type platelets from host mice were effectively removed as most of the 
population in Stim2+/+ -/-BM chimeras were STIM2-deficient platelets, derived 
from the donor Stim2-/- bone marrow (Fig. 26C). Stim2+/+ -/-BM chimeric mice did 
not show the protective observed in Stim2-/- mice, and body temperature time 
course was similar to wild-type controls after IgE injection (n = 6) (Fig. 26B). 
Thus, the protective effect displayed by Stim2-/- mice in IgE-mediated 
anaphylaxia model is independent of mast cells. Therefore, it is most likely due 
to an altered function in other cell types such as the endothelial cells of blood 
vessels. Despite the interest of these findings, our aim was more focused on the 
analysis of STIM2 deficiency in hematopoietic system. Since our data indicated 
that mast cells seem not to be altered, the study was not followed up in this 
work. However these questions will be addressed in further studies. 
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Figure 26. IgE-mediated anaphylaxia in vivo model. Stim2-/-, wild-type or bone marrow 
chimeras (Stim2+/+BM-/-) were injected i.v. with 30 µg anti-DNP IgE per mouse 24 h before, and 
the next day the body temperature was measured every 10 min after injection of the DNP-HSA 
antigen (250 µg per mouse). (A) Graph representation of Stim2-/- (gray line) and wild-type (black 
line) body temperature at the indicated time points after i.v. injection of IgE (n = 6). (B) Graph 
representation of Stim2+/+BM-/- (gray line) and wild-type (black line) body temperature at the 
indicated time points after i.v. injection of IgE (n = 6). (C) Representative western blot analysis 
of wild-type and STIM2-deficient platelets from wild-type control mice and Stim2+/+ -/-BM 
chimeras, respectively. *p < 0.05, **p < 0.01. Differences were considered significant if p < 0.05 
(Mann-Whitney U-test). 
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5.6.2. The effect of STIM2 deletion on the innate immune system: 
Macrophages 
 
5.6.2.1. Stim2 deletion does not alter Ca2+ homeostasis and SOCE in 
macrophages 
 
Although STIM1 seems to be strongly expressed in macrophages, western blot 
analysis showed a weak expression of STIM2 (Fig. 27A). Additionally, Oh-hora 
et al. showed that murine T cell activation leads  to a substantial increase in 
STIM2 expression, nevertheless amounted to only a small proportion (3–10%) 
of total STIM protein [5]. Therefore, to analyze the role of STIM2 in Ca2+ 
homeostasis and SOCE in macrophages, [Ca2+]i changes were assessed in 
Fura-2-loaded macrophages isolated by lavage of the peritoneal cavity from 
Stim2-/- and wild-type adult mice (Fig. 27). Under resting conditions, Stim2-/- 
macrophages showed slightly (but statistically not significant) elevated basal 
[Ca2+]i as compared to controls (basal wt: 28.20 ± 14.18 nM; basal   Stim2-/-: 
37.67 ± 15.08 nM; n = 5; p > 0.05), indicating normal basal [Ca2+]i in the 
absence of STIM2 (Fig. 27C). To assess SOCE, Ca2+ store release was 
induced by addition of 5 µM TG in the absence of extracellular Ca2+ 
(Fig. 27B, C). Ten min after TG stimulation, Ca2+ release from the intracellular 
stores was also slightly higher in amplitude as compared to wild-type control 
mice but this difference was not significant (wt: 30.20 ± 6.72 nM; Stim2-/-: 
36.83 ± 17.99 nM; n = 5; p > 0.05), indicating normal Ca2+ content in the ER 
stores in Stim2-/- macrophages (Fig. 27C). After addition of 1 mM extracellular 
Ca2+, a second [Ca2+]i peak was observed indicating the presence of SOCE in 
wild-type macrophages (Fig. 27B). Again, the increase in amplitude in Stim2-/- 
cells was not significant as compared to wild-type control macrophages 
(wt: 91.60 ± 25.50 nM; Stim2-/-: 118.83 ± 34.83 nM; n = 5; p > 0.05) (Fig. 27C). 
Thus, STIM2 deletion does not alter basal [Ca2+]i, Ca2+ content in the ER and 
SOCE in macrophages after stimulation of  intracellular Ca2+ stores depletion.  
Fc receptors for IgG (FcRs) control a wide variety of cellular responses in 
macrophages, such as antibody-dependent cell-mediated cytotoxicity, 
phagocytosis and release of inflammatory mediators. These responses are 
involved in cellular destruction and the amplification of normal and pathologic 
immune reactions in vivo [145]. Braun et al. found severely defective TG-
induced SOCE and FcRs-triggered Ca2+ responses in Stim1-/- macrophages, 
demonstrating for the first time that SOCE is the predominant mechanism of 
Ca2+ entry downstream of FcRs activation and that STIM1 is a critical mediator 
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of this process [173]. Therefore, changes in [Ca2+]i in response to direct FcR 
activation were also assessed (Fig. 27E, F).  
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Figure 27. Normal Ca2+ homeostasis and SOCE in Stim2-/- macrophages. Fura-2-loaded 
peritoneal macrophages were stimulated for 10 min with 5 μM thapsigargin (TG) or for 180 sec 
with 2.4G2 (10 µg/mL) cross-linking (X-link) followed by addition of extracellular Ca2+, and 
[Ca2+]i was monitored. (A) Representative western blot analysis of STIM1 and STIM2 
expression in cells isolated by peritoneal lavage of 2 month old wild-type mice. Tubulin 
expression was used as loading control (n = 3). (B, E) Representative measurements of [Ca2+]i 
in wild-type (black line) and Stim2-/- (gray line) macrophages stimulated with TG or 2.4G2 Ig 
cross-linking, respectively (n = 5 per group). Black arrows indicate the time points of agonist 
addition. (C) Bar graphs representation of basal [Ca2+]i, increase after store depletion by TG 
(TG) and maximal increase in [Ca2+]i compared to basal levels, given as mean Δ[Ca2+]i (nM) ± 
s.d. (n = 5 per group), before and after addition of 1 mM extracellular Ca2+.(D) H&E stainings of 
peritoneal resting wild-type and Stim2-/- macrophages. Bar scale: 10 µm. (F) Bar graphs 
representation of [Ca2+]i increase after store depletion by 2.4G2 Ig plus cross-linking (x-link) and 
maximal increase in [Ca2+]i, given as mean Δ[Ca2+]i (nM) ± s.d. (n = 5 per group), before and 
after addition of 1 mM extracellular Ca2+. Differences were considered significant if p < 0.05 
(Mann-Whitney U-test). 
 
To assess SOCE, cells were incubated for 15 min with 10 µg/mL 2.4G2 Ig, a 
monoclonal antibody against the extracellular homologous region of both FcRII 
and FcRIII [147], and Ca2+ store release was induced by 2.4G2 cross-linking 
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with a secondary Ig (10 µg/mL) in the absence of extracellular Ca2+ (Fig. 27E). 
180 sec after cross-link stimulation, Ca2+ release from intracellular stores was 
similar in Stim2-/- cells as compared to wild-type controls (wt: 20.00 ± 5.00 nM; 
Stim2-/-: 20.75 ± 15.56 nM; n = 5; p > 0.05), indicating normal Ca2+ release from 
the ER Ca2+ store in Stim2-/- macrophages (Fig. 27F). After addition of 1 mM 
extracellular Ca2+, no differences in SOCE were observed in Stim2-/- cells as 
compared to wild-type controls (wt: 62.00 nM ± 32.13 nM; Stim2-/-: 62.25 ± 
30.05 nM; n = 5; p > 0.05) (Fig. 30F).  
Finally, resting STIM2-deficient macrophages stained with H&E showed no 
obvious abnormalities in their cellular morphology (Fig. 27D). 
Thus, STIM2-deletion does not alter SOCE in macrophages, neither after Ca2+ 
store release stimulation with 5 µM TG, nor by direct stimulation of FcR. 
 
 
5.6.2.2. Upregulated FcR expression in Stim2-/- macrophages 
 
In mice, there are three different activating FcRs; the high affinity receptor 
FcRI, the low-affinity receptor FcRIII, and the recently described FcRIV [127], 
and one inhibitory receptor, the FcRII. 
To test the expression levels of FcRs, flow cytometric analysis of resting 
peritoneal macrophages was performed using specific antibodies against FcRI, 
FcRIII, FcRIV and the antibody 2.4G2 (used for assessment of [Ca2+]i 
changes upon FcR activation). The last one binds to FcRII, III, and probably 
also IV (Fig. 28) [147]. Unexpectedly, apart from FcRI, all activatory FcRs 
were upregulated by 25 % in Stim2-/- mice (FcRIII: 617.40 ± 63.21; FcRIV: 
395.20 ± 36.21; 2.4G2: 139.00 ± 23.25; n = 5; p < 0.05) as compared to wild-
type control mice (FcRIII: 433.80 ± 29.00; FcRIV: 395.20 ± 63.21; 
2.4G2: 448.80 ± 58.47; n = 5). 2.4G2 Ig binds equally to FcRII and FcRIII. The 
observation that the 2.4G2 signal was increased to a smaller extent than the 
FcRIII signal in Stim2-/- macrophages might indicate that the inhibitory receptor 
FcRII is expressed at similar level in STIM2-deficient and wild-type 
macrophages. Unfortunately, due to the absence of an anti-FcRII Ig suitable for 
expression studies, this hypothesis could not be directly confirmed. 
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Figure 28. Surface FcRs expression in Stim2-/- macrophages. Peritoneal macrophages 
were isolated and stained with Alexa 647–conjugated FcRI, FcRIII, and FcRIV-specific Igs at 
saturating concentrations for 15 min at RT and analyzed directly by flow cytometry. 
Macrophages were gated by FSC/SSC characteristics and PE-F4/80 expression, as a specific 
marker from macrophages and monocytes. Results are given as the mean fluorescence 
intensity ± s.d. of 5 mice per group. *p < 0.05, **p < 0.01, differences were considered 
significant if p < 0.05 using the Mann-Whitney U-test. 
 
 
5.6.2.3. Stim2-/- mice are protected in experimental thrombocytopenia and 
anaphylaxis 
 
Immune thrombocytopenic purpura (ITP) is a rather common autoimmune 
disease in humans, characterized by the production of autoantibodies against 
platelet glycoproteins, resulting in an increased platelet clearance, normally 
accompanied by severe bleeding. Platelet surface glycoprotein IIb/IIIa 
(GPIIb/IIIa, IIb3 integrin) is the most common antigenic target in ITP [148]. In 
mice, i.v. injection of anti-GPIIb/IIIa antibodies leads to a FcR-dependent 
platelet clearance, mainly via macrophages located in the spleen and kupffer 
cells in the liver [132,149]. 
The in vivo relevance of STIM2 deficiency was tested in the murine model of 
IgG-induced ITP (Fig. 29). FcRs activation was induced by i.v. injection of the 
anti-GPIIb/IIIa antibodies JON3 (IgG1 which induces ITP predominantly through 
FcRIII) or JON1 (IgG2b which induces ITP predominantly through FcRIII and 
probably also FcRIV) [132] in Stim2-/- or wild-type mice. After i.v. injection of 
4.7 or 11 µg of JON or PBS as control, 50 µL whole blood samples were 
collected at day 0, 1, 2 and 3 after and platelet counts were measured. Both 
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JON1 and JON3 induced profound thrombocytopenia in wild-type controls as 
expected, with a maximal reduction of 66.3 % in platelet counts (after injection 
of 11 µg JON, n = 5) and 56.5 % (after injection of 4 µg JON, n = 5) one day 
after injection (Fig. 29A). In contrast, Stim2-/- mice showed significantly higher 
platelet counts as compared to wild-type controls, showing a maximal reduction 
of 10.9 % in platelet counts (after injection of 4 µg JON, n = 5) and 20.5 % (after 
injection of 7 µg JON, n = 5) 1 day after injection, respectively (Fig. 29A). 
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Figure 29. Stim2-/- mice are protected from anti-GPIIb/IIIa IgG-induced thrombocytopenia 
and anaphylaxis. (A) Wild-type (black circles) or Stim2-/- (open circles) mice received the 
indicated amounts of JON1, JON3 or vehicle and platelet counts were monitored (n = 5). 
(B) Wild-type or Stim2-/- mice received vehicle or 100 µg of JON1 or JON3 and body 
temperature was measured using a rectal probe (n = 5). *p < 0.05, **p < 0.01, ***p < 0.001, 
differences were considered significant if p < 0.05 (Mann-Whitney U-test). 
 
However, no significant differences were observed in mice injected with 11 µg 
of JON 3 (Fig. 29A). To study the effect of STIM2 deficiency in anti-GPIIbIIIa-
induced anaphylaxia, a higher amount (100 µg/mL) of JON1 or JON3 was i.v. 
injected to Stim2-/- or wild-type control mice, in order to activate the low-affinity 
receptor FcRIII [132], and the body temperature was measured over time using 
a rectal probe (Fig. 29B). Both JON1 and JON3 induced strong hypothermia in 
wild-type control mice as expected, with a minimal body temperature of 33.5 °C 
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(0.5 h after JON 1 injection, n = 5) and 31.7 °C (1 h after JON 3 injection, n = 5), 
respectively (Fig. 29B). In contrast, Stim2-/- mice showed significantly milder 
hypothermia as compared to wild-type control mice, with a minimal body 
temperature of 35.7 °C (0.5 h after JON 1 injection, n = 5) and 35.5 °C (1 h after 
JON 3 injection, n = 5), respectively (Fig. 29B). 
These results indicate a protective effect to FcRs-dependent immune 
thrombocytopenia in Stim2-/- mice. Since previously, a normal surface 
glycoprotein expression was shown in Stim2-/- platelets in this work (Fig. 17C), 
this protective effect is not based on a decrease of GPIIbIIIa levels in platelets. 
Taking all these results together, the connection between the unexpected 
upregulation of FcRs, the normal Ca2+ influx mediated by FcRs activation and 
the protective effect of STIM2 deletion in ITP model in mice is not clear. These 
results require further studies that are still ongoing. 
 
 
5.6.3. Effect of STIM2 deletion on the adaptive immune system: T and B 
cells 
 
5.6.3.1. Decreased SOCE in STIM2-deficient T cells 
 
As previously shown, STIM2 is also expressed in lymph nodes, indicating a 
function in T cells (Fig. 9A, 11E). Previous reports indicated a potential role of 
STIM2 in Jurkat T cell Ca2+ homeostasis [2,9,53]. Therefore, the effect of STIM2 
deficiency on Ca2+ homeostasis and SOCE was analyzed in Fura-2-loaded 
CD4+ T cells isolated from spleen and lymph nodes (Fig. 30). Deletion of STIM2 
in lymphocytes did not alter STIM1 expression (Fig. 30A). In resting conditions 
no differences were observed in Stim2-/- basal [Ca2+]i as compared to wild-type 
control mice (wt: 27.00 ± 12.00 nM; Stim2-/-: 37.00 ± 26.54 nM; n = 5; p  0.05) 
(Fig. 30B, C). Store-release upon TG treatment in Stim2-/- (38.33 ± 11.87 nM; 
n = 6; p > 0.05) cells was also similar as compared to wild-type controls 
(28.90 ± 5.76 nM; n = 8) indicating normal Ca2+ levels in ER Ca2+ stores 
(Fig. 30B, C). After addition of 1 mM extracellular Ca2+, a second [Ca2+]i peak 
indicated the presence of SOCE in Stim2-/- CD4+ T cells, which showed 40 % 
decrease in amplitude as compared to wild-type control mice (297.83 ± 
81.99 nM vs. 565.03 ± 65.56 nM in wt cells; p < 0.05) (Fig. 30B, C). Thus, 
STIM2 deficiency does not alter basal [Ca2+]i and ER Ca2+ levels, but leads to a 
significant 40 % reduction in SOCE after TG-induced Ca2+ store depletion in 
CD4+ T cells. 
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Additionally, changes in [Ca2+]i were assessed in response to direct T cell 
receptor (TCR) activation by the anti-CD3 IgG cross-linked by a secondary Ig 
(Fig. 30E, F). Stimulated CD3 receptor associates with the TCR and comprises 
the main activating pathway in T cells [25].  
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Figure 30. Reduced SOCE in Stim2-/- CD4+ T cells. Fura-2-loaded CD4+ T cells isolated with 
MACS columns were stimulated for 10 min with 5 μM TG or for 180 sec 10 µg/mL anti-CD3 IgG 
cross-link, followed by addition of 1 mM extracellular Ca2+, and [Ca2+]i was monitored. 
(A) Representative western blot analysis of STIM1 and STIM2 expression in lymph nodes of 
8 weeks old wild-type or   Stim2-/- mice (n = 3). Tubulin expression was used as loading control. 
(B, E) Representative measurements of [Ca2+]i in wild-type (Black line) and Stim2-/- (gray line) 
CD4+ T cells. Black arrows indicate the time points of agonist addition, TG = thapsigargin. 
(C, F) Basal levels, increase after store depletion (-) and maximal increase in intracellular Ca2+ 
concentrations compared to baseline levels (Δ[Ca2+]i) ± s.d. (n = 5 per group) before and after 
addition of 1 mM extracellular Ca2+ are shown. (D) Representative pictures of H&E stained 
CD4+ T cells. Scale bar: 5 μm. *p < 0.05. Differences were considered significant if p < 0.05 
(Mann-Whitney U-test). 
 
To assess SOCE, cells were incubated for 15 min with 10 µg/mL anti-CD3 and 
Ca2+ store release was induced by cross-linking the bound anti-CD3 IgG by a 
secondary Ig in the absence of extracellular Ca2+ (Fig. 30E, F). 180 sec after 
the cross-link stimulation, the Ca2+ release from intracellular stores in Stim2-
deficient cells was similar as compared to wild-type controls (wt: 29.14 ± 
5.78 nM; Stim2-/-: 15.17 ± 4.09 nM; n = 6; p > 0.05), indicating normal Ca2+ 
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release from ER Ca2+ stores in Stim2-/- CD4+ T cells (Fig. 30E, F). After addition 
of 1 mM extracellular Ca2+, SOCE was reduced by 60 % in Stim2-/- T cells 
(142.00 ± 26.90 nM; n = 6; p < 0.05) as compared to wild-type controls 
(327.36 ± 61.81 nM; n = 6) (Fig. 30E, F). 
Finally, resting STIM2-deficient CD4+ T cells stained with H&E showed no 
obvious abnormalities in morphology (Fig. 30D).Thus, STIM2 seems not to play 
a major role in regulation of basal [Ca2+]i, ER Ca2+ levels in CD4+ T cells, but 
STIM2 deficiency markedly reduces SOCE after intracellular Ca2+ stores 
depletion by TG or by direct TCR activation. 
 
 
5.6.3.2. STIM2 deficiency does not alter CD3 and T cell receptor (TCR) 
expression in lymphocytes and splenocytes 
 
Since STIM2 deletion reduced SOCE after Ca2+ store depletion by direct TCR 
activation, CD3 and TCR expression levels were studied in naive resting 
lymphocytes and splenocytes by flow cytometry (Fig. 31). Stim2-/- CD4+ or CD8+ 
T cells from lymph node (Fig. 31A) or spleen (Fig. 31B) showed no differences 
in TCR expression levels and a non-significant decrease of CD3 expression in 
CD4+ (lymph node: 185.00 ± 56.76 in wt; 131.55 ± 43.08 in Stim2-/-; spleen: 
175.39 ± 69.70 in wt; 129.89 ± 45.95 in Stim2-/-; n = 5; p > 0.05) or CD8+ (lymph 
node: 79.92 ± 26.62 in wt; 58.98 ± 20.51 in Stim2-/-; spleen: 79.82 ± 30.80 in 
wt; 64.26 ± 17.82 in Stim2-/-; n = 5; p > 0.05) T cells as compared to wild-type 
control mice.  
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Figure 31. CD3 and TCR surface protein expression in CD4+ T or CD8+ cells. Analysis of 
CD3 and TCR expression by lymphocytes (A) and splenocytes (B) isolated from wild-type 
(black bar) or Stim2-/- (gray bar) mice and assessed directly by flow cytometry. T cells were 
gated by FSC/SSC characteristics and CD4 or CD8 surface protein expression. Results are 
given as the mean fluorescence intensity ± s.d. of 6 mice per group. Differences were 
considered significant if p < 0.05 (Mann-Whitney U-test). 
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This result indicates that STIM2 deficiency does not affect CD3 or TCR 
expression in T cells and the decreased SOCE seen after T cell stimulation 
through CD3 receptor is not due to a reduced expression of those surface 
molecules. 
 
 
5.6.3.3. Normal cellularity and decreased CD8+ cells in primary and secondary 
lymphoid organs 
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Figure 32. Normal cellularity in primary and secondary lymphoid organs. (A) Bar graph 
representation of thymocytes (thymus), bone marrow cells (BM), lymphocytes (LN) and 
splenocytes (Spl) isolated from wild-type (black bar) and Stim2-/- (gray bar) mice and analyzed 
directly by flow cytometry. Cell counts given as mean (x107) total cells ± s.d. (n = 3). (B) Bar 
graphs representation of CD4 and CD8 positive lymphocytes (left graph) and splenocytes (right 
graph) in wild-type (black bar) or Stim2-/- (gray bar) mice, given as mean frequency (%) of the 
total ± s.d. (n = 3). (C) Representative dot plot of CD4 versus CD8 expression by lymphocytes 
(left) and splenocytes (right) in wild-type (left square) or Stim2-/- (right square) mice measured 
by flow cytometry. *p <  0.05. Differences were considered significant if p < 0.05 (Mann-Whitney 
U-test). 
 
Previously in this work it was shown that the major organs of Stim2-/- mice 
exhibit no obvious abnormalities, including bone marrow, thymus and spleen 
(Fig. 13A-C). Furthermore, the effect of STIM2 deficiency on cellularity in 
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primary and secondary lymphoid organs was studied by flow cytometry. Naive 
Stim2-/- mice displayed normal numbers of thymocytes, bone marrow cells, 
lymphocytes and splenocytes (6.80x107 ± 1.82x107 cells; 7.17x107 ± 
0.07x107 cells ; 1.93x107 ± 0.21x107 cells; 3.53x107 ± 0.83x107 cells, 
respectively; n = 4; p > 0.05) as compared to wild-type control mice (7.60x107 ± 
0.66x107 cells; 0.8x107 ± 0.17x107 cells ; 2.37x107 ± 0.45x107 cells; 2.93x107 ± 
0.72x107 cells, respectively; n = 4; p > 0.05) (Fig. 32A ). Further, the lymphocyte 
and splenocyte subset distribution was examined in Stim2-/- mice and wild-type 
littermates by flow cytometry using anti-CD4 and anti-CD8 antibodies as 
markers (Fig. 32B-C). No significant differences were found in Stim2-/- CD4+ 
lymphocytes (Stim2-/-: 40.44 ± 4.43 %; wt: 36.58 ± 2.98 %; n = 6; p > 0.05) or 
splenocytes (Stim2-/-: 19.62 ± 2.31 %; wt: 18.54 ± 3.13 %; n = 6; p > 0.05) as 
compared to wild-type control mice (Fig. 32B-C). In contrast, a mild significant 
decrease (28 %) in Stim2-/- CD8+ lymphocytes (Stim2-/-: 18.07 ± 2.07 %; 25.83 ± 
1.88 %; n = 6; p > 0.05) and splenocytes (Stim2-/-: 8.62 ± 1.21 %; wt: 11.70 ± 
2.12 %; n = 6; p > 0.05) was observed (Fig. 32B-C). 
Thus, STIM2 deficiency leads to a reduced number of CD8+ T cells and 
splenocytes in mice, suggesting a possible role of STIM2 in CD8+ T cell 
maturation. However, analysis of thymocyte subset distribution showed no 
differences in Stim2-/- mice as compared to wild-type control mice (Fig. 33A, B), 
indicating that CD8+ T cell maturation in thymus is normal. Therefore, such a 
reduced number of CD8+ lymphocytes and splenocytes can not be explained by 
an altered maturation of T cells in thymus. 
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Figure 33. Normal CD4+ or CD8+ subset distribution in thymus. (A) Representative dot plot 
of CD4 versus CD8 expression by thymocytes in wild-type (left square) or Stim2-/- (right square) 
mice measured by flow cytometry. (B) Bar graph representation of CD4 and CD8 positive 
thymocytes in wild-type (black bar) or Stim2-/- (gray bar) mice, given as mean frequency (%) of 
the total ± s.d. (n = 5).Differences were considered significant if p < 0.05 (Mann-Whitney U-test). 
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To study the effect of STIM2 deficiency in naive and effector/memory cells 
distribution, the expression of CD44 and CD62L surface proteins by CD4+ and 
CD8+ lymphocytes or splenocytes was examined in Stim2-/- mice and wild-type 
littermates using flow cytometry (Fig. 34) [150]. Naive T cells express a 
CD62LhighCD44low expression profile, whereas effector memory T cells exhibit a 
CD62LlowCD44high expression profile. Analysis of CD62L and CD44 expression 
in naive lymphocytes and splenocytes showed no differences in Stim2-/- mice as 
compared to wild-type control mice (Fig. 34A, B). 
Taken together, these results revealed a mild decrease of CD8+ in lymph node 
and spleen, suggesting a specific role of STIM2 in CD8+ T cell survival or 
maturation. Additional studies are currently ongoing to clarify the precise role of 
STIM2 in CD8+ T cell fate. 
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Figure 34. CD4+ T or CD8+ cell subset distribution in spleen and lymph nodes as 
assessed by flow cytometry for CD4, CD8, CD44 and CD62L surface protein expression. 
(A) Representative dot plots of CD62L versus CD44 expression by splenocytes (left) and 
lymphocytes (right) in wild-type (upper dot plots) or Stim2-/- (lower dot plots) mice measured by 
flow cytometry. (B) Table showing the frequencies of the CD62L and CD44 immune subtypes in 
CD4+ and CD8+ lymphocytes or splenocytes in wild-type or Stim2-/- mice, given as mean 
percentage ± s. d. Differences were considered significant if p < 0.05 (Mann-Whitney U-test). 
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5.6.3.4. Normal T cell proliferation in naive and normal immune response in 
Keyhole limpet hemocyanin (KLH)-immunized Stim2-/- mice 
 
To study the effect of STIM2 deficiency in splenocyte proliferation ex vivo, 
freshly isolated cells from naive Stim2-/- and wild-type littermates were assessed 
by flow cytometry, using CD4, CD8 and B220 as markers of T and B cell 
respectively, and Ki-67 as a marker of proliferating cells (Fig. 35A). The Ki-67 
protein is present during all active phases of the cell division (G1, S, G2, and 
mitosis), but is absent from resting cells (G0). No differences in numbers of Ki-
67 positive cells were observed in Stim2-/- mice (CD4+: 19.36 ± 1.10 %; CD8+: 
9.87 ± 1.59 %; B220+: 10.60 ± 2.63 %; n = 6; p > 0.05) as compared to wild-type 
control mice (CD4+: 20.24 ± 4.66 %; CD8+: 8.66 ± 1.13 %; B220+: 11.56 ± 
4.45 %; n = 6; p > 0.05). Thus, STIM2 deficiency does not alter proliferation in 
naive splenocytes. 
To study the effect of STIM2 deficiency in B cell activity, the serum titers of 
IgG1, IgG2a, IgE and IgM antibodies were tested by isotype specific anti-Ig 
antibody-coated ELISA in naive mice (Fig. 35B). No differences were found in 
IgG1 (Stim2-/-: 1494x106 ± 357.25 x106 ng/mL ; wt: 1398x106 ± 
379.45x106 ng/mL; n = 5; p > 0.05), IgG2a (Stim2-/-: 583.8x106 ± 
377.15x106 ng/mL ; wt: 643.5x106 ± 266.58x106 ng/mL; n = 5; p > 0.05), IgE 
(Stim2-/-: 1.55x106 ± 0.62x106 ng/mL ; wt: 1.49x106 ± 0.43x106 ng/mL; n = 5; 
p > 0.05) or IgM   (Stim2-/-: 1.48x106 ± 0.63x106 ng/mL ; wt: 1.44x106 ± 
0.45x106 ng/mL; n = 5; p > 0.05) isotype titer in Stim2-/- mice serum as 
compared to wild-type control serum. 
To examine the effect of STIM2 deletion in adaptive immune response after 
antigen challenge, Stim2-/- and wild-type control littermates were immunized 
with the T cell-dependent model antigen KLH, and the specific KLH-reactive T 
cell proliferation and IgG production by B cells were assessed (Fig. 35C, D). 
These experiments were performed in collaboration with Dr. Niklas Beyersdorf 
and Dr. Thomas Kerkau from the Immunology and Virology department, 
University of Würzburg. Mice were injected intraperitoneally (i.p.) with 25 µg of 
KLH antigen and after three weeks they were boosted with an additional 
injection of 25 µg of KLH antigen and 15 µL TiterMax adjuvant. Three weeks 
after CD4+ T cells were isolated from spleen, co-cultured with irradiated antigen 
presenting cells (APC) and re-stimulated for two days with 10 µg/mL of KLH 
antigen in vitro, in presence of radioactive H3-thymidine. T cell proliferation was 
assessed by radioactive H3-thymidine uptake, the so-called T cell recall assay. 
Specific KLH-reactive Stim2-/- CD4+ T cells showed similar proliferation rates in 
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vitro as compared to wild-type control T cells (wt: 8211 ± 1359 c.p.m.; Stim2-/-: 
10802 ± 1498 c.p.m.; n = 3; p > 0.05) (Fig. 35C). 
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Figure 35. T cell proliferation in naive and normal immune response in KLH-immunized 
Stim2-/- mice. (A) Bar graph representation of Ki-67 positive cells in Stim2-/- (gray) and wild-type 
(black) splenocytes as assessed by flow cytometry, given as mean Ki-67 positive cells (%) ± 
s.d. (B) Bar graphs representation of Ig titers in naive Stim2-/- (gray) and wild-type (black) mice 
blood serum assessed by isotype-specific anti-Ig antibody-coated ELISA, given as mean Ig 
concentration (x106 ng/mL) ± s.d. (C) Bar graph representation of the proliferative response of 
Stim2-/- (gray) and wild-type (black) KLH-reactive CD4+ T cells in presence of KLH antigen at the 
indicated concentrations, given as mean H3-thymidine counts per minute (c.p.m.) ± s.d. 
0.5 µg/mL -CD3 Ig stimulation was used as a positive control (D) Bar graph representation of 
KLH-specific IgG titers in Stim2-/- (gray) and wild-type (black) mice blood serum three weeks 
after boosted immunization with the KLH antigen, given as mean optical density (O.D.) ± s. d.. 
Differences were considered significant if p < 0.05 (Mann-Whitney U-test). 
 
In parallel, specific IgGs against KLH were measured in blood serum by KLH-
coated ELISA (Fig. 35D). Again, mice were injected i.p. with 25 µg of KLH 
antigen and after three weeks they were boosted with an additional injection of 
25 µg of KLH antigen and 15 µL TiterMax adjuvant. Three weeks after i.p. 
injection, comparable titers of specific IgG anti-KLH antibody were found in 
Stim2-/- and wild-type control mice blood serum (Stim2-/-: 0.481 ± 0.21 O.D.; wt: 
0.485 ± 0.29 O.D.; n = 3; p > 0.05) (Fig. 35D). This result indicates that T cell-
mediated antibody production in serum is not impaired in STIM2-deficient mice. 
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Taken together, these results indicate that STIM2 does not play a role in T cell 
proliferation, B cell antibody production in naive mice or in KLH-mediated 
adaptive immune response in mice. 
 
 
5.6.3.5. Experimental autoimmune encephalomyelitis (EAE) is significantly 
ameliorated in STIM2-deficient mice 
 
T cells are considered to orchestrate inflammation in Multiple sclerosis (MS), an 
inflammatory-demyelinating disorder of the central nervous system (CNS) 
[151,152]. Disturbed Ca2+ signaling and deregulation of the intracellular Ca2+ 
levels in T lymphocytes have been associated with inflammatory and 
autoimmune disorders, including MS [25]. Since it was previously shown in this 
work that STIM2-deficient T cells displayed a 40 % reduced SOCE after 
intracellular store depletion or CD3 cross-link stimulation (Fig. 30), it was 
hypothesized a possible role of STIM2 in autoimmune disorders in mice. 
In an initial experiment in collaboration with Michael K. Schuhmann and Dr. 
Sven G. Meuth from the Department of Neurology, University of Würzburg, the 
role of STIM2 in myelin oligodendrocyte glycoprotein (MOG35-55-peptide)-
induced EAE as an in vivo model of autoimmune response was examined 
(Fig. 36) [153]. 13 days after MOG-peptide immunization Stim2-/- mice showed a 
significantly reduced disease maximum (wt: day 13.8; score: 6.4  0.8; Stim2-/-: 
day 15.2; score: 4.6  1.2; p  0.05), while disease incidence, overall disease 
course and residual disease scores at day 50 were unaltered (Fig. 36A). 
Consequences of STIM-deficiency for inhibiting EAE development were further 
analyzed by immunohistopathology (Fig. 36B and C). Since Stim2-/- mice 
showed significant clinical differences only at the disease maximum, the lesion 
pattern in the spinal cord was investigated at this time point. H&E staining 
showed focal regions of T cell infiltration in Stim2-/- and wild-type control mice 
(Fig. 36B, upper panels). Stim2-/- mice showed a tendency to reduced 
demyelization in the white matter (neuronal axons) of the spinal cord (wt: 1.25  
0.18 %, Stim2-/-: 0.97  0.18 %, p = 0.295; n = 3 each) (Fig. 36B middle, C 
upper), but a comparable number of infiltrating T cells (Fig. 36B lower, C lower). 
Thus, Stim2-/- mice developed an attenuated EAE, indicating a possible role of 
this STIM2 during early phase of EAE progression, more precisely during 
disease maximum onset. 
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These initial results gave rise to a fruitful collaboration to study the role of 
STIM2 in a murine EAE in vivo model (see publication list: Schuhmann, MK. et al. 
2009, accepted manuscript, in press). 
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Figure 36. Mice lacking STIM2 show a significantly altered disease course and 
histopathology after EAE induction. (A) EAE was induced by MOG immunization (200 µg) in 
6-12 weeks old Stim2-/- (grey line, n = 10) or wild-type (black line, n = 9/10) littermates. 
(B) (upper panels) Hematoxylin and eosin (HE) staining of spinal cord sections from wild-type 
(wt, n = 3) and Stim2-/- mice (n = 3). (central panels) Luxol fast blue (LFB) staining of spinal cord 
myelin to study demyelination activity. (lower panels) Immunohistochemistry of spinal cord 
lesions using anti-CD3 IgG as marker of infiltrating T lymphocytes (n = 4). White arrows indicate 
the areas of T cell infiltration. Scale bar: 100 µm for all images. (C) Bar graph representation of 
demyelination (upper graph) and number of infiltrated CD3+ (lower graph) as a marker for T 
cells, in wild-type and Stim2-/- animals, given as mean demyelinated area (%)  s.d. and mean 
number T cells/mm2  s.d.. *p < 0.05. Differences were considered significant if p < 0.05 
(student’s t-test). 
 
 
5.7. Analysis of STIM2 deficiency in neurons 
 
5.7.1. STIM2 regulates SOCE and ischemia-induced Ca2+ accumulation in 
neurons 
 
Previously in this work it was shown that STIM2 is the dominant isoform in brain 
(Fig. 9). To test the effect of STIM2 deficiency on neuronal Ca2+ homeostasis, 
Ca2+ imaging experiments were performed in neuronal cultures extracted from 
E19 embryonic cortical tissue (in collaboration with Prof. Jens Eilers, Carl-
Ludwig-Institute for Physiology, University of Leipzig). To assess SOCE 
(referred to as CCE in neurons), Ca2+ store release was induced by the SERCA 
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pump inhibitor cyclopiazonic acid (CPA) in the absence of extracellular Ca2+. 
This treatment caused a transient Ca2+ signal, followed by a second [Ca2+]i 
increase after addition of external Ca2+ which exceeded the basal Ca2+ level, 
suggesting the presence of SOCE (Fig. 37A). Strikingly, SOCE was severely 
reduced in Stim2-/- neurons compared to wild-type controls (Stim2-/-: 27 ± 9 nM; 
wt: 82 ± 16 nM; n = 7 each representing the average signal from 20-35 cells; 
p < 0.05) (Fig. 37A). Thus, SOCE is regulated by STIM2 in cultured neurons. 
A
B
 
Figure 37. STIM2 regulates Ca2+ homeostasis in cortical neurons. Neuronal cultures [5 to 
9 days in vitro (DIV 5-9)] were loaded with Fura-2 and averaged [Ca2+]i responses in Stim2-/- 
were compared to wild-type (WT) cells (n = 5-7 experiments per group, each representing the 
average signal from 20-35 cells). (A) Cells were stimulated with cyclopiazonic acid (CPA, 
20 µM) followed by exchange of 1 mM EGTA for 2 mM Ca2+. Basal and peak [Ca2+]i were 
obtained during the time intervals indicated. (B) Ca2+ release from intracellular stores was 
monitored by addition of 5 µM ionomycin in the presence of EGTA. This Ca2+ release was 
normalized to the maximum response after exchange of 1 mM EGTA for 2 mM Ca2+. All bars 
represent means of 5-7 experiments. Error bars indicate SEM. Asterisks indicate significant 
differences (p < 0.05, two-tailed Mann-Whitney U test). 
 
As mentioned previously, Brandman et al. have shown that STIM2 regulates 
basal Ca2+ concentrations in the cytosol and the ER of different non-neuronal 
cell lines [9]. In line with this report, Stim2-/- neurons displayed lower basal 
cytosolic Ca2+ levels than wild-type cells (Stim2-/-: 62 ± 9 nM; wt: 103 ± 12 nM; 
n = 7; p < 0.05) (Fig. 37A). In order to evaluate the Ca2+ content of intracellular 
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stores, the release of free Ca2+ from this compartments was measured by 
application of the membrane permeant Ca2+ ionophore ionomycin in the 
absence of extracellular Ca2+ [9]. The amplitude of the relative Ca2+ peak was 
decreased in Stim2-/- cells (Stim2-/-: 0.12 ± 0.02; wt: 0.33 ± 0.07; n = 5; p < 0.05), 
whereas the subsequent Ca2+ entry induced by re-addition of extracellular Ca2+ 
was indistinguishable between Stim2-/- and control neurons (Fig. 37B). 
During brain ischemia, an excessive increase in [Ca2+]i is thought to be a main 
activator of neuronal cell death [111]. To test a possible role of SOCE in this 
process, Ca2+ imaging experiments were performed on wild-type and Stim2-/- 
neuronal cultures under conditions of oxygen-glucose deprivation (OGD) 
[154,155], optionally combined with a lowered pH [135], an established system 
for the examination of Ca2+-dependent and Ca2+-independent mechanisms in 
neuronal injury (Fig. 38A). OGD was reported to trigger cumulative increases in 
[Ca2+]i that were mostly reversible when the duration of the insult was limited to 
1 h [155]. A robust [Ca2+]i rise could be confirmed in the wild-type cultures 
(131 ± 46 nM; n = 5) but found only a very small increase during a 1 h OGD in 
Stim2-/- cells (11 ± 15 nM; n = 5; p < 0.05) (Fig. 38A). In Stim2-/- cultures, a 
marked [Ca2+]i increase was only visible when OGD was extended to 2 h. 
 Mitochondrial damage is one of the major features of ischemic cell death, as a 
result of the decreased available oxygen, and plays a role in the further 
development of the ischemic damage in the cell [111]. The inhibition of 
mitochondrial oxidative phosphorylation or significant uncoupling of the 
mitochondrial electron transport, which lower ATP levels in the cell, increase the 
production of mitochondrial free radicals, activate caspases and remove the 
Ca2+ buffering ability of the organelle. The disruption of the mitochondrial 
membrane and their increased permeation depletes the mitochondrial Ca2+ 
store, contributing further to the increased [Ca2+]i in the cell [111]. Therefore, 
this phenomenon was mimicked using a mitochondrial uncoupling agent, 
carbonyl cyanide m-chlorophenylhydrazone (CCCP) (Fig. 38B). In the presence 
of CCCP, a rapid and excessive [Ca2+]i increase was detectable in both wild-
type and Stim2-/- neurons (Fig. 38B). However, after 1 h washout of CCCP, the 
cytosolic Ca2+ level in Stim2-/- cells declined more efficiently than in wild-type 
cells (89 ± 3 % vs. 72 ± 3 %; n = 5; p < 0.05) (Fig. 38B). Thus, ischemia-induced 
[Ca2+]i increases develop slower and recover faster in Stim2-/- neurons 
compared to wild-type which may in part be explained by the lower store 
content in these cells, which promotes a faster cytoplasm Ca2+ clearance by 
SERCA ( explained in detail in the discussion part). 
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Figure 38. STIM2 regulates ischemia-induced Ca2+ accumulation in neurons. Neuronal 
cultures (DIV 5-9) were loaded with Fura-2 and averaged [Ca2+]i responses in Stim2-/- were 
compared to wild-type (WT) cells (n = 5-7 experiments per group, each representing the 
average signal from 20-35 cells). (A) Effect of combined oxygen-glucose deprivation (OGD) on 
[Ca2+]i. Cultured neurons (DIV12-14) were exposed for 1 h (WT) or 2 h (Stim2-/-) to a glucose-
free bath solution continuously bubbled with N2. (B) Chemical anoxia was induced in Stim2-/- or 
WT cells by CCCP (2 µM, 30 min). Recovery from increases in [Ca2+]i was obtained after wash-
out of CCCP for 60 min. All bars represent means of 5-7 experiments. Error bars indicate SEM. 
Asterisks indicate significant differences (p < 0.05, two-tailed Mann-Whitney U test). 
 
 
5.7.2. STIM2-defective neurons are protected from ischemia 
 
The marked impairment of OGD-induced Ca2+ accumulation in Stim2-/- neurons 
indicated a possible neuroprotective effect of STIM2 deficiency under ischemic 
conditions. To test this directly, cultured hippocampal neurons from E18 
embryos were subjected to OGD (in collaboration with Michael K. Schuhmann 
and Dr. Sven G. Meuth from the Department of Neurology, University of 
Würzburg) (Fig. 39). After five to seven days under normal culture conditions, 
80.6 ± 4.4 % (n = 5) wild-type neurons were viable in agreement with previous 
reports (Fig. 39B) [156]. Neurons prepared from Stim2-/- mice showed increased 
viability (Stim2-/-: 88.7 ± 2.6 %; wt: 52.4  6.6 %; n = 3; p < 0.01) as compared to 
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wild-type controls. After 6 h under ischemic conditions (OGD, low glucose, N2, 
pH 6.4) [135], Stim2-/- neurons survived significantly better as compared to wild-
type controls (Stim2-/-: 72.9  4.3 %; wt: 52.4  6.6 %; n = 3, p < 0.001) 
(Fig. 39A, B). In the next set of experiments, the involvement of STIM2 in 
alternative cell death inducing pathways was assessed in cultured neurons. For 
this, the cells were treated with staurosporine, which is known to also modulate 
intracellular Ca2+ [157], or with N,N,N´,N´-tetrakis(2-pyridylmehtyl) 
ethylenediamine (TPEN), which induces protein synthesis-dependent caspase-
11 mediated apoptosis that occurs largely Ca2+-independent (Fig. 40) [158].  
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Figure 39. Lack of STIM2 is neuroprotective under ischemic conditions in vitro and ex 
vivo. (A) Representative images of apoptotic (Casp3, red) cultured hippocampal neurons 
(MAP2a/b, green) from wild type and Stim2-/- E18 embryos under control (0 h, O2) conditions 
and after in vitro ischemia (6 h, N2). Scale bar represents 50 µm. (B) Bar graph representation 
of dead neurons (%) under the different experimental conditions. (C) Representative images of 
caspase3 (Casp3, red) positive hippocampal neurons (NeuN, green) under ischemic and control 
conditions in brain slices from 6-10 weeks old Stim2-/- mice. DAPI counterstaining (DAPI, blue). 
Scale bars represent 10 (left panels) or 100 µm (right panel). (D) Bar graph representation of 
neuronal cell death (dead neurons/mm2) under normal (6 h, O2 black columns) and ischemic 
conditions (6 h, N2, grey columns) in brain slices from Stim2-/- mice and control littermates. The 
results are presented as mean ± s.d.. *p < 0.05, **p < 0.01, *** p < 0.001, using a modified 
student’s t-test. 
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These additional experiments clearly showed that Stim2-/- neurons are protected 
from staurosporine (300 nM) induced cell death compared to wild-type neurons 
(Fig. 40A), while treatment with TPEN (2 µM) induced apoptosis in wild-type 
and Stim2-/- neurons to the same extent (Fig. 40B). These results suggested 
that Stim2-/- neurons are less sensitive to Ca2+-related apoptotic mechanisms. 
To study whether Stim2-/- neurons display a protection to hypoxia in adult mice, 
neuronal death was also monitored in hemi-brain slices from 6-10 weeks old 
mice cultured under ischemia-like conditions (Fig. 39C, D). After 6 h, slices from 
wild-type mice kept under control conditions (normoglycemia, O2, pH 7.25) 
showed 16.0  1.7 dead neurons per mm2 whereas this number was increased 
in consecutive slices that were kept under ischemic conditions (hypoglycemia, 
N2, pH 6.4; 30  0.9; n = 3, p < 0.01). In contrast, less dead neurons were found 
in slices from Stim2-/- mice under control (7.7  5.7, n = 3, p < 0.05) and ischemic 
conditions (18.6  0. 4, n = 3, p < 0.05) (Fig. 39C, D). Thus, in vitro results 
showed that STIM2-deficient neurons are protected from apoptosis during 
ischemic-like conditions (OGD, low glucose, N2, pH 6.4) and to Ca2+-related 
apoptotic mechanisms.  
 
A B
 
Figure 40. The neuroprotective effect of STIM2 deficiency is Ca2+-dependent. (A) Bar 
graph representation of dead neurons (%) under the different experimental conditions in wild-
type and Stim2-/- neurons. Staurosporine (300 nM) was used to induce an alternative Ca2+-
dependent pathway leading to cell death. (B) N,N,N´,N´-tetrakis(2-pyridylmehtyl) 
ethylenediamine (TPEN; 2 µM) or the vehicle (DMSO) was added to neuronal cell cultures for 
10 h to induce mainly Ca2+-independent cell death. The results are presented as mean ± s.d.. 
*p < 0.05, **p < 0.01, *** p < 0.001, using a modified student’s t-test. 
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5.7.3. Stim2-/- mice are protected from ischemic stroke 
 
Cardiovascular diseases such as ischemic stroke are among the leading 
causes of death and disability in Western countries [159]. Microvascular 
integrity is disturbed during cerebral ischemia, and the involvement of platelets 
and intravascular thrombus formation after blood reperfusion is crucial for the 
development of a secondary ischemic area called “penumbra”, leading to a 
further increase of the ischemia [160]. To determine the effect of STIM2 deletion 
in this process, the development of neuronal damage was studied (in 
collaboration with Dr. Christoph Kleinschnitz and Prof. Guido Stoll from the 
Department of Neurology, University of Würzburg) in Stim2-/- mice following 
transient cerebral ischemia in a model that depends on thrombus formation in 
microvessels downstream of a middle cerebral artery (MCA) occlusion (Fig. 41). 
This in vivo model is known as transient middle cerebral artery occlusion 
(tMCAO) [161]. Surprisingly, after 24 h, infarct volumes in Stim2-/- mice were 
reduced to < 40 % compared to wild-type as assessed by 2,3,5-
triphenyltetrazolium chloride (TTC) staining (18.6 ± 5.5 vs. 57.9 ± 13.1 mm3, 
p < 0.01) (Fig. 41A, B). Reductions in infarct size were functionally relevant, as 
the Bederson score assessing global neurological function (1.6 ± 0.8 vs 3.0 ± 
1.0, respectively; p < 0.05) and the grip test, which specifically measures motor 
function and coordination (2.0 ± 1.3 versus 4.1 ± 0.9, respectively; p < 0.05), 
were significantly better in Stim2-/- mice as compared to wild-type control mice 
(Fig. 41C, D). 
Serial magnetic resonance imaging (MRI) on living mice up to day 5 after 
tMCAO showed that infarct volume did not increase over time in Stim2-/- mice, 
indicating a sustained protective effect (Fig. 42). Because the severity of the 
brain damage, all wild-type mice were sacrificed for ethical reasons on day 1 
and, therefore, not assessed by MRI on day 5. In line with this, histological 
analysis revealed that the infarctions were restricted to the basal ganglia in 
Stim2-/- mice 24 h after tMCAO induction (Fig. 41E).  
In order to analyse the role of Stim2-/- blood cells or neuronal tissue in the 
protective phenotype, bone marrow chimeric mice were generated by 
transplantation of Stim2-/- or wild-type bone marrow in lethally irradiated wild-
type (Stim2+/+ -/-BM) or Stim2-/- (Stim2-/- +/+BM) donor mice, respectively. Twelve 
weeks after transplantation, chimeric mice were analyzed in the tMCAO model 
(Fig. 41A). Stim2+/+ -/-BM mice developed regular infarcts, while infarctions 
remained small in Stim2-/- +/+BM mice (Fig. 41B). Additionally, Stim2-/- +/+BM 
mice reached better scores in the Bederson score test and grip test as 
compared to Stim2+/+ -/-BM or wild-type control mice (Fig. 41C, D).  
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Figure 41. Stim2-/- mice are protected from neuronal damage after cerebral ischemia.     
(A-C) Wild-type and Stim2-/- mice were subjected to tMCAO and analysed after 24 h. In parallel, 
the experiments were performed with wild-type mice transplanted with Stim2-/- bone marrow 
(Stim2+/+BM-/-) and Stim2-/- mice transplanted with wild-type bone marrow (Stim2-/- BM+/+). 
(A) TTC stains of three coronal brain sections representative of each group. (B) Brain infarct 
volumes as measured by planimetry at day 1 after tMCAO (n = 8-10/group). (C) Neurological 
Bederson score and (D) grip test assessed at day 1 after tMCAO. Graphs plot mean ± s.d. (n = 
8-10/group). *p < 0.05, **p < 0.01, Bonferroni-1-Way ANOVA tested against wild-type mice. 
(E) H&E stained sections in the ischemic hemispheres of wild-type and Stim2-/- mice. Note that 
infarcts are restricted to the basal ganglia in Stim2-/- mice, but consistently include the neocortex 
in the wild-type. Scale bars, 300 μm. 
 
These results indicate that STIM2 deletion protects mice from ischemic 
neuronal damage independently of functional alterations within the 
hematopoietic system, and gave rise to a fruitful collaboration with Prof. Jens 
Eilers at the University of Leipzig to analyse the function of STIMs and Orai1 in 
Ca2+ homeostasis in neuronal cells (see publication list: Berna-Erro, A. et al. Sci 
Signal. 2009 Oct 20;2(93):ra67). 
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Figure 42 . Sustained neuroprotection after tMCAO in Stim2-/- mice. Representative coronal 
T2-w MR brain images of wild-type or Stim2-/- mice at day 1 and 5 after tMCAO. Infarcts are 
indicated by white arrows. Because the severity of the brain damage, all wild-type mice were 
sacrificed for ethical reasons on day 1 and were, therefore, not assessed by MRI on day 5. 
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6. DISCUSSION 
 
Agonist-induced elevation of [Ca2+]i is a central step during activation of cells of 
the immune system and platelets, but the underlying mechanisms are not fully 
understood. A major pathway for Ca2+ entry in electrically non-excitable cells 
involves SOCE. In this mechanism it was clear that the activation of SOC 
channels in the PM is associated with a previous release of Ca2+ from 
intracellular stores. However, the molecular mechanisms, as well as the identity 
of the molecule/s that could link both processes were unknown for the past two 
decades, until the identification of the molecule STIM1. In 2001, Stim1 and 
Stim2 were indentified as a gene family coding for a novel class of 
transmembrane proteins [44]. Most of the studies about STIM function 
performed by others were reported one year before and during the time period 
of the current thesis. In 2005, STIM1 was described as a Ca2+ sensor protein 
located in the ER of Drosophila S2 cells and in Jurkat T cell lines [2-4]. 
Additionally, Zhang et al. performed mutations leading to a single amino acid 
change in the EF-hand domain of STIM1 [4]. As a result, mutated STIM1 
permanently opened SOC channels in the PM due to a disrupted Ca2+ binding 
of the mutated N terminus, demonstrating that STIM1 is a Ca2+ sensor essential 
for SOC channel activation and SOCE. The function of STIM2 instead, was 
completely unknown. 
The elevation of [Ca2+]i as a central step in platelet activation was clear at that 
time [162]. RT-PCR performed in our lab, together with The Platelet 
Proteosome Project performed by Prof. Albert Stickman’s group at the 
University of Würzburg, showed strong expression of STIM molecules in human 
and mouse platelets. Later, the expression of STIM1 and STIM2 was confirmed 
in platelets by western blot (Fig. 9). Therefore, I started my PhD project in June 
2006 to understand the function of STIM2 in Ca2+ homeostasis in murine 
platelets using the mouse knock-out technology.  
 
 
6.1. General description of the STIM2-deficient mouse 
 
Mice heterozygous for the STIM2-null allele were apparently healthy and had a 
normal life expectancy. Stim2-/- mice were born at the expected Mendelian ratio, 
developed normally in size and weight to adulthood and were fertile (Fig. 12). 
Western blot analysis showed that STIM1 expression levels were unaltered in 
Stim2-/- mice (Fig. 11E). However, a pronounced sudden death in Stim2-/- mice 
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was observed, starting at the age of 8 weeks after birth (Fig. 12C). In humans, 
sudden death has been observed in cases of cardio-vascular alterations such 
as heart hypertrophy and arrhythmia, genetic malformations of the heart as well 
as epileptic episodes and seizures in the brain [139,163]. Alterations in 
intracellular Ca2+ release channels located in the ER, for instance IP3R and 
RyR, have been associated with seizures in brain and heart arrhythmias in mice 
[164-166], events which in many cases led to sudden death. The analysis of 
heart physiology by electrocardiography (ECG) revealed a normal heart function 
(data not shown), indicating that sudden death in Stim2-/- mice is not based on 
abnormal ECG records. However, these results do not completely rule out a 
possible cardiac origin, since transient short heart alterations or other 
alterations were not predictable and therefore hardly detectable by ECG.  
Stim2-/- mice also showed normal levels of different parameters in blood serum 
(Fig. 14), used extensively as indicators to detect possible alterations in the 
physiology and metabolism and therefore in organ’s function. Histological 
examination of major organs showed no obvious abnormalities (Fig. 13). Thus, 
sudden death in Stim2-/- mice is neither based on alterations in the tested blood 
parameters, nor on macroscopic alterations in the structure of the main organs, 
and it is most likely not related to heart dysfunction. Since episodes of sudden 
death related to altered neuronal functions have been described in humans 
[163,167], a possible hypothesis could be that sudden death in Stim2-/- mice is 
related to brain dysfunction, although the mechanism remains unclear. It has 
been reported that PLC1 null mice suffered from epileptic seizures which 
finally led to the sudden death of the mice [123]. This evidence suggests that an 
altered SOCE in neuronal cells might also contribute to sudden death. 
Early death has also been observed in Stim1-/- mice generated in our lab [6]. 
Approximately, 70 % of mice lacking STIM1 died within a few hours after birth. 
Marked cyanosis was noted before death, suggesting a cardiopulmonary defect. 
Surviving Stim1−/− mice exhibited marked growth retardation, achieving ~50 % 
of the weight of wild-type littermates at 3 and 7 weeks of age. Such higher and 
earlier mortality in the Stim1-/- mice compared to Stim2-/- mice indicates a more 
relevant function of STIM1 in murine development. 
Finally, spontaneous death of Stim2-/- mice was also reported by others during 
the last year of my PhD [5], although it occurred before adulthood (4-5 weeks 
after birth), which may be related to the variability in the genetic background 
between the two Stim2-/- mouse strains. In that report, the reason of the 
spontaneous death was also unknown. 
Furthermore, Stim2-/- females were not able to feed their offspring (Fig. 15B, C), 
probably due to a mammary gland dysfunction, and such alteration could be 
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partially rescued in further pregnancies (Fig. 15B, C). Macroscopic histological 
analysis suggested that during pregnancy the mammary gland developed faster 
in Stim2-/- mice as compared to wild-type controls but failed to develop further 
during delivery, impeding a complete expansion of alveoli and impairing the 
production of a sufficient amount of milk to feed the litters (Fig. 16). Such a 
phenotype has been reported before in other knockout mice, however, the 
respective proteins were not related to SOCE. For instance, local 
overexpression of prolactin (PRL) in mouse mammary gland induced increased 
development of the alveoli at early stages of pregnancy and the glands tended 
to be less developed during lactation. In addition, half of the PRL mutant 
females exhibited lactation defects, leading to significantly increased mortality of 
their offspring [168].  
Stat5 is a transcription factor essential for milk protein gene expression in 
mammary epithelial cells and it is activated by PRL. Over-expression of a 
constitutively activated Stat5 mutant in mice led to a similar phenotype to that 
observed in Stim2-/- and in the over-expressed PRL mutant mammary gland 
[169]. However, impaired lactation or offspring mortality were not reported. This 
study identified Stat5 also as a regulator of mammary cell proliferation. 
Socs5 has been shown to be an inhibitor of IL-4/IL-13 signaling. This last 
signaling pathway activate the transcription factor Stat6, and it is primarily 
expressed in Th1 cells of the immune system. Interestingly, it has been reported 
that Socs5–/– mice had accelerated mammary gland development compared to 
controls, and showed increased number of alveoli [170]. This suggests that 
enhanced IL-4/IL-13 signaling, and therefore increased activation of Stat6 in the 
mammary epithelium of Socs5–/– mice, results in accelerated mammary gland 
development. In the same study Khaled et al. reported that IL-4/IL-13 double 
knockout and Stat6-/- mice exhibited delayed mammary gland development, 
confirming the unexpected importance of these signaling pathways related to 
the immune system in mammary gland. It would be interesting, therefore, to 
study the expression of hormones and different important factors during 
mammary gland development in Stim2-/- mice, specially stat5, stat6 and gata-3. 
Moreover, regarding the observation that multiparous Stim2-/- females were also 
not able to feed their offspring (Fig. 15B), the reduced luminal area found in the 
alveoli in primiparous Stim2-/- females can not explain itself the impairment in 
offspring feeding. Therefore, measurements of milk volumes in Stim2-/- lactating 
mice will be performed, as well as the determination of fat and protein content, 
in order to study possible alterations in milk composition. Transplantation 
experiments of newborn Stim2-/- or wild-type mammary epithelial cells in wild-
type or Stim2-/- mammary pads are planned, in order to find out whether the 
   
 -117- 
   Discussion 
altered mammary function and development is dependent on mammary 
epithelial cells or other external tissues.  
 
 
6.2. Analysis of STIM2-deficient platelets 
 
Since our lab is interested in functional mechanisms in platelets, the effect of 
STIM2 deficiency in these cells was studied. Western blot assay demonstrated 
that STIM2 is expressed in these cells and that the protein is completely absent 
in Stim2-/- platelets (Fig. 17A). Surprisingly, no alteration in Ca2+ homeostasis or 
function could be detected in these cells in the absence of STIM2. A deep 
analysis was performed in order to detect possible specialized functions of this 
isoform in platelet function but all our results suggested that STIM2 does not 
play any detectable role in platelets. 
In 2006, Soboloff et al. suggested that STIM2 is an inhibitor of STIM1-mediated 
store-operated Ca2+ entry [53]. One year later, our group reported that a 
constitutively active STIM1 mutant causes premature platelet activation and 
bleeding in mice [56]. The mouse line was named “Saxcoburggotski” (Sax). This 
STIM1 mutant molecule bears a point mutation in the EF-hand motif that 
impairs Ca2+ binding, mimicking the depletion of the intracellular Ca2+ stored in 
the ER. As a result, Sax mutant platelets were preactivated under non-
stimulating conditions and the mice showed increased platelet consumption in 
the bloodstream and suffered from macrothrombocytopenia and an associated 
bleeding disorder [56]. Therefore, one would expect a similar phenotype in 
Stim2-/- and Sax mice according to Soboloff´s hypothesis. However, STIM2-
deficient platelets were not preactivated and Stim2-/- mice showed normal 
platelet clearance from the blood stream (Fig. 17D). Additionally, flow cytometric 
studies of GPIIbIIIa (integrin IIb3) activation and of degranulation-dependent 
P-selectin surface exposure under resting conditions confirmed that STIM2-
deficient platelets were not pre-activated (Fig. 19). 
Later in the course of the current project, a study by Brandman et al. proposed 
STIM2 as a Ca2+ sensor in the ER, regulating basal [Ca2+]i and ER Ca2+ levels 
in HeLa, HUVEC, and HEK293T cells [9]. The effect of STIM2 deficiency on 
Ca2+ homeostasis was tested in platelets (Fig. 18). In contrast to the proposed 
function of STIM2 by Brandman et al., STIM2-deficient platelets showed 
unaltered basal [Ca2+]i and normal Ca2+ concentration in the ER. Additionally, 
despite robust expression of STIM2 in platelets, lack of the protein did not alter 
SOCE upon different agonist activation (Fig. 18). Moreover, STIM2-deficient 
platelets were normally activable (Fig. 19) and aggregated normally ex vivo 
   
 -118- 
   Discussion 
(Fig. 24), indicating a non-essential function of STIM2 in platelet’s, Ca2+ 
homeostasis and activation. In the course of the current project, a parallel study 
for STIM1 function in platelets was performed in our lab. Varga-Szabó et al. 
reported that STIM1 is not essential for megakaryopoiesis or platelet production 
in Stim1-/- mice [6]. However, [Ca2+]i measurements on Stim1-/- platelets showed 
severely defective Ca2+ responses to all major agonists. Unexpectedly, the ER 
Ca2+ concentration was significantly decreased, as one would expect in STIM2-
deficient platelets [9]. In addition, analysis of platelets lacking the STIM1-
regulated Ca2+ channel, Orai1, revealed defective SOCE, but unaltered ER Ca2+ 
content [36]. These results suggest that STIM1 rather than STIM2 regulates the 
Ca2+ store content in platelets and indicate that this function does not require 
Orai1. A possible explanation for these contradictory results with the study by 
Brandman et al. is that the relevance of the STIM isoform function in Ca2+ 
homeostasis regulation strongly depends on the cell type.  
Previous studies reported that STIM2 also interacts with the Orai1 channel and 
the co-expression of both molecules increases SOCE in cell lines [63,65]. A 
very interesting study would be to test for competition mechanisms between 
both STIM isoforms and the Orai1 channel in platelets. Such an experiment 
could also explain in part the unaltered function and Ca2+ homeostasis in 
STIM2-deficient platelets by the existence of compensatory mechanisms 
between both STIM isoforms. However, STIM1-deficient platelets showed 
severely defective responses to all major agonists [6], indicating that STIM2 can 
not take over the function of STIM1 thereby questioning this idea. Interestingly, 
these mutant cells showed a residual Ca2+ influx, suggesting that other 
molecules may regulate SOC influx to a minor extent. One candidate molecule 
could be STIM2, and this residual Ca2+ influx could be explained by a partial 
compensation, possibly due to the lower expression of STIM2 in platelets as 
compared to STIM1 (Fig. 9) or/and a partial but not completely overlapping 
function of both isoforms. Supporting this idea, Oh-hora et al. overexpressed 
STIM2 in STIM1-deficient mouse embryonic fibroblasts (MEFs), isolated from 
conditional STIM1 knock-out mice (Stim1-/-) [5]. They found that STIM2 partially 
restored SOCE in the STIM1-deficient background, indicating a partial overlap 
of the STIM function in these cells. 
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6.3. Analysis of STIM2 deficiency in immune cells 
 
In immune cells, the predominant pathway of Ca2+ entry is thought to involve 
IP3R-mediated SOCE. Therefore, the effect of STIM2 deletion in the innate 
(mast cells and macrophages) and the adaptive (B and T cells) immune system 
was also studied. 
 
 
6.3.1. The effect of STIM2 deletion on the innate immune system: Mast 
cells 
 
The analysis of Ca2+ homeostasis and SOCE in PMC and BMMC in vitro 
differentiated mast cells showed that STIM2 deletion does not alter the basal 
[Ca2+]i, nor the basal ER Ca2+ levels in these cells, nor SOCE after stimulation 
via store depletion or IgE-mediated FcR activation (Fig. 25). Surprisingly, 
Stim2-/- mice were protected from IgE-mediated systemic anaphylaxia 
(Fig. 26A). In contrast, Stim2+/+ -/-BM chimeric mice did not show such a 
protective effect to anaphylaxis, indicating that STIM2-deficient blood cells were 
not involved in the phenotype (Fig. 26B). In the IgE-mediated anaphylaxia 
model, the mast cell activity was assessed indirectly by measuring the body 
temperature. The histamine released by mast cells is primarily responsible for 
the development of the hypothermia, while platelet-activating factor (PAF) is 
responsible for the increased vascular permeation and hypotension (for review, 
see [171]). This released histamine during the systemic anaphylaxis seems to 
act in the brain, presumably by binding to histamine receptors in the 
hypothalamus, which is known to be involved in body thermoregulation [172]. 
Thus, in conclusion the protective effect in Stim2-/- mice in IgE-mediated 
anaphylaxia model is independent of mast cells and is most likely due to an 
altered function in other STIM2-deficient cell types such as certain neuronal 
circuits of the hypothalamus or the endothelial cells of blood vessels. An 
essential function of Stim1 in mast cell activation and anaphylactic responses 
has been described previously [146]. STIM1-deficient mast cells showed 
impaired SOCE after FcRI-mediated stimulation and abolished activation of the 
transcription factors NF-B and NFAT. Mast cells lacking STIM1 also displayed 
much less degranulation and cytokine production and Stim1-/- mice were less 
sensitive to immunoglobulin E–mediated immediate-phase anaphylactic 
responses in vivo. These results support the idea that the relevance of STIM 
function is strongly dependent of the cell type. 
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6.3.2. The effect of STIM2 deletion on the innate immune system: 
Macrophages 
 
Ca2+ homeostasis and SOCE was also analyzed in Stim2-/- macrophages. 
STIM2 deletion did not alter SOCE in these cells, neither after stimulation of 
Ca2+ store release with 5 µM TG, nor by direct stimulation through FcR 
activation (Fig. 27). However, the expression of the activating receptors FcRIII 
and IV was increased by 25 % in Stim2-/- macrophages (Fig. 28). It can be 
speculated that this rather mild increase could not have a significant effect on 
SOCE, or that there is a compensatory mechanism during macrophage 
maturation in order to re-establish normal Ca2+ homeostasis. Unfortunately, 
there is no good anti-FcRII antibody commercially available to study whether 
the expression of the inhibitory receptor is increased as well, which might 
indicate compensation mechanisms to the increased expression of FcRIII and 
FcRIV. Strikingly, Stim2-/- mice were protected to FcR-mediated ITP after i.v. 
injection of anti-GPIIb/IIIa antibodies (Fig. 29). Since surface glycoprotein 
expression is normal in Stim2-/- platelets (Fig. 17C), the protective effect can not 
be associated to an alteration in the described glycoproteins. Our lab found that 
STIM1 is also essential for FcR activation and autoimmune inflammation [173]. 
This could be explained by an abolishment of SOCE after FcR activation in the 
absence of STIM1, indicating that SOCE is an important mechanism for FcR-
dependent activation in macrophages. The protective affect of Stim2-/- mice in 
ITP is however, not easy to explain, since SOCE is not altered in these cells. 
Therefore, a possible hypothesis is that this protective phenotype could be due 
to another STIM2-deficient cells. 
The apparent contradiction between the unexpected upregulation of FcRs, the 
normal Ca2+ influx after FcR activation and the protective effect of Stim2-/- mice 
in the ITP model remains to be clarified. These results require further studies 
that are still ongoing. It is necessary to perform the same experiments using 
bone marrow chimeras, in order to study whether the upregulation of FcR and 
the protective phenotype seen in the ITP model is dependent on the STIM2 
deficiency in blood cells or in other cells. In mice, i.v. injection of anti-GPIIb/IIIa 
antibodies leads to FcR-dependent platelet clearance, mainly via macrophages 
located in the spleen [132,149]. Therefore, it is also important to study the 
platelet clearance occurring in the spleen in this model. 
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6.3.3. Effect of STIM2 deletion on the adaptive immune system: T and B 
cells 
 
In this study, it was shown that STIM2 is also expressed in lymph nodes, 
suggesting a function in T cells (Fig. 9A, 11E). Previous reports indicated a 
potential role of STIM2 in T cell Ca2+ homeostasis [2,53]. Therefore, the effect 
of STIM2 deficiency on Ca2+ homeostasis and SOCE in CD4+ T cells isolated 
from spleen and lymph nodes was analyzed. STIM2 deficiency did not play a 
role in the regulation of basal [Ca2+]i and the ER Ca2+ levels in CD4+ T cells. 
However, SOCE was markedly reduced after Ca2+ store depletion by TG or 
direct TCR activation (Fig. 30), but it was independent of altered CD3 or TCR 
expression in the cells (Fig. 31). In contrast to the proposed function of STIM2 
by Brandman et al.[9], basal [Ca2+]i and the ER Ca2+ concentration was 
unaltered in STIM2-deficient CD4+ T cells. However, in contrast to the results 
obtained in platelets, mast cells or macrophages, STIM2 deficiency significantly 
altered SOCE in T cells, suggesting again that the relevance of the respective 
STIM isoform function strongly depends on the cell type. In 2008, Oh-hora et al. 
generated conditional knock-out mice for STIM1 and STIM2 and showed that T 
cells and fibroblasts lacking STIM1 had severely impaired store-operated Ca2+ 
influx, whereas deficiency in STIM2 had a small or even no effect [5]. They 
showed that naive CD4+ T cells had almost no expression of STIM2, while T cell 
activation led to a substantial increase in STIM2 expression up to 3–10 % of 
total STIM protein. They proposed this as a possible explanation for this 
discrepancy. In our study, in contrast to Oh-hora’s model, wild-type naive CD4+ 
T cells substantially expressed STIM2 (Fig. 30A), which may be related to the 
variability in the genetic background between the two Stim2-/- mouse strains, 
and deletion of STIM2 led to a 50 % decrease of SOCE in these cells 
(Fig. 30B, C, D, F).  
A mild decrease in the number of CD8+ lymphocytes and splenocytes was also 
found in naive Stim2-/- mice (Fig. 32B, C). Although SOCE has been implicated 
in negative selection of thymic T cell precursors [174], Stim2-/- mice had a 
normal composition of thymocyte subsets (Fig. 33). Analysis of the splenocyte 
proliferation ex vivo from naive Stim2-/- mice revealed no differences in 
proliferation as compared to control cells (Fig. 35A), indicating that this mild 
decrease in the numbers of CD8+ T cells can not be explained by an abnormal 
maturation of T cells in the thymus or by an altered turnover in spleen. I can be 
speculated that this mild decrease could be the consequence of many 
alterations that are too small to be statistically significant. For instance, the 
CD4+ thymocyte subset showed a slightly increase in numbers in Stim2-/- mice, 
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while the CD8+ thymocyte subset showed a decrease in numbers (Fig. 33), but 
these differences were statistically non-significant. Similar results were obtained 
in lymph nodes and spleen, where the CD4+ T subset was slightly increased in 
numbers, but this difference was again statistically non-significant (Fig. 32B, C). 
Thus, such small differences could have an additive effect that at the end could 
significantly influence the percentages of CD4+ T and CD8+ cells in the 
secondary lymphoid organs (lymph nodes and spleen). Additional processes 
not studied in this work that might be altered, such as apoptosis or migration 
could also influence the cellularity in lymphoid organs.  
Furthermore, the adaptive immune response in Stim2-/- mice was examined 
after immunization with the T cell-dependent model antigen KLH (Fig. 35C, D), 
but no differences were found compared to wild-type controls, indicating that 
STIM2 does not play a role in T cell proliferation or B cell antibody production in 
this model (Fig. 35C, D). Beyersdorf et al. reported that Stim1-/- mice were able 
to drive a normal humoral immune response after vaccination despite the fact 
that SOCE was virtually absent in isolated STIM1-deficient T cells [7]. 
Additionally Stim1-/- mice developed a lymphoproliferative disease, 
characterized by a hyper-proliferation of CD4+ T cells, despite normal thymic T 
cell maturation [5,7]. Our results, together with these results obtained in Stim1-/- 
mice, suggest that the STIM family is involved in homeostatic T cell 
proliferation, but it is much less important for thymic T cell differentiation or 
humoral T cell-dependent responses. 
Finally, the effect of STIM2 deficiency in an in vivo model of autoimmune 
response was tested in collaboration with Michael K. Schuhmann and Dr. Sven 
G. Meuth from the Department of Neurology, University of Würzburg, referred to 
as myelin oligodendrocyte glycoprotein (MOG35-55-peptide)-induced EAE 
(Fig. 36). Strikingly, Stim2-/- mice showed a significantly reduced disease 
maximum (Fig. 36A) while the disease incidence, overall disease course and 
residual disease scores at day 50 were unaltered. Additionally, Stim2-/- mice 
showed a tendency to reduced demyelination in spinal cord white matter 
(neuronal axons) at disease maximum (Fig. 36B middle, C upper), but a 
comparable number of infiltrating T cells (Fig. 36B lower, C lower). Thus, in 
contrast to the T cell-dependent model antigen KLH of adaptive immune 
response, where Stim2-/- mice did not show an altered response (Fig. 35C, D), 
these mice developed an attenuated EAE, indicating a possible role of STIM2 
during the early phase of EAE progression. The reason why Stim2-/- mice 
showed an attenuated disease progression in the EAE model but a normal 
adaptive immune response in the KLH-antigen model is not clear. KLH is a very 
strong exogenous antigen, transiently present in blood, that elicits T cell-
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dependent anti-KLH antibody production (humoral immune response) and a 
memory T cell response [175,176]. An altered level of anti-KLH antibodies in 
blood serum is indicative of alterations in antigen presenting T-B cell function, T 
cell proliferation or B cell antibody production.  
EAE is a complex model for autoimmune diseases where many factors and cell 
types are involved, and where an auto-antigen (MOG) elicits a chronic immune 
response against a component of the myelin, in other words, the antigen is 
always present during the disease. The role of B cells and autoantibodies in the 
pathogenesis of EAE remains controversial. Mice immunized against mouse 
MOG produce autoantibodies directed against conformation-dependent 
epitopes of the extracellular domain of the native protein expressed at the cell 
surface, and these autoantibodies play a major role in the immunopathogenesis 
of demyelination in EAE. However, these autoantibodies generated after MOG-
immunization do not recognize the native protein in mouse strains with the 
haplotype H-2b, for instance in C57Bl/6 mice [177,178]. Since the genetically 
engineered Stim2 chimeras were backcrossed with the C57BL/6 background to 
obtain Stim2-/- mice, and murine MOG was used to immunize them, the 
resulting auto-antibodies should not play an important role in the EAE 
progression in our study. 
It is very important to point out that in the EAE model the disease progression in 
mice was monitored daily (Fig. 36A), while the titer of the anti-KLH antibody in 
blood serum of KLH-injected mice was measured at only one time point, at 
week 6 after immunization, where according to the standard protocol the 
antibodies show the maximum levels in blood serum (Fig. 35D). Stim2-/- mice 
showed differences in the EAE scores only at early stages of the disease 
progression. However, there is no information about the antibody titer at earlier 
stages after KLH immunization and therefore, data from both models can not be 
contrasted. It is not known whether the KLH autoantibody production is 
attenuated in Stim2-/- mice at early time points after immunization or not. 
Regarding this consideration, the results obtained in both models would not 
contradict each other and it is clear that further studies must be performed to 
investigate the role of STIM2 in humoral responses and EAE progression. Such 
studies are currently ongoing (see publications list: Schuhmann, MK. et al. J 
Immunol, 2009, acepted manuscript). 
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6.4. Analysis of STIM2 deficiency in neurons 
 
In brain, the absence of STIM2 had a greater impact on Ca2+ homeostasis and 
it correlated with the finding that STIM2 is the dominant isoform in this organ 
(Fig. 9). The existence of SOCE (referred to as CCE in neurons) in wild-type 
neurons was confirmed using the agent CPA (Fig. 37A). The analysis of Ca2+ 
homeostasis in E19 embryonic cultured neurons showed that STIM2 deletion 
lowered the basal [Ca2+]i and the basal ER Ca2+ levels in these cells (Fig. 37), 
indicating that STIM2 is a regulator that stabilizes basal cytosolic and ER Ca2+ 
levels in neurons, which is in agreement to previous results reported by 
Brandman et al. [9]. Strikingly, SOCE was severely reduced in Stim2-/- neurons 
compared to wild-type controls, indicating that STIM2 is also essential for SOCE 
in neurons (Fig. 37A). This finding is in line with the notion that STIM2 regulates 
store refilling as well as the basal cytosolic Ca2+ concentration in neurons by 
sensing the ER Ca2+ content and, if it is too low, activating SOCE, possibly via 
Orai channels [63,179]. The resulting Ca2+ influx is used to refill Ca2+ stores in 
the wild-type cell [27]. Correspondingly, due to the severely decreased SOCE in 
Stim2-/- neurons, the ER Ca2+ content and the [Ca2+]i are reduced. For 
pathophysiological conditions such as ischemia, our study assigned a key role 
to STIM2 and SOCE in Ca2+-dependent cell death (Fig. 38-40), which evolves 
from and/or into glutamate-mediated neurotoxicity [114]. The existing literature 
describes that anoxia reduces SERCA activity in neurons [180,181], but also 
appears to involve active Ca2+ release mediated by the IP3R and RyR channels 
located in the ER, as evidenced by protection of neurons against excitotoxic 
injury through blockade of IP3R or RyR [182,183]. Together, these events lead 
to Ca2+ accumulation in the cytosol and a corresponding store depletion, the 
latter inducing an additional Ca2+ load via SOCE. In turn, SOCE may trigger a 
further Ca2+ influx by increasing the release of glutamate and the subsequent 
activation of ionotropic glutamate receptors [114]. Both, SOCE and 
glutamatergic Ca2+ entry, then rapidly push the cytosolic Ca2+ concentration to 
damaging levels. Our results showed that Stim2-/- neurons subjected to a longer 
period of OGD were less sensitive to apoptosis (Fig. 39) because they did not 
undergo SOCE (Fig. 37A) and had a lower Ca2+ content in the intracellular 
stores (Fig. 37B), which critically depends on a functional SOCE [27]. The 
decreased store content limits the initial Ca2+ release (Fig. 37B) and helps to 
better utilize the remaining Ca2+ sequestration capacity during the ischemic 
challenge (Fig. 38). This protective phenotype was observed only in Ca2+-
related apoptotic mechanisms (Fig. 40A), since treatment with TPEN, an 
   
 -125- 
   Discussion 
apoptotic agent that does not alter [Ca2+]i, induced apoptosis in wild-type and 
Stim2-/- neurons to the same extent (Fig. 40B). 
Finally, the in vivo implication of these findings was studied using a model of 
cerebral ischemia, referred to as tMCAO (Fig. 41). Surprisingly, STIM2 
deficiency significantly protected mice from ischemic neuronal damage 
independently of functional alterations within blood cells (Fig. 41A, B), 
presumably since STIM2 deficiency in platelets did not alter platelet function. 
This is the first evidence for the involvement of SOCE in ischemic neuronal 
damage. Varga-Szabó et al. demonstrated that STIM1 is also an essential 
mediator of ischemic brain infarction [6]. However, in contrast to Stim2+/+ -/-BM 
chimeric mice, which developed regular infarcts, Stim1+/+ -/-BM chimeric mice 
were protected from neuronal damage following transient cerebral ischemia, 
displaying a 30 % reduction in the infarct volume. This result indicated that the 
absence of STIM1 in platelets conferred the protective effect to neuronal 
damage to Stim1-/- mice. Interestingly, densitometric analysis of STIM proteins 
performed in this thesis revealed a dominant expression of STIM2 in brain 
compared to platelets and to other organs, where STIM1 seems to be the most 
abundant isoform (Fig. 9B). It is presently not clear why neurons use STIM2 but 
not STIM1 to regulate SOCE, but our data suggest that the relevance of the 
STIM isoform function strongly depends on the cell type and correlates with 
their relative cellular expression. At the beginning of the current project, there 
was no report in the literature about the possible role of SOCE in ischemic 
processes, and few studies about its role in other neuronal processes have 
been reported. However, different knockout models for proteins related with IP3-
mediated intracellular Ca2+ release suggested an important role of this 
mechanism in neuronal functions. For instance, the absence of PLC1 led to 
epileptic-type seizures in mice [123], which indicated an involvement of PLC1 
in the development and control of brain inhibitory pathways. IP3R type I null 
mice exhibited severe neurological symptoms, including ataxia and epilepsy 
[124]. These evidences, together with our results in neurons, suggest an 
unexpectedly important role of SOCE in diverse functions in electrically 
excitable cells such as neurons. Clearly, further studies are required to draw a 
full picture of i) the role that STIM2 plays under physiological conditions in 
neurons, ii) which molecular partners interact with STIM2 (e.g., Orai/CRACM 
and/or TRP channels [27,63] iii) which neuronal activity triggers SOCE (e.g., 
burst firing or high frequency discharges of excitatory inputs), and iv) whether 
STIM2-deficiency affects synaptic activity and plasticity. 
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In summary, the studies shown here provide new insights into the in vivo 
function of STIM2 in mice. The presented data strongly suggest that STIM2 is a 
functional ER Ca2+ sensor in vivo and plays an important role in brain, 
mammary gland and T cells. The presented results could not provide a 
comprehensive molecular explanation of the phenotypes found in Stim2-/- mice 
but they were the starting point for three ongoing parallel studies.  
STIM2 seems to be not relevant for the function of platelets, at least under the 
experimental conditions tested. Furthermore, STIM2 seems to be involved in 
mammary gland development during pregnancy and essential for mammary 
gland function during lactation.  
In T cells, STIM2 is involved in SOCE as a positive regulator of Ca2+ signaling 
rather than being an inhibitor of STIM1, as was proposed before [53]. 
Additionally, our data suggest that the function of STIM2 is very specific in the 
immune system, involved in EAE at the early stages of disease progression.  
In brain, our results evidenced that STIM2 participates in mechanisms of 
neuronal damage after ischemic events. This is the first time that the 
involvement of SOCE in ischemic neuronal damage has been reported, but 
further analysis of these processes will be necessary. These findings may serve 
as a basis for the development of novel neuroprotective agents for the 
treatment of ischemic stroke but possibly also other neurodegenerative 
disorders in which disturbances in cellular Ca2+ homeostasis are considered a 
major pathophysiological component [112,113].  
Most of the reports published during my thesis suggested that STIM2 has a 
minor function in Ca2+ homeostasis compared to STIM1. In contrast, the data 
presented in this work suggest that the relevance of the STIM function is 
strongly dependent on the cell type and correlates with the relative isoform 
expression in the studied cell type. 
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